Patent Publication Number: US-2011059463-A1

Title: Serine and Threonine Phosphorylation Sites

Description:
RELATED APPLICATIONS 
     This application claims priority to U.S. provisional application Ser. No. 61/270,495 filed Jul. 9, 2009, the entire contents of which is hereby incorporated by reference. 
    
    
     FIELD OF THE INVENTION 
     The invention relates generally to novel serine and threonine phosphorylation sites, methods and compositions for detecting, quantitating and modulating same. 
     BACKGROUND OF THE INVENTION 
     The activation of proteins by post-translational modification is an important cellular mechanism for regulating most aspects of biological organization and control, including growth, development, homeostasis, and cellular communication. Protein phosphorylation, for example, plays a critical role in the etiology of many pathological conditions and diseases, including to mention but a few: cancer, developmental disorders, autoimmune diseases, and diabetes. Yet, in spite of the importance of protein modification, it is not yet well understood at the molecular level, due to the extraordinary complexity of signaling pathways, and the slow development of technology necessary to unravel it. 
     Protein phosphorylation on a proteome-wide scale is extremely complex as a result of three factors: the large number of modifying proteins, e.g., kinases, encoded in the genome, the much larger number of sites on substrate proteins that are modified by these enzymes, and the dynamic nature of protein expression during growth, development, disease states, and aging. The human genome, for example, encodes over 520 different protein kinases, making them the most abundant class of enzymes known. (Hunter, Nature 411: 355-65 (2001)). Most kinases phosphorylate many different substrate proteins, at distinct tyrosine, serine, and/or threonine residues. Indeed, it is estimated that one-third of all proteins encoded by the human genome are phosphorylated, and many are phosphorylated at multiple sites by different kinases. 
     Many of these phosphorylation sites regulate critical biological processes and may prove to be important diagnostic or therapeutic targets for molecular medicine. For example, of the more than 100 dominant oncogenes identified to date, 46 are protein kinases. See Hunter, supra. 
     Protein kinases are often divided into two groups based on the amino acid residue they phosphorylate. The Ser/Thr kinases, which phosphorylate serine or threonine (Ser, S; Thr, T) residues, include cyclic AMP(cAMP-) and cGMP-dependent protein kinases, calcium- and phospholipid-dependent protein kinase C, calmodulin dependent protein kinases, casein kinases, cell division cycle (CDC) protein kinases, and others. These kinases are usually cytoplasmic or associated with the particulate fractions of cells, possibly by anchoring proteins. The second group of kinases, which phosphorylate Tyrosine (Tyr, Y) residues, are present in much smaller quantities, but play an equally important role in cell regulation. These kinases include several receptors for molecules such as growth factors and hormones, including epidermal growth factor receptor, insulin receptor, platelet-derived growth factor receptor, and others. Some Ser/Thr kinases are known to be downstream to tyrosine kinases in cell signaling pathways. 
     Many of the protein kinases and their phosphorylated substrates regulate critical biological processes and may prove to be important diagnostic or therapeutic targets for molecular medicine. For example, of the more than 100 dominant oncogenes identified to date, 46 are protein kinases. See Hunter, supra. Understanding which proteins are modified by these kinases will greatly expand our understanding of the molecular mechanisms underlying oncogenic transformation. Therefore, the identification of, and ability to detect, phosphorylation sites on a wide variety of cellular proteins is crucially important to understanding the key signaling proteins and pathways implicated in the progression of diseases like cancer. 
     Carcinoma is one of the two main categories of cancer, and is generally characterized by the formation of malignant tumors or cells of epithelial tissue original, such as skin, digestive tract, glands, etc. Carcinomas are malignant by definition, and tend to metastasize to other areas of the body. The most common forms of carcinoma are skin cancer, lung cancer, breast cancer, and colon cancer, as well as other numerous but less prevalent carcinomas. Current estimates show that, collectively, various carcinomas will account for approximately 1.65 million cancer diagnoses in the United States alone, and more than 300,000 people will die from some type of carcinoma during 2005. (Source: American Cancer Society (2005)). The worldwide incidence of carcinoma is much higher. 
     It has been shown that a number of Ser/Thr kinase family members are involved in tumor growth or cellular transformation by either increasing cellular proliferation or decreasing the rate of apoptosis. For example, the mitogen-activated protein kinases (MAPKs) are Ser/Thr kinases which act as intermediates within the signaling cascades of both growth/survival factors, such as EGF, and death receptors, such as the TNF receptor. Expression of Ser/Thr kinases, such as protein kinase A, protein kinase B and protein kinase C, have been shown be elevated in some tumor cells. Further, cyclin dependent kinases (cdk) are Ser/Thr kinases that play an important role in cell cycle regulation. Increased expression or activation of these kinases may cause uncontrolled cell proliferation leading to tumor growth. (See Cross et al.,  Exp. Cell Res.  256: 34-41, 2000). 
     Leukemia, another form of cancer in which a number of underlying signal transduction events have been elucidated, has become a disease model for phosphoproteomic research and development efforts. As such, it represent a paradigm leading the way for many other programs seeking to address many classes of diseases (See,  Harrison&#39;s Principles of Internal Medicine , McGraw-Hill, New York, N.Y.). 
     Most varieties of leukemia are generally characterized by genetic alterations associated with the etiology of the disease, and it has recently become apparent that, in many instances, such alterations (chromosomal translocations, deletions or point mutations) result in the constitutive activation of protein kinase genes, and their products, particularly tyrosine kinases. The most well known alteration is the oncogenic role of the chimeric BCR-Abl gene, which is generated by translocation of chromosome 9 to chromosome 22, creating the so-called Philadelphia chromosome characteristic of CML (see Nowell,  Science  132: 1497 (1960)). The resulting BCR-Abl kinase protein is constitutively active and elicits characteristic signaling pathways that have been shown to drive the proliferation and survival of CML cells (see Daley,  Science  247: 824-830 (1990); Raitano et al.,  Biochim. Biophys. Acta . December 9; 1333(3): F201-16 (1997)). The recent success of Imanitib (also known as STI571 or Gleevec®), the first molecularly targeted compound designed to specifically inhibit the tyrosine kinase activity of BCR-Abl, provided critical confirmation of the central role of BCR-Abl signaling in the progression of CML (see Schindler et al.,  Science  289: 1938-1942 (2000); Nardi et al.,  Curr. Opin. Hematol.  11: 35-43 (2003)). 
     The success of Gleevec® now serves as a paradigm for the development of targeted drugs designed to block the activity of other tyrosine kinases known to be involved in many diseased including leukemias and other malignancies (see, e.g., Sawyers,  Curr. Opin. Genet. Dev . February; 12(1): 111-5 (2002); Druker,  Adv. Cancer Res.  91:1-30 (2004)). For example, recent studies have demonstrated that mutations in the FLT3 gene occur in one third of adult patients with AML. FLT3 (Fms-like tyrosine kinase 3) is a member of the class III receptor tyrosine kinase (RTK) family including FMS, platelet-derived growth factor receptor (PDGFR) and c-KIT (see Rosnet et al.,  Crit. Rev. Oncog.  4: 595-613 (1993). In 20-27% of patients with AML, internal tandem duplication in the juxta-membrane region of FLT3 can be detected (see Yokota et al.,  Leukemia  11: 1605-1609 (1997)). Another 7% of patients have mutations within the active loop of the second kinase domain, predominantly substitutions of aspartate residue 835 (D835), while additional mutations have been described (see Yamamoto et al.,  Blood  97: 2434-2439 (2001); Abu-Duhier et al.,  Br. J. Haematol.  113: 983-988 (2001)). Expression of mutated FLT3 receptors results in constitutive tyrosine phosphorylation of FLT3, and subsequent phosphorylation and activation of downstream molecules such as STATS, Akt and MAPK, resulting in factor-independent growth of hematopoietic cell lines. 
     Although most of the research effort regarding leukemia to date has been focused on tyrosine kinases, a small of group of serine/threonine kinases, cyclin dependent kinase (Cdks), Erks, Raf, PI3K, PKB, and Akt, have been identified as major players in cell proliferation, cell division, and anti-apoptotic signaling. Akt/PKB (protein kinase B) kinases mediate signaling pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. Akt kinases regulate diverse cellular processes including cell proliferation and survival, cell size and response to nutrient availability, tissue invasion and angiogenesis. Many oncoproteins and tumor suppressors implicated in cell signaling/metabolic regulation converge within the Akt signal transduction pathway in an equilibrium that is altered in many human cancers by activating and inactivating mechanisms, respectively, targeting these inter-related proteins. 
     Despite the identification of a few key signaling molecules involved in cancer and other disease progression are known, the vast majority of signaling protein changes and signaling pathways underlying these disease types remain unknown. Therefore, there is presently an incomplete and inaccurate understanding of how protein activation within signaling pathways drives various diseases including these complex cancers, such as leukemia for example. Accordingly, there is a continuing and pressing need to unravel the molecular mechanisms of disease progression by identifying the downstream signaling proteins mediating cellular transformation in these diseases. 
     Presently, diagnosis of many diseases including carcinoma and leukemia is made by tissue biopsy and detection of different cell surface markers. However, misdiagnosis can occur since some disease types can be negative for certain markers and because these markers may not indicate which genes or protein kinases may be deregulated. Although the genetic translocations and/or mutations characteristic of a particular form of a disease including cancer can be sometimes detected, it is clear that other downstream effectors of constitutively active signaling molecules having potential diagnostic, predictive, or therapeutic value, remain to be elucidated. 
     Accordingly, identification of downstream signaling molecules and phosphorylation sites involved in different types of diseases including for example, carcinoma or leukemia and development of new reagents to detect and quantify these sites and proteins may lead to improved diagnostic/prognostic markers, as well as novel drug targets, for the detection and treatment of many diseases. 
     SUMMARY OF THE INVENTION 
     The present invention provides in one aspect novel serine and threonine phosphorylation sites (Table 1) identified in carcinoma and/or leukemia. The novel sites occur in proteins such as: Adaptor/Scaffold proteins, adhesion/extra cellular matrix proteins, cell cycle regulation, chaperone proteins, chromatin or DNA binding/repair/proteins, cytoskeleton proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, g proteins or regulator proteins, kinases, protein kinases receptor/channel/transporter/cell surface proteins, transcriptional regulators, ubiquitan conjugating proteins, RNA processing proteins, secreted proteins, motor or contractile proteins, apoptosis proteins proteins of unknown function and vesicle proteins. 
     In another aspect, the invention provides peptides comprising the novel phosphorylation sites of the invention, and proteins and peptides that are mutated to eliminate the novel phosphorylation sites. 
     In another aspect, the invention provides modulators that modulate serine or threonine phosphorylation at a novel phosphorylation sites of the invention, including small molecules, peptides comprising a novel phosphorylation site, and binding molecules that specifically bind at a novel phosphorylation site, including but not limited to antibodies or antigen-binding fragments thereof. 
     In another aspect, the invention provides compositions for detecting, quantitating or modulating a novel phosphorylation site of the invention, including peptides comprising a novel phosphorylation site and antibodies or antigen-binding fragments thereof that specifically bind at a novel phosphorylation site. In certain embodiments, the compositions for detecting, quantitating or modulating a novel phosphorylation site of the invention are Heavy-Isotype Labeled Peptides (AQUA peptides) comprising a novel phosphorylation site. 
     In another aspect, the invention discloses phosphorylation site specific antibodies or antigen-binding fragments thereof. In one embodiment, the antibodies specifically bind to an amino acid sequence comprising a phosphorylation site identified in Table 1 when the serine or threonine identified in Column D is phosphorylated, and do not significantly bind when the serine or threonine is not phosphorylated. In another embodiment, the antibodies specifically bind to an amino acid sequence comprising a phosphorylation site when the serine or threonine is not phosphorylated, and do not significantly bind when the serine or threonine is phosphorylated. 
     In another aspect, the invention provides an isolated phosphorylation site-specific antibody that specifically binds a human signaling protein selected from Column A of Table 1 only when phosphorylated at the threonine or serine listed in corresponding Column D of Table 1, comprised within the phosphorylatable peptide sequence listed in corresponding Column E of Table 1 (SEQ ID NOs: 1-726), wherein said antibody does not bind said signaling protein when not phosphorylated at said threonine or serine. In some embodiments, the human signaling protein is 4ET. In some embodiments, the SEQ ID NO is SEQ ID NO: 726. 
     In yet another aspect, the invention provides an isolated phosphorylation site-specific antibody that specifically binds a human signaling protein selected from Column A of Table 1 only when not phosphorylated at the threonine or serine listed in corresponding Column D of Table 1, comprised within the phosphorylatable peptide sequence listed in corresponding Column E of Table 1 (SEQ ID NOs: 1-726), wherein said antibody does not bind said signaling protein when phosphorylated at said threonine or serine. In some embodiments, the human signaling protein is 4ET. In some embodiments, the SEQ ID NO is SEQ ID NO: 726. 
     In another aspect, the invention provides a method for making phosphorylation site-specific antibodies. 
     In another aspect, the invention provides compositions comprising a peptide, protein, or antibody of the invention, including pharmaceutical compositions. 
     In a further aspect, the invention provides methods of treating or preventing carcinoma and/or leukemia in a subject, wherein the carcinoma and/or leukemia is associated with the phosphorylation state of a novel phosphorylation site in Table 1, whether phosphorylated or dephosphorylated. In certain embodiments, the methods comprise administering to a subject a therapeutically effective amount of a peptide comprising a novel phosphorylation site of the invention. In certain embodiments, the methods comprise administering to a subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds at a novel phosphorylation site of the invention. 
     In a further aspect, the invention provides methods for detecting and quantitating phosphorylation at a novel serine or threonine phosphorylation site of the invention. 
     In another aspect, the invention provides a method for identifying an agent that modulates a serine or threonine phosphorylation at a novel phosphorylation site of the invention, comprising: contacting a peptide or protein comprising a novel phosphorylation site of the invention with a candidate agent, and determining the phosphorylation state or level at the novel phosphorylation site. A change in the phosphorylation state or level at the specified serine or threonine in the presence of the test agent, as compared to a control, indicates that the candidate agent potentially modulates serine or threonine phosphorylation at a novel phosphorylation site of the invention. 
     In another aspect, the invention discloses immunoassays for binding, purifying, quantifying and otherwise generally detecting the phosphorylation of a protein or peptide at a novel phosphorylation site of the invention. 
     Also provided are pharmaceutical compositions and kits comprising one or more antibodies or peptides of the invention and methods of using them. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  is a diagram depicting the immuno-affinity isolation and mass-spectrometric characterization methodology (IAP) used in the Examples to identify the novel phosphorylation sites disclosed herein. 
         FIG. 2  is a western blot analysis of extracts from serum starved MKn45 cells, untreated or treated with Su11274 and from serum starved 3T3 cells, untreated or treated with insulin, using a phospho-4ET (Ser258) antibody (i.e., an antibody that specifically binds to the 4eT protein when it is phosphorylated on serine at position 258). The phospho-4ET (Ser258) antibody is a non-limiting example of an antibody of the present invention. Note that although this antibody recognizes phoshorylated serine 259 in context of the peptide set forth below as SEQ ID NO: 726, because of the alternate numbering of the amino acids in the full length protein, this antibody is referred to as being p-4ET (Se258)-specific (and not phospho-4ET (Ser259)-specific). 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The inventors have discovered and disclosed herein novel serine or threonine phosphorylation sites in signaling proteins extracted from the cell line/tissue/patient sample listed in column G of Table I. The newly discovered phosphorylation sites significantly extend our knowledge of kinase substrates and of the proteins in which the novel sites occur. The disclosure herein of the novel phosphorylation sites and reagents including peptides and antibodies specific for the sites add important new tools for the elucidation of signaling pathways that are associate with a host of biological processes including cell division, growth, differentiation, developmental changes and disease. Their discovery in carcinoma and leukemia cells provides and focuses further elucidation of the disease process. And, the novel sites provide additional diagnostic and therapeutic targets. 
     1. Novel Phosphorylation Sites in Carcinoma and Leukemia 
     In one aspect, the invention provides 726 novel serine or threonine phosphorylation sites in signaling proteins from cellular extracts from a variety of human carcinoma and leukemia-derived cell lines and tissue samples (such as HeLa, K562 and Jurkat etc., as further described below in Examples), identified using the techniques described in “Immunoaffinity Isolation of Modified Peptides From Complex Mixtures,” U.S. Patent Publication No. 20030044848, Rush et al. Table 1 summarizes the identified novel phosphorylation sites. 
     These phosphorylation sites thus occur in proteins found in carcinoma and leukemia. The sequences of the human homologues are publicly available in SwissProt database and their Accession numbers listed in Column B of Table 1. The novel sites occur in proteins such as: adaptor/scaffold proteins, kinase/protease/phosphatase/enzyme proteins, protein kinases, cytoskeletal proteins ubiquitan conjugating system proteins, chromatin or DNA binding/repair proteins, g proteins or regulator proteins, receptor/channel/transporter/cell surface proteins, transcriptional regulators and cell cycle regulation proteins. (see Column C of Table 1). 
     The novel phosphorylation sites of the invention were identified according to the methods described by Rush et al., U.S. Pat. Nos. 7,300,753 and 7,198,896, which are herein incorporated by reference in its entirety. Briefly, phosphorylation sites were isolated and characterized by immunoaffinity isolation and mass-spectrometric characterization (IAP) ( FIG. 1 ), using the following human carcinoma-derived cell lines and tissue samples: Jurkat, Adult mouse brain, Embryo mouse brain, H128, H1703, H3255, H446, H524, H838, HEL, HT29, HeLa, K562, Kyse140, M059J, M059K, MKN-45, mouse brain, mouse heart, mouse liver, MV4-11, N06CS91, SCLC T3, SEM, XY2(0607)-140. In addition to the newly discovered phosphorylation sites (all having a phosphorylatable serine or threonine), many known phosphorylation sites were also identified. 
     The immunoaffinity/mass spectrometric technique described in Rush et al, i.e., the “IAP” method, is described in detail in the Examples and briefly summarized below. 
     The IAP method generally comprises the following steps: (a) a proteinaceous preparation (e.g., a digested cell extract) comprising phosphopeptides from two or more different proteins is obtained from an organism; (b) the preparation is contacted with at least one immobilized antibody selected from the group consisting of AMPK/Snf1_BL6504 — 6, ATM/ATR, Akt — 9611, Akt — 9614, CDK — 2324, MAPK — 2325, MAPK — 4391, pho_tXR, PKA — 9621 — 9624, PKC_[KR]XsX[KR], RXX[st]P, SsP, [st], [st]F, [st]P, [st]PP, [st][DE]X[DE], [sty], tPE, YX[st]; (c) at least one phosphopeptide specifically bound by the immobilized antibody in step (b) is isolated; and (d) the modified peptide isolated in step (c) is characterized by mass spectrometry (MS) and/or tandem mass spectrometry (MS-MS). Subsequently, (e) a search program (e.g., Sequest) may be utilized to substantially match the spectra obtained for the isolated, modified peptide during the characterization of step (d) with the spectra for a known peptide sequence. A quantification step, e.g., using SILAC or AQUA, may also be used to quantify isolated peptides in order to compare peptide levels in a sample to a baseline. 
     In the IAP method as disclosed herein, utilized at least one immobilized antibody selected from the group consisting of AMPK/Snf1_BL6504 — 6, ATM/ATR, Akt — 9611, Akt — 9614, CDK — 2324, MAPK — 2325, MAPK — 4391, pho_tXR, PKA — 9621 — 9624, PKC_[KR]XsX[KR], RXX[st]P, SsP, [st], [st]F, [st]P, [st]PP, [st][DE]X[DE], [sty], tPE, YX[st] (See Cell Signaling Technology, Danvers MA Catalogue or Website) in the immunoaffinity step to isolate the widest possible number of phospho-serine and/or phosphothreonine containing peptides from the cell extracts. 
     As described in more detail in the Examples, lysates may be prepared from various carcinoma cell lines or tissue samples and digested with trypsin after treatment with DTT and iodoacetamide to alkylate cysteine residues. Before the immunoaffinity step, peptides may be pre-fractionated (e.g., by reversed-phase solid phase extraction using Sep-Pak C 18  columns) to separate peptides from other cellular components. The solid phase extraction cartridges may then be eluted (e.g., with acetonitrile). Each lyophilized peptide fraction can be redissolved and treated with at least one antibody selected from the group consisting of AMPK/Snf1_BL6504 — 6, ATM/ATR, Akt — 9611, Akt — 9614, CDK 2324, MAPK — 2325, MAPK — 4391, pho_tXR, PKA — 9621 — 9624, PKC_[KR]XsX[KR], RXX[st]P, SsP, [st], [st]F, [st]P, [st]PP, [st][DE]X[DE], [sty], tPE, YX[st] (See Cell Signaling Technology, Danvers MA Catalogue or Website) immobilized on protein Agarose. Immunoaffinity-purified peptides can be eluted and a portion of this fraction may be concentrated (e.g., with Stage or Zip tips) and analyzed by LC-MS/MS (e.g., using a ThermoFinnigan LCQ Deca XP Plus ion trap mass spectrometer or LTQ). MS/MS spectra can be evaluated using, e.g., the program Sequest with the NCBI human protein database. 
     The novel phosphorylation sites identified are summarized in Table 1. SEQ ID NOs: 1-726 were identified using Trypsin digestion of the parent proteins. Table I summarizes the 726 novel phosphorylation sites of the invention: For each row, the following parameters are shown. Column A lists the parent (signaling) proteins from which the phosphorylation sites are derived (i.e., the phosphorylation sites occur in these parent proteins); Column B sets forth the SwissProt accession number for the human homologue of the identified parent proteins; Column C lists the parent protein&#39;s protein type/classification; Column D sets forth the serine (S) or threonine (T) residues at which phosphorylation occurs (each number refers to the amino acid residue position of the serine or threonine in the parent human protein, according to the published sequence retrieved by the SwissProt accession number). Column E shows the flanking sequences of the phosphorylatable serine or threonine residues set forth in Column D. The sequences shown in Column E are from trypsin-digested peptides; in each sequence, the serine or threonine (see corresponding rows in Column D) appears in lowercase. Column F lists the particular type of disease(s) with which the phosphorylation site (of Column D) is associated. Column G lists the cell type(s)/Tissue/Patient Sample in which each of the phosphorylation sites (of Column D) was discovered; and Column H lists the SEQ ID NO of the trypsin-digested peptides identified in Column E. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Novel Serine and Threonine Phosphorylation Sites. 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                 E 
                   
                   
                 H 
                   
               
               
                   
                 A 
                   
                   
                 D 
                 Phosphorylation 
                   
                 Cell 
                 SEQ 
               
               
                   
                 Protein 
                 B 
                 C 
                 Phospho- 
                 Site 
                   
                 Line/ 
                 ID 
               
               
                 1 
                 Name 
                 Accession No. 
                 Protein Type 
                 Residue 
                 Sequence 
                 Diseases 
                 Tissue 
                 NO: 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 2 
                 2′-PDE 
                 Q6L8Q7.2 
                 Enzyme, misc. 
                 S222 
                 EAKPGAAEPEVGVPS 
                 cancer, leukemia 
                 Jurkat 
                 1 
                   
               
               
                   
                   
                   
                   
                   
                 SLSPSSPsSSWTETDV 
               
               
                   
                   
                   
                   
                   
                 EER 
               
               
                   
               
               
                 3 
                 53BP1 
                 NP_005648.1 
                 Transcriptional 
                 S320 
                 TVSSDGCsTPSREEG 
                 cancer, lung, 
                 H1703 
                 2 
               
               
                   
                   
                   
                 regulator 
                   
                 GCSLASTPATTLHLLQ 
                 non-small cell 
               
               
                   
                   
                   
                   
                   
                 LSGQR 
               
               
                   
               
               
                 4 
                 53BP1 
                 NP_005648.1 
                 Transcriptional 
                 T1055 
                 SEDPPtTPIR 
                 cancer, 
                 K562 
                 3 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 5 
                 ABCB6 
                 NP_005680.1 
                 Unassigned 
                 T444 
                 RAMNtQENATR 
                 cancer, cervical, 
                 HeLa 
                 4 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 6 
                 ABCB6 
                 NP_005680.1 
                 Unassigned 
                 T449 
                 RAMNTQENAtR 
                 cancer, cervical, 
                 HeLa 
                 5 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 7 
                 Abi-2 
                 NP_005750.4 
                 Adaptor/ 
                 S190 
                 GTLGRHsPYR 
                 cancer, leukemia 
                 Jurkat 
                 6 
               
               
                   
                   
                   
                 scaffold 
               
               
                   
               
               
                 8 
                 acinus 
                 NP_055792.1 
                 Apoptosis 
                 S115 
                 HsTPHAAFQPNSQIGE 
                 cancer, cervical, 
                 HeLa 
                 7 
               
               
                   
                   
                   
                   
                   
                 EMSQNSFIK 
                 adenocarcinoma 
               
               
                   
               
               
                 9 
                 ADD2 
                 NP_001608.1 
                 Cytoskeletal 
                 T711 
                 FRtPSFLK 
                 cancer, leukemia 
                 Jurkat 
                 8 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 10 
                 ADD3 
                 NP_001112.2 
                 Cytoskeletal 
                 T659 
                 FRtPSFLK 
                 cancer, leukemia 
                 Jurkat 
                 9 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 11 
                 ADSL 
                 NP_000017.1 
                 Enzyme, misc. 
                 S434 
                 IQVDAYFsPIHSQLDHL 
                 cancer, leukemia 
                 Jurkat 
                 10 
               
               
                   
                   
                   
                   
                   
                 LDPSSFTGR 
               
               
                   
               
               
                 12 
                 AEBP2 
                 Q6ZN18.2 
                 Transcriptional 
                 S241 
                 sTPAMMNGQGSTTSS 
                 cancer, lung, 
                 H1703 
                 11 
               
               
                   
                   
                   
                 regulator 
                   
                 SK 
                 non-small cell 
               
               
                   
               
               
                 13 
                 AF15q14 
                 NP_653091.2 
                 Cell cycle 
                 T412 
                 ILAMtPESIYSNPSIQG 
                 cancer, cervical, 
                 HeLa 
                 12 
               
               
                   
                   
                   
                 regulation 
                   
                 CK 
                 adenocarcinoma 
               
               
                   
               
               
                 14 
                 AF-4 
                 NP_005926.1 
                 Transcriptional 
                 S847 
                 IKSQSSSSSSSHKEsS 
                 cancer, leukemia 
                 Jurkat 
                 13 
               
               
                   
                   
                   
                 regulator 
                   
                 KTK 
               
               
                   
               
               
                 15 
                 AHCP 
                 NP_057339.1 
                 Receptor, 
                 T195 
                 TAAGIStPAPVAGLGPR 
                 cancer, leukemia 
                 Jurkat 
                 14 
               
               
                   
                   
                   
                 channel, 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 16 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 S637 
                 MPTFsTPGAK 
                 cancer, cervical, 
                 HeLa 
                 15 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 17 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T1192 
                 FKMPEMHFKtPK 
                 cancer, cervical, 
                 HeLa 
                 16 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 18 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T1986 
                 FKMPEMHFKtPK 
                 cancer, cervical, 
                 HeLa 
                 17 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 19 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T2181 
                 FKMPEMHFKtPK 
                 cancer, cervical, 
                 HeLa 
                 18 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 20 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T2309 
                 FKMPEMHFKtPK 
                 cancer, cervical, 
                 HeLa 
                 19 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 21 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T2832 
                 FKMPEMHFKtPK 
                 cancer, cervical, 
                 HeLa 
                 20 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 22 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T3366 
                 VQtPEVDVK 
                 cancer, cervical, 
                 HeLa 
                 21 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 23 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 S3426 
                 VSMPDVELNLKsPK 
                 cancer, leukemia 
                 Jurkat 
                 22 
               
               
                   
                   
                   
                 scaffold 
               
               
                   
               
               
                 24 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 S4516 
                 FKMPDVHFKsPQISMS 
                 cancer, cervical, 
                 HeLa 
                 23 
               
               
                   
                   
                   
                 scaffold 
                   
                 DIDLNLK 
                 adenocarcinoma 
               
               
                   
               
               
                 25 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 T5184 
                 VKtPSFGISAPQVSIPD 
                 cancer, cervical, 
                 HeLa 
                 24 
               
               
                   
                   
                   
                 scaffold 
                   
                 VNVNLKGPK 
                 adenocarcinoma 
               
               
                   
               
               
                 26 
                 AHNAK 
                 NP_001611.1 
                 Adaptor/ 
                 S5414 
                 LPQFGIsTPGSDLHVN 
                 cancer, cervical, 
                 HeLa 
                 25 
               
               
                   
                   
                   
                 scaffold 
                   
                 AK 
                 adenocarcinoma 
               
               
                   
               
               
                 27 
                 AKAP12 
                 NP_005091.2 
                 Adaptor/ 
                 S792 
                 SEDSIAGSGVEHsTPD 
                 cancer, cervical, 
                 HeLa 
                 26 
               
               
                   
                   
                   
                 scaffold 
                   
                 TEPGKEESWVSIK 
                 adenocarcinoma 
               
               
                   
               
               
                 28 
                 AKAP12 
                 NP_005091.2 
                 Adaptor/ 
                 T793 
                 SEDSIAGSGVEHStPD 
                 cancer, cervical, 
                 HeLa 
                 27 
               
               
                   
                   
                   
                 scaffold 
                   
                 TEPGKEESWVSIK 
                 adenocarcinoma 
               
               
                   
               
               
                 29 
                 AKAP12 
                 NP_005091.2 
                 Adaptor/ 
                 T1115 
                 VVGQtTPESFEKAPQV 
                 cancer, cervical, 
                 HeLa 
                 28 
               
               
                   
                   
                   
                 scaffold 
                   
                 TESIESSELVTTCQAE 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 TLAGVK 
               
               
                   
               
               
                 30 
                 AKAP12 
                 NP_005091.2 
                 Adaptor/ 
                 T1116 
                 VVGQTtPESFEK 
                 cancer, cervical, 
                 HeLa 
                 29 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 31 
                 AKAP12 
                 NP_005091.2 
                 Adaptor/ 
                 T1484 
                 StPVIVSATTK 
                 cancer, cervical, 
                 HeLa 
                 30 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 32 
                 AKAP13 
                 NP_009131.2 
                 Adaptor/ 
                 T813 
                 GtATPELHTATDYR 
                 cancer, cervical, 
                 HeLa 
                 31 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 33 
                 AKAP13 
                 NP_009131.2 
                 Adaptor/ 
                 T1149 
                 AVTDPQGVGtPEMIPL 
                 cancer, leukemia 
                 Jurkat 
                 32 
               
               
                   
                   
                   
                 scaffold 
                   
                 DWEK 
               
               
                   
               
               
                 34 
                 AKAP13 
                 NP_009131.2 
                 Adaptor/ 
                 T1887 
                 SAVLLVDETATtPIFAN 
                 cancer, cervical, 
                 HeLa 
                 33 
               
               
                   
                   
                   
                 scaffold 
                   
                 RR 
                 adenocarcinoma 
               
               
                   
               
               
                 35 
                 Akt1S1 
                 NP_115751.2 
                 Apoptosis 
                 T198 
                 tEARSSDEENGPPSSP 
                   
                 mouse 
                 34 
               
               
                   
                   
                   
                   
                   
                 DLDR 
                   
                 liver 
               
               
                   
               
               
                 36 
                 aldolase A 
                 NP_000025.1 
                 Enzyme, misc. 
                 T9 
                 PYQYPALtPEQK 
                 cancer, leukemia 
                 Jurkat 
                 35 
               
               
                   
               
               
                 37 
                 AML2 
                 NP_004341.1 
                 Transcriptional 
                 S211 
                 VTPsTPSPR 
                 cancer, cervical, 
                 HeLa 
                 36 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 38 
                 AML2 
                 NP_004341.1 
                 Transcriptional 
                 T212 
                 VTPStPSPR 
                 cancer, leukemia 
                 Jurkat 
                 37 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 39 
                 A-Myb 
                 NP_001073885.1 
                 Unassigned 
                 T442 
                 FStPPAILR 
                 cancer, cervical, 
                 HeLa 
                 38 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 40 
                 ANKHD1 
                 NP_060217.1 
                 Apoptosis 
                 T2323 
                 VFLQGPAPVGtPSFNR 
                 cancer, lung, 
                 H1703 
                 39 
               
               
                   
                   
                   
                   
                   
                   
                 non-small cell 
               
               
                   
               
               
                 41 
                 ANKRD17 
                 NP_942592.1 
                 Cell 
                 T735 
                 GGHTSVVCYLLDYPN 
                 cancer, cervical, 
                 HeLa 
                 40 
               
               
                   
                   
                   
                 development/ 
                   
                 NLLSAPPPDVTQLtPP 
                 adenocarcinoma 
               
               
                   
                   
                   
                 differentiation 
                   
                 SHDLNR 
               
               
                   
               
               
                 42 
                 ANKRD40 
                 NP_443087.1 
                 Unassigned 
                 T199 
                 DHTSLALVQNGDVSA 
                 cancer, leukemia 
                 Jurkat 
                 41 
               
               
                   
                   
                   
                   
                   
                 PSAILRtPESTKPGPVC 
               
               
                   
                   
                   
                   
                   
                 QPPVSQSR 
               
               
                   
               
               
                 43 
                 ANKRD53 
                 Q8N9V6.1 
                 Unassigned 
                 T84 
                 RPASLtPPR 
                 cancer, cervical, 
                 HeLa 
                 42 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 44 
                 AP-4 
                 NP_003214.1 
                 Transcriptional 
                 T37 
                 EVIGGLCSLANIPLtPE 
                 cancer, 
                 K562 
                 43 
               
               
                   
                   
                   
                 regulator 
                   
                 TQRDQER 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 45 
                 APRIN 
                 NP_055847.1 
                 Chromatin, 
                 S1366 
                 AESPESSAIEsTQSTP 
                 cancer, lung, 
                 H1703 
                 44 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 QKGR 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 46 
                 APXL 
                 NP_001640.1 
                 Receptor, 
                 S422 
                 FPQsPHSGR 
                 cancer, cervical, 
                 HeLa 
                 45 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 47 
                 ARC 
                 NP_003937.1 
                 Apoptosis 
                 T114 
                 SYDPPCPGHWtPEAP 
                 cancer, leukemia 
                 Jurkat 
                 46 
               
               
                   
                   
                   
                   
                   
                 GSGTTCPGLPR 
               
               
                   
               
               
                 48 
                 ARHGAP21 
                 Q5T5U3.1 
                 G protein or 
                 T233 
                 QQTStPVLTQPGR 
                 cancer, cervical, 
                 HeLa 
                 47 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 49 
                 ARHGAP23 
                 Q9P227.2 
                 G protein or 
                 T504 
                 KVQLtPAR 
                   
                 Adult 
                 48 
               
               
                   
                   
                   
                 regulator 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 50 
                 ARHGEF12 
                 NP_056128.1 
                 G protein or 
                 T703 
                 QVGETSAPGDTLDGtPR 
                 cancer, leukemia 
                 Jurkat 
                 49 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 51 
                 ARHGEF17 
                 NP_055601.2 
                 G protein or 
                 S418 
                 GSGGWGVYRsPSFGA 
                 cancer, cervical, 
                 HeLa 
                 50 
               
               
                   
                   
                   
                 regulator 
                   
                 GEGLLR 
                 adenocarcinoma 
               
               
                   
               
               
                 52 
                 ARID1A 
                 NP_006006.3 
                 Transcriptional 
                 T1599 
                 tSPSKSPFLHSGMK 
                 cancer, leukemia 
                 Jurkat 
                 51 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 53 
                 ARID1A 
                 NP_006006.3 
                 Transcriptional 
                 S1604 
                 TSPSKsPFLHSGMK 
                 cancer, leukemia 
                 Jurkat 
                 52 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 54 
                 ARID2 
                 NP_689854.2 
                 Unassigned 
                 S1724 
                 SSTKQPTVGGTsSTPR 
                 cancer, cervical, 
                 HeLa 
                 53 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 55 
                 ARID2 
                 NP_689854.2 
                 Unassigned 
                 T1726 
                 QPTVGGTSStPR 
                 cancer, leukemia 
                 Jurkat 
                 54 
               
               
                   
               
               
                 56 
                 ASH1L 
                 NP_060959.2 
                 Transcriptional 
                 S730 
                 WTKVVARSTCRsPKG 
                 cancer, cervical, 
                 HeLa 
                 55 
               
               
                   
                   
                   
                 regulator 
                   
                 LELER 
                 adenocarcinoma 
               
               
                   
               
               
                 57 
                 ATAD2 
                 NP_054828.2 
                 Unknown 
                 S337 
                 LSsAGPRSPYCK 
                 cancer, leukemia 
                 Jurkat 
                 56 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 58 
                 ATAD5 
                 NP_079133.3 
                 Unassigned 
                 T603 
                 ISStPTTETIR 
                 cancer, leukemia 
                 Jurkat 
                 57 
               
               
                   
               
               
                 59 
                 ATRX 
                 NP_000480.2 
                 Chromatin, 
                 T662 
                 VKTtPLR 
                 cancer, cervical, 
                 HeLa 
                 58 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 60 
                 B99 
                 Q9NYZ3.2 
                 Cell cycle 
                 T489 
                 VTVHStPVR 
                 cancer, cervical, 
                 HeLa 
                 59 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 61 
                 BASP1 
                 NP_006308.3 
                 Adaptor/ 
                 S182 
                 SDGAPASDSKPGSSE 
                 cancer, cervical, 
                 HeLa 
                 60 
               
               
                   
                   
                   
                 scaffold 
                   
                 AAPsSKETPAATEAPS 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 STPK 
               
               
                   
               
               
                 62 
                 BAT2D1 
                 NP_055987.2 
                 Cell cycle 
                 S1269 
                 GSETDTDsEIHESASD 
                 cancer, lung, 
                 H1703 
                 61 
               
               
                   
                   
                   
                 regulation 
                   
                 KDSLSK 
                 non-small cell 
               
               
                   
               
               
                 63 
                 BAT2D1 
                 NP_055987.2 
                 Cell cycle 
                 S1274 
                 RQRGSETDTDSEIHEs 
                 cancer, lung, 
                 H3255 
                 62 
               
               
                   
                   
                   
                 regulation 
                   
                 ASDKDSLSK 
                 non-small cell 
               
               
                   
               
               
                 64 
                 BAT2L 
                 Q5JSZ5.1 
                 Unknown 
                 S792 
                 VRSPDEALPGGLSGC 
                 cancer, cervical, 
                 HeLa 
                 63 
               
               
                   
                   
                   
                 function 
                   
                 SSGsGHSPYALER 
                 adenocarcinoma 
               
               
                   
               
               
                 65 
                 BAT2L iso6 
                 NP_037450.2 
                 Unknown 
                 S1139 
                 VASETHSEGsEYEELP 
                 cancer, 
                 K562 
                 64 
               
               
                   
                   
                   
                 function 
                   
                 KR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 66 
                 BAT8 
                 NP_006700.3 
                 Enzyme, misc. 
                 T44 
                 VHGSLGDtPR 
                 cancer, 
                 K562 
                 65 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 67 
                 BAT8 
                 NP_006700.3 
                 Enzyme, misc. 
                 S118 
                 SFPsSPSKGGSCPSR 
                 cancer, 
                 K562 
                 66 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 68 
                 BAT8 
                 NP_006700.3 
                 Enzyme, misc. 
                 S119 
                 SFPSsPSKGGSCPSR 
                 cancer, 
                 K562 
                 67 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 69 
                 BAZ1A 
                 NP_038476.2 
                 Chromatin, 
                 S1547 
                 LGLHVTPSNVDQVsTP 
                 cancer, lung, 
                 H1703 
                 68 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 PAAK 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 70 
                 BAZ2B 
                 NP_038478.2 
                 Unknown 
                 S450 
                 sLKKVIAALSNPKATSS 
                 cancer, cervical, 
                 HeLa 
                 69 
               
               
                   
                   
                   
                 function 
                   
                 SPAHPK 
                 adenocarcinoma 
               
               
                   
               
               
                 71 
                 BAZ2B 
                 NP_038478.2 
                 Unknown 
                 S466 
                 SLKKVIAALSNPKATSs 
                 cancer, cervical, 
                 HeLa 
                 70 
               
               
                   
                   
                   
                 function 
                   
                 SPAHPK 
                 adenocarcinoma 
               
               
                   
               
               
                 72 
                 BAZ2B 
                 NP_038478.2 
                 Unknown 
                 S467 
                 SLKKVIAALSNPKATSS 
                 cancer, cervical, 
                 HeLa 
                 71 
               
               
                   
                   
                   
                 function 
                   
                 sPAHPK 
                 adenocarcinoma 
               
               
                   
               
               
                 73 
                 BCAR3 
                 NP_038895.1 
                 Adaptor/ 
                 T124 
                 HIMDRtPEK 
                   
                 mouse 
                 72 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                   
                 liver 
               
               
                   
               
               
                 74 
                 Bcl-9 
                 NP_084209.3 
                 Transcriptional 
                 S154 
                 SsTPSHGQTTATEPTP 
                   
                 Embryo 
                 73 
               
               
                   
                   
                   
                 regulator 
                   
                 AQK 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 75 
                 Bcl-9L 
                 NP_872363.1 
                 Unknown 
                 T514 
                 LGQDSLtPEQVAWR 
                 cancer, cervical, 
                 HeLa 
                 74 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 76 
                 Bcr 
                 NP_067585.2 
                 Protein kinase, 
                 T693 
                 ISQNFLSSINEEItPR 
                 cancer, leukemia 
                 Jurkat 
                 75 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 77 
                 BDP1 
                 NP_001135842.1 
                 Phosphatase 
                 T286 
                 SAEEAPLYSKVtPR 
                 cancer, cervical, 
                 HeLa 
                 76 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 78 
                 BIKE 
                 NP_942595.1 
                 Protein kinase, 
                 T1014 
                 KTLKPTYRtPER 
                 cancer, 
                 HEL 
                 77 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 leukemia, acute 
               
               
                   
                   
                   
                 receptor) 
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 79 
                 BMP2KL 
                 XP_293293.1 
                 Unassigned 
                 T264 
                 KTLKPTYRtPER 
                 cancer, 
                 HEL 
                 78 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 80 
                 Borealin 
                 NP_060571.1 
                 Cell cycle 
                 T185 
                 LEVSMVKPtPGLTPR 
                 cancer, cervical, 
                 HeLa 
                 79 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 81 
                 Borealin 
                 NP_060571.1 
                 Cell cycle 
                 T199 
                 VFKtPGLRTPAAGER 
                 cancer, cervical, 
                 HeLa 
                 80 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 82 
                 BPAG1 
                 NP_065121.2 
                 Cytoskeletal 
                 S1056 
                 AMVDSQQKsPVKR 
                 cancer, cervical, 
                 HeLa 
                 81 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 83 
                 BPAG1 
                 NP_056363.2 
                 Cytoskeletal 
                 S5106 
                 AsSRRGSDASDFDISEI 
                 cancer, cervical, 
                 HeLa 
                 82 
               
               
                   
                   
                   
                 protein 
                   
                 QSVCSDVETVPQTHR 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 PTPR 
               
               
                   
               
               
                 84 
                 BPAG1 
                 NP_065121.2 
                 Cytoskeletal 
                 T1755 
                 CHCGEPEHEEtPENR 
                 cancer, cervical, 
                 HeLa 
                 83 
               
               
                   
                 iso7 
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 85 
                 BRCA2 
                 NP_000050.2 
                 Transcriptional 
                 T2035 
                 EENTAIRtPEHLISQK 
                 cancer, cervical, 
                 HeLa 
                 84 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 86 
                 BRD7 
                 NP_037395.2 
                 Transcriptional 
                 S289 
                 EREDSGDAEAHAFKs 
                 cancer, leukemia 
                 Jurkat 
                 85 
               
               
                   
                   
                   
                 regulator 
                   
                 PSKENK 
               
               
                   
               
               
                 87 
                 BRD7 
                 NP_037395.2 
                 Transcriptional 
                 S291 
                 EDSGDAEAHAFKSPsK 
                 cancer, leukemia 
                 Jurkat 
                 86 
               
               
                   
                   
                   
                 regulator 
                   
                 ENK 
               
               
                   
               
               
                 88 
                 BRD8 
                 NP_006687.3 
                 Transcriptional 
                 T175 
                 QAVKtPPR 
                 cancer, cervical, 
                 HeLa 
                 87 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 89 
                 Bsdc1 
                 Q9NW68.1 
                 Unassigned 
                 T378 
                 VFELNSDSGKStPSNN 
                 cancer, cervical, 
                 HeLa 
                 88 
               
               
                   
                   
                   
                   
                   
                 GK 
                 adenocarcinoma 
               
               
                   
               
               
                 90 
                 C10orf119 
                 NP_079110.1 
                 Unknown 
                 S162 
                 VSPSTSYTPsR 
                 cancer, cervical, 
                 HeLa 
                 89 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 91 
                 C10orf12 
                 NP_056467.2 
                 Unknown 
                 T1218 
                 ARPSTKtPESSAAQR 
                 cancer, cervical, 
                 HeLa 
                 90 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 92 
                 C10orf56 
                 Q8N2G6.1 
                 Unassigned 
                 S93 
                 GAsPYGSLNNIADGLS 
                 cancer, leukemia 
                 Jurkat 
                 91 
               
               
                   
                   
                   
                   
                   
                 SLTEHFSDLTLTSEAR 
               
               
                   
               
               
                 93 
                 C10orf56 
                 Q8N2G6.1 
                 Unassigned 
                 S97 
                 GASPYGsLNNIADGLS 
                 cancer, 
                 K562 
                 92 
               
               
                   
                   
                   
                   
                   
                 SLTEHFSDLTLTSEAR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 94 
                 C11orf56 
                 NP_001092264.1 
                 Unassigned 
                 T902 
                 DGAGLGLSGGSPGAS 
                 cancer, cervical, 
                 HeLa 
                 93 
               
               
                   
                   
                   
                   
                   
                 tPVLLTR 
                 adenocarcinoma 
               
               
                   
               
               
                 95 
                 C12orf41 
                 NP_060292.3 
                 Unknown 
                 T131 
                 TELGSQtPESSR 
                 cancer, leukemia 
                 Jurkat 
                 94 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 96 
                 C12orf52 
                 NP_116237.1 
                 Unassigned 
                 S248 
                 SVsISVPSTPR 
                 cancer, cervical, 
                 HeLa 
                 95 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 97 
                 C12orf52 
                 NP_116237.1 
                 Unassigned 
                 S253 
                 SVSISVPsTPR 
                 cancer, lung, 
                 H1703 
                 96 
               
               
                   
                   
                   
                   
                   
                   
                 non-small cell 
               
               
                   
               
               
                 98 
                 C14orf149 
                 NP_653182.1 
                 Unassigned 
                 S271 
                 PTTNICVFADEQVDRs 
                 cancer, gastric 
                 MKN- 
                 97 
               
               
                   
                   
                   
                   
                   
                 PTGSGVTARIALQYHK 
                   
                 45 
               
               
                   
               
               
                 99 
                 C14orf149 
                 NP_653182.1 
                 Unassigned 
                 T278 
                 PTTNICVFADEQVDRS 
                 cancer, gastric 
                 MKN- 
                 98 
               
               
                   
                   
                   
                   
                   
                 PTGSGVtARIALQYHK 
                   
                 45 
               
               
                   
               
               
                 100 
                 C15orf39 
                 NP_056307.2 
                 Unknown 
                 S322 
                 GTGYQAGGLGsPYLR 
                 cancer, cervical, 
                 HeLa 
                 99 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 101 
                 C15orf42 
                 NP_689472.3 
                 Unknown 
                 S820 
                 LAGVLPTDFFSDDSMT 
                 cancer, cervical, 
                 HeLa 
                 100 
               
               
                   
                   
                   
                 function 
                   
                 QENKsPLLSVPFLSSAR 
                 adenocarcinoma 
               
               
                   
               
               
                 102 
                 C15orf42 
                 NP_689472.3 
                 Unknown 
                 S1115 
                 SLsFSKTTPR 
                 cancer, leukemia 
                 Jurkat 
                 101 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 103 
                 C15orf42 
                 NP_689472.3 
                 Unknown 
                 T1120 
                 SLSFSKTtPR 
                 cancer, leukemia 
                 Jurkat 
                 102 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 104 
                 C22orf9 
                 NP_056079.1 
                 Unknown 
                 S294 
                 VTSFsTPPTPER 
                 cancer, leukemia 
                 Jurkat 
                 103 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 105 
                 C2orf33 
                 NP_064579.3 
                 Unknown 
                 S93 
                 IVVAGNNEDVsFSRPA 
                 cancer, cervical, 
                 HeLa 
                 104 
               
               
                   
                   
                   
                 function 
                   
                 DLDLIQSTPFKPLALKT 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 PPR 
               
               
                   
               
               
                 106 
                 C2orf33 
                 NP_064579.3 
                 Unknown 
                 T106 
                 IVVAGNNEDVSFSRPA 
                 cancer, cervical, 
                 HeLa 
                 105 
               
               
                   
                   
                   
                 function 
                   
                 DLDLIQStPFKPLALKT 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 PPR 
               
               
                   
               
               
                 107 
                 C2orf33 
                 NP_064579.3 
                 Unknown 
                 T115 
                 IVVAGNNEDVSFSRPA 
                 cancer, leukemia 
                 Jurkat 
                 106 
               
               
                   
                   
                   
                 function 
                   
                 DLDLIQSTPFKPLALKt 
               
               
                   
                   
                   
                   
                   
                 PPR 
               
               
                   
               
               
                 108 
                 C9orf5 
                 NP_114401.2 
                 Unassigned 
                 S30 
                 AVGPsGGGGETPR 
                 cancer, cervical, 
                 HeLa 
                 107 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 109 
                 CAF-1A 
                 NP_005474.2 
                 Chromatin, 
                 T309 
                 QHSStSPFPTSTPLRR 
                 cancer, cervical, 
                 HeLa 
                 108 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 110 
                 CAF-1A 
                 NP_005474.2 
                 Chromatin, 
                 S310 
                 QHSSTsPFPTSTPLRR 
                 cancer, leukemia 
                 Jurkat 
                 109 
               
               
                   
                   
                   
                 DNA-binding, 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 111 
                 CAF-1A 
                 NP_005474.2 
                 Chromatin, 
                 T316 
                 QHSSTSPFPTStPLRR 
                 cancer, cervical, 
                 HeLa 
                 110 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 112 
                 CAF-1B 
                 NP_005432.1 
                 Chromatin, 
                 T485 
                 RVtLNTLQAWSKTTPR 
                 cancer, cervical, 
                 HeLa 
                 111 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 113 
                 CAF-1B 
                 NP_005432.1 
                 Chromatin, 
                 T496 
                 RVTLNTLQAWSKTtPR 
                 cancer, cervical, 
                 HeLa 
                 112 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 114 
                 CAMSAP1 
                 Q5T5Y3.2 
                 Unknown 
                 T1389 
                 CSStPDNLSR 
                 cancer, cervical, 
                 HeLa 
                 113 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 115 
                 CCDC130 
                 NP_110445.1 
                 Unknown 
                 S306 
                 SRDVPEsPQHAADTPK 
                 cancer, lung, 
                 H446 
                 114 
               
               
                   
                   
                   
                 function 
                   
                   
                 small-cell 
               
               
                   
               
               
                 116 
                 CCDC130 
                 NP_110445.1 
                 Unknown 
                 T313 
                 SRDVPESPQHAADtPK 
                 cancer, leukemia 
                 Jurkat 
                 115 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 117 
                 CCDC50 
                 NP_777568.1 
                 Inhibitor 
                 T162 
                 EAVStPSR 
                 cancer, cervical, 
                 HeLa 
                 116 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 118 
                 CCDC6 
                 NP_005427.2 
                 Cytoskeletal 
                 S395 
                 AGMSYYNsPGLHVQH 
                 cancer, cervical, 
                 HeLa 
                 117 
               
               
                   
                   
                   
                 protein 
                   
                 MGTSHGITRPSPR 
                 adenocarcinoma 
               
               
                   
               
               
                 119 
                 CCDC6 
                 NP_005427.2 
                 Cytoskeletal 
                 T410 
                 AGMSYYNSPGLHVQH 
                 cancer, cervical, 
                 HeLa 
                 118 
               
               
                   
                   
                   
                 protein 
                   
                 MGTSHGItRPSPR 
                 adenocarcinoma 
               
               
                   
               
               
                 120 
                 CCDC6 
                 NP_005427.2 
                 Cytoskeletal 
                 S413 
                 AGMSYYNSPGLHVQH 
                 cancer, cervical, 
                 HeLa 
                 119 
               
               
                   
                   
                   
                 protein 
                   
                 MGTSHGITRPsPR 
                 adenocarcinoma 
               
               
                   
               
               
                 121 
                 CCDC9 
                 NP_056418.1 
                 Unknown 
                 T381 
                 EGAASPAPEtPQPTSP 
                 cancer, cervical, 
                 HeLa 
                 120 
               
               
                   
                   
                   
                 function 
                   
                 ETSPK 
                 adenocarcinoma 
               
               
                   
               
               
                 122 
                 CD2AP 
                 NP_036252.1 
                 Adaptor/ 
                 S556 
                 DTCYSPKPSVYLSTPS 
                 cancer, cervical, 
                 HeLa 
                 121 
               
               
                   
                   
                   
                 scaffold 
                   
                 SAsK 
                 adenocarcinoma 
               
               
                   
               
               
                 123 
                 CDAN1 
                 NP_612486.2 
                 Unassigned 
                 T71 
                 VLPQGPPtPAK 
                 cancer, cervical, 
                 HeLa 
                 122 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 124 
                 CDC5L 
                 NP_001244.1 
                 Transcriptional 
                 S427 
                 sGTTPKPVINSTPGRT 
                 cancer, cervical, 
                 HeLa 
                 123 
               
               
                   
                   
                   
                 regulator 
                   
                 PLRDK 
                 adenocarcinoma 
               
               
                   
               
               
                 125 
                 CENPH 
                 NP_075060.1 
                 Cell cycle 
                 T68 
                 SMVDASEEKtPEQIMQ 
                 cancer, lung, 
                 H838 
                 124 
               
               
                   
                   
                   
                 regulation 
                   
                 EK 
                 non-small cell 
               
               
                   
               
               
                 126 
                 CENPT 
                 NP_079358.3 
                 Chromatin, 
                 T27 
                 VLDTADPRtPR 
                 cancer, 
                 SEM 
                 125 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 leukemia, acute 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                 DNA replication 
                   
                   
                 (ALL) 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 127 
                 CEP4 
                 NP_079285.2 
                 Unknown 
                 T488 
                 SSIFRtPEKGDYNSEIH 
                 cancer, 
                 SEM 
                 126 
               
               
                   
                   
                   
                 function 
                   
                 QITR 
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 128 
                 CEPT1 
                 NP_006081.1 
                 Unassigned 
                 T40 
                 LFQLPtPPLSR 
                   
                 mouse 
                 127 
               
               
                   
                   
                   
                   
                   
                   
                   
                 liver 
               
               
                   
               
               
                 129 
                 ChaK1 
                 NP_060142.3 
                 Protein kinase, 
                 T555 
                 NTSSStPQLR 
                 cancer, cervical, 
                 HeLa 
                 128 
               
               
                   
                   
                   
                 atypical 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 130 
                 CHD-1 
                 NP_001261.2 
                 Enzyme, misc. 
                 S1683 
                 ASSSGPRSPLDQRsP 
                 cancer, leukemia 
                 Jurkat 
                 129 
               
               
                   
                   
                   
                   
                   
                 YGSR 
               
               
                   
               
               
                 131 
                 CHD-1 
                 NP_001261.2 
                 Enzyme, misc. 
                 S1687 
                 SPYGsRSPFEHSVEHK 
                 cancer, leukemia 
                 Jurkat 
                 130 
               
               
                   
               
               
                 132 
                 CHD-2 
                 NP_001262.3 
                 Chromatin, 
                 S1795 
                 SPPSQKsPHDSKSPLD 
                 cancer, cervical, 
                 HeLa 
                 131 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 HR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 133 
                 CHD-3 
                 NP_005843.2 
                 Chromatin, 
                 S324 
                 KGGSYVFQSDEGPEP 
                 cancer, cervical, 
                 HeLa 
                 132 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 EAEEsDLDSGSVHSAS 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
                   
                 GRPDGPVR 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 134 
                 CHD-3 
                 NP_005843.2 
                 Chromatin, 
                 T1535 
                 ASSPtKTSPTTPEASAT 
                 cancer, cervical, 
                 HeLa 
                 133 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 NSPCTSKPATPAPSEK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
                   
                 GEGIR 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 135 
                 CHD-3 
                 NP_005843.2 
                 Chromatin, 
                 S1545 
                 TSPTTPEAsATNSPCT 
                 cancer, cervical, 
                 HeLa 
                 134 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SKPATPAPSEK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 136 
                 CHD-3 
                 NP_005843.2 
                 Chromatin, 
                 T1552 
                 TSPTTPEASATNSPCt 
                 cancer, cervical, 
                 HeLa 
                 135 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SKPATPAPSEK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 137 
                 CHD-3 
                 NP_666131.2 
                 Chromatin, 
                 S1585 
                 ASsPTKTSPTTPEASA 
                   
                 Embryo 
                 136 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 TNSPCTSKPATPAPSEK 
                   
                 mouse 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                   
                 brain 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 138 
                 CHD-3 
                 NP_666131.2 
                 Chromatin, 
                 T1592 
                 ASSPTKTSPtTPEASAT 
                   
                 Embryo 
                 137 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 NSPCTSKPATPAPSEK 
                   
                 mouse 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                   
                 brain 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 139 
                 CHD-3 
                 NP_666131.2 
                 Chromatin, 
                 T1599 
                 TSPTTPEASAtNSPCT 
                   
                 Embryo 
                 138 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SKPATPAPSEKGEGIR 
                   
                 mouse 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                   
                 brain 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 140 
                 CHD-7 
                 NP_060250.2 
                 Chromatin, 
                 T1555 
                 NNLVIDtPR 
                 cancer, cervical, 
                 HeLa 
                 139 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 141 
                 CHD-8 
                 NP_065971.2 
                 Transcriptional 
                 T1703 
                 CStPLLHQQYTSR 
                 cancer, leukemia 
                 Jurkat 
                 140 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 142 
                 CHED 
                 NP_003709.3 
                 Protein kinase, 
                 S352 
                 SRKSPSPAGGGSSPY 
                 cancer, lung, 
                 XY2 
                 141 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 sR 
                 non-small cell 
                 (0607)- 
               
               
                   
                   
                   
                 receptor) 
                   
                   
                   
                 140 
               
               
                   
               
               
                 143 
                 CHED 
                 NP_003709.3 
                 Protein kinase, 
                 S363 
                 RLPRSPSPYsR 
                 cancer, 
                 SEM 
                 142 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 leukemia, acute 
               
               
                   
                   
                   
                 receptor) 
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 144 
                 CHED 
                 NP_003709.3 
                 Protein kinase, 
                 S374 
                 SPSYSRHsSYERGGD 
                 cancer, cervical, 
                 HeLa 
                 143 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 VSPSPYSSSSWR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 145 
                 CHED 
                 NP_003709.3 
                 Protein kinase, 
                 S390 
                 SPSYSRHSSYERGGD 
                 cancer, cervical, 
                 HeLa 
                 144 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 VSPSPYSSsSWR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 146 
                 CIP29 
                 NP_149073.1 
                 Unassigned 
                 T100 
                 ITSEIPQtER 
                 cancer, cervical, 
                 HeLa 
                 145 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 147 
                 CIZ1 
                 NP_036259.2 
                 Cell cycle 
                 S584 
                 PSDSVSSTPAATsTPSK 
                 cancer, cervical, 
                 HeLa 
                 146 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 148 
                 CIZ1 
                 NP_036259.2 
                 Cell cycle 
                 T585 
                 PSDSVSSTPAATStPSK 
                 cancer, cervical, 
                 HeLa 
                 147 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 149 
                 CLASP2 
                 NP_055912.1 
                 Cytoskeletal 
                 S1246 
                 DYNPYNYSDSISPFNK 
                 cancer, cervical, 
                 HeLa 
                 148 
               
               
                   
                   
                   
                 protein 
                   
                 sALK 
                 adenocarcinoma 
               
               
                   
               
               
                 150 
                 claudin 1 
                 NP_066924.1 
                 Cytoskeletal 
                 T195 
                 KTTSYPtPR 
                 cancer, cervical, 
                 HeLa 
                 149 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 151 
                 CLOCK 
                 NP_004889.1 
                 Transcriptional 
                 S460 
                 IPTDTsTPPR 
                 cancer, cervical, 
                 HeLa 
                 150 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 152 
                 cofilin 1 
                 NP_005498.1 
                 Cytoskeletal 
                 T25 
                 KSStPEEVK 
                 cancer, leukemia 
                 Jurkat 
                 151 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 153 
                 COL18A1 
                 NP_569712.2 
                 Unassigned 
                 S755 
                 GsPGPKGEK 
                 cancer, cervical, 
                 HeLa 
                 152 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 154 
                 COP, beta 
                 NP_004757.1 
                 Vesicle protein 
                 S847 
                 DFQPSRsTAQQELDG 
                 cancer, cervical, 
                 HeLa 
                 153 
               
               
                   
                 prime 
                   
                   
                   
                 KPASPTPVIVASHTANK 
                 adenocarcinoma 
               
               
                   
               
               
                 155 
                 cordon- 
                 NP_056013.2 
                 Cytoskeletal 
                 T794 
                 GPPStPVPTQTQNPESR 
                 cancer, cervical, 
                 HeLa 
                 154 
               
               
                   
                 bleu 
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 156 
                 CRIK 
                 NP_009105.1 
                 Protein kinase, 
                 S1305 
                 KATDHPHPsTPATAR 
                 cancer, leukemia 
                 Jurkat 
                 155 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 157 
                 CRIK 
                 NP_009105.1 
                 Protein kinase, 
                 T1306 
                 ATDHPHPStPATAR 
                 cancer, leukemia 
                 Jurkat 
                 156 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 158 
                 CRIK 
                 NP_009105.1 
                 Protein kinase, 
                 T1345 
                 ESStPEEFSR 
                 cancer, cervical, 
                 HeLa 
                 157 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 159 
                 CRIK 
                 NP_009105.1 
                 Protein kinase, 
                 T1955 
                 VASSPAPPEGPSHPR 
                   
                 Adult 
                 158 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 EPStPHR 
                   
                 mouse 
               
               
                   
                   
                   
                 receptor) 
                   
                   
                   
                 brain 
               
               
                   
               
               
                 160 
                 CRMP-4 
                 ABV80252.1 
                 Enzyme, misc. 
                 T85 
                 GSGSRPGIEGDtPR 
                 cancer, cervical, 
                 HeLa 
                 159 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 161 
                 CRMP-4 
                 ABV80252.1 
                 Enzyme, misc. 
                 S586 
                 FIPCsPFSDYVYK 
                   
                 Embryo 
                 160 
               
               
                   
                   
                   
                   
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 162 
                 CSIG 
                 NP_056474.2 
                 RNA 
                 S400 
                 HATGKKSPAKSPNPsT 
                 cancer, lung, 
                 H1703 
                 161 
               
               
                   
                   
                   
                 processing 
                   
                 PR 
                 non-small cell 
               
               
                   
               
               
                 163 
                 DAB2 
                 NP_001334.2 
                 Adaptor/ 
                 S325 
                 KENSsSSSTPLSNGPL 
                 cancer, cervical, 
                 HeLa 
                 162 
               
               
                   
                   
                   
                 scaffold 
                   
                 NGDVDYFGQQFDQIS 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 NR 
               
               
                   
               
               
                 164 
                 DAB2 
                 NP_001334.2 
                 Adaptor/ 
                 S327 
                 KENSSSsSTPLSNGPL 
                 cancer, cervical, 
                 HeLa 
                 163 
               
               
                   
                   
                   
                 scaffold 
                   
                 NGDVDYFGQQFDQIS 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 NR 
               
               
                   
               
               
                 165 
                 DAB2 
                 NP_001334.2 
                 Adaptor/ 
                 T329 
                 KENSSSSStPLSNGPL 
                 cancer, cervical, 
                 HeLa 
                 164 
               
               
                   
                   
                   
                 scaffold 
                   
                 NGDVDYFGQQFDQIS 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 NR 
               
               
                   
               
               
                 166 
                 DAG1 
                 NP_004384.2 
                 Cytoskeletal 
                 S888 
                 NMTPYRsPPPYVPP 
                   
                 Embryo 
                 165 
               
               
                   
                   
                   
                 protein 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 167 
                 DARS2 
                 NP_060592.2 
                 Enzyme, misc. 
                 S242 
                 FYSLPQsPQQFK 
                 cancer, 
                 K562 
                 166 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 168 
                 DATF1 
                 NP_542987.2 
                 Transcriptional 
                 S1036 
                 SILAKPSSSPDPRYLS 
                 cancer, cervical, 
                 HeLa 
                 167 
               
               
                   
                   
                   
                 regulator 
                   
                 VPPSPNISTsESR 
                 adenocarcinoma 
               
               
                   
               
               
                 169 
                 DBC-1 
                 NP_954675.1 
                 Apoptosis 
                 T484 
                 RNAEtPEATTQQETDT 
                 cancer, cervical, 
                 HeLa 
                 168 
               
               
                   
                   
                   
                   
                   
                 DLPEAPPPPLEPAVIAR 
                 adenocarcinoma 
               
               
                   
               
               
                 170 
                 DCAMKL2 
                 NP_001035351.3 
                 Protein kinase, 
                 S306 
                 YSGsKSPGPSRRSKS 
                 cancer, cervical, 
                 HeLa 
                 169 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 PASVNGTPSSQLSTPK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 171 
                 DCAMKL2 
                 NP_001035351.3 
                 Protein kinase, 
                 S327 
                 YSGSKSPGPSRRSKS 
                 cancer, cervical, 
                 HeLa 
                 170 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 PASVNGTPSsQLSTPK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 172 
                 DCAMKL2 
                 NP_001035351.3 
                 Protein kinase, 
                 T331 
                 YSGSKSPGPSRRSKS 
                 cancer, 
                 K562 
                 171 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 PASVNGTPSSQLStPK 
                 leukemia, 
               
               
                   
                   
                   
                 receptor) 
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 173 
                 DCBLD1 
                 EAW48207.1 
                 Unknown 
                 T602 
                 HEYALPLAPPEPEYAt 
                 cancer, leukemia 
                 Jurkat 
                 172 
               
               
                   
                   
                   
                 function 
                   
                 PIVER 
               
               
                   
               
               
                 174 
                 DCP1A 
                 NP_060873.3 
                 RNA 
                 T348 
                 NSTMMQAVKTtPR 
                 cancer, leukemia 
                 Jurkat 
                 173 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 175 
                 DCP1A 
                 NP_060873.3 
                 RNA 
                 S422 
                 GAMVASFsPAAGQLA 
                 cancer, cervical, 
                 HeLa 
                 174 
               
               
                   
                   
                   
                 processing 
                   
                 TPESFIEPPSK 
                 adenocarcinoma 
               
               
                   
               
               
                 176 
                 DCP1A 
                 NP_060873.3 
                 RNA 
                 S433 
                 GAMVASFSPAAGQLA 
                 cancer, cervical, 
                 HeLa 
                 175 
               
               
                   
                   
                   
                 processing 
                   
                 TPEsFIEPPSK 
                 adenocarcinoma 
               
               
                   
               
               
                 177 
                 DENND4C 
                 NP_060395.4 
                 Receptor, 
                 T1078 
                 FKQQtPSR 
                 cancer, cervical, 
                 HeLa 
                 176 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 178 
                 Destrin 
                 NP_006861.1 
                 Cytoskeletal 
                 T25 
                 CStPEEIK 
                   
                 Adult 
                 177 
               
               
                   
                   
                   
                 protein 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 179 
                 DHX38 
                 NP_054722.2 
                 RNA 
                 T265 
                 GKYSDDtPLPTPSYK 
                 cancer, lung, 
                 H1703 
                 178 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 180 
                 DHX38 
                 NP_054722.2 
                 RNA 
                 T269 
                 GKYSDDTPLPtPSYK 
                 cancer, lung, 
                 H1703 
                 179 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 181 
                 DKFZP547 
                 NP_849152.1 
                 Unknown 
                 S84 
                 MITNSLNHDsPPSTPP 
                 cancer, lung, 
                 H1703 
                 180 
               
               
                   
                 B1415 
                   
                 function 
                   
                 RRPDTSTSK 
                 non-small cell 
               
               
                   
               
               
                 182 
                 DKFZP547 
                 NP_849152.1 
                 Unknown 
                 S87 
                 MITNSLNHDSPPsTPP 
                 cancer, cervical, 
                 HeLa 
                 181 
               
               
                   
                 B1415 
                   
                 function 
                   
                 RRPDTSTSK 
                 adenocarcinoma 
               
               
                   
               
               
                 183 
                 DKFZp686 
                 Q6MZP7.2 
                 Unknown 
                 T280 
                 VLSQSTPGtPSK 
                 cancer, lung, 
                 H1703 
                 182 
               
               
                   
                 L1814 
                   
                 function 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 184 
                 DNAJB1 
                 NP_006136.1 
                 Chaperone 
                 T307 
                 KVPGEGLPLPKtPEKR 
                 cancer, cervical, 
                 HeLa 
                 183 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 185 
                 DNCI2 
                 NP_001369.1 
                 Motor or 
                 S92 
                 sVSTPSEAGSQDSGD 
                 cancer, lung, 
                 H1703 
                 184 
               
               
                   
                   
                   
                 contractile 
                   
                 GAVGSR 
                 non-small cell 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 186 
                 DNMBP 
                 NP_056036.1 
                 Adaptor/ 
                 S1436 
                 CPsDPDSTSQPR 
                 cancer, cervical, 
                 HeLa 
                 185 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 187 
                 DOCK1 
                 NP_001371.1 
                 Adaptor/ 
                 T1772 
                 FSVSPSSPSSQQTPP 
                 cancer, cervical, 
                 HeLa 
                 186 
               
               
                   
                   
                   
                 scaffold 
                   
                 PVtPR 
                 adenocarcinoma 
               
               
                   
               
               
                 188 
                 DOCK7 
                 NP_212132.2 
                 G protein or 
                 T186 
                 SMSIDDtPR 
                 cancer, cervical, 
                 HeLa 
                 187 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 189 
                 DRPLA 
                 NP_001931.2 
                 Ubiquitin 
                 S168 
                 PYHPPPLFPPsPQPPD 
                 cancer, cervical, 
                 HeLa 
                 188 
               
               
                   
                   
                   
                 conjugating 
                   
                 STPR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 system 
               
               
                   
               
               
                 190 
                 DSCR2 
                 NP_003711.1 
                 Endoplasmic 
                 T31 
                 AGTEDEEEEEEGRREt 
                 cancer, cervical, 
                 HeLa 
                 189 
               
               
                   
                   
                   
                 reticulum or 
                   
                 PEDR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 golgi 
               
               
                   
               
               
                 191 
                 elF4ENIF1 
                 NP_062817.1 
                 Receptor, 
                 S766 
                 SsCSTPLSQANR 
                 cancer, cervical, 
                 HeLa 
                 190 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 192 
                 elF4G 
                 NP_004944.2 
                 Translation 
                 S8 
                 TAsTPTPPQTGGGLEP 
                 cancer, lung, 
                 H1703 
                 191 
               
               
                   
                   
                   
                   
                   
                 QANGETPQVAVIVRPD 
                 non-small cell 
               
               
                   
                   
                   
                   
                   
                 DR 
               
               
                   
               
               
                 193 
                 elF4G 
                 NP_004944.2 
                 Translation 
                 T471 
                 LQGINCGPDFtPSFAN 
                 cancer, cervical, 
                 HeLa 
                 192 
               
               
                   
                   
                   
                   
                   
                 LGR 
                 adenocarcinoma 
               
               
                   
               
               
                 194 
                 Elf-2 
                 NP_006865.1 
                 Unassigned 
                 T461 
                 LSMPTQQASGQtPPR 
                 cancer, cervical, 
                 HeLa 
                 193 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 195 
                 ELG 
                 NP_061023.1 
                 Transcriptional 
                 S132 
                 MIsTPSPK 
                 cancer, leukemia 
                 Jurkat 
                 194 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 196 
                 ELP4 
                 NP_061913.3 
                 Unknown 
                 T151 
                 EFDEDVYNHKtPESNIK 
                 cancer, cervical, 
                 HeLa 
                 195 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 197 
                 EPB41L2 
                 NP_001422.1 
                 Cytoskeletal 
                 S908 
                 TITYEsPQIDGGAGGD 
                 cancer, cervical, 
                 HeLa 
                 196 
               
               
                   
                   
                   
                 protein 
                   
                 SGTLLTAQTITSESVST 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 TTTTHITK 
               
               
                   
               
               
                 198 
                 ESX1L 
                 Q8N693.3 
                 Unassigned 
                 T55 
                 PEYGtEAENNVGTEGS 
                 cancer, cervical, 
                 HeLa 
                 197 
               
               
                   
                   
                   
                   
                   
                 VPSDDQDR 
                 adenocarcinoma 
               
               
                   
               
               
                 199 
                 ESX1L 
                 Q8N693.3 
                 Unassigned 
                 S69 
                 PEYGTEAENNVGTEG 
                 cancer, cervical, 
                 HeLa 
                 198 
               
               
                   
                   
                   
                   
                   
                 SVPsDDQDR 
                 adenocarcinoma 
               
               
                   
               
               
                 200 
                 ETV3 
                 P41162.2 
                 Unassigned 
                 S245 
                 PGMYPDPHsPFAVSPI 
                 cancer, 
                 K562 
                 199 
               
               
                   
                   
                   
                   
                   
                 PGR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 201 
                 ETV3 
                 P41162.2 
                 Unassigned 
                 S250 
                 PGMYPDPHSPFAVsPI 
                 cancer, 
                 K562 
                 200 
               
               
                   
                   
                   
                   
                   
                 PGR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 202 
                 FALZ 
                 NP_004450.3 
                 Transcriptional 
                 T2241 
                 GQPVSTAVSAPNTVS 
                 cancer, cervical, 
                 HeLa 
                 201 
               
               
                   
                   
                   
                 regulator 
                   
                 StPGQK 
                 adenocarcinoma 
               
               
                   
               
               
                 203 
                 FAM105B 
                 NP_612357.4 
                 Unassigned 
                 T20 
                 GTMPQPEAWPGASC 
                 cancer, cervical, 
                 HeLa 
                 202 
               
               
                   
                   
                   
                   
                   
                 AEtPAR 
                 adenocarcinoma 
               
               
                   
               
               
                 204 
                 FAM21A 
                 NP_001005751.1 
                 Unassigned 
                 S1091 
                 AASGEDsTEEALAAAA 
                 cancer, leukemia 
                 Jurkat 
                 203 
               
               
                   
                   
                   
                   
                   
                 APWEGGPVPGVDRSP 
               
               
                   
                   
                   
                   
                   
                 FAK 
               
               
                   
               
               
                 205 
                 FAM21B 
                 NP_060702.1 
                 Unassigned 
                 S1003 
                 AASGEDsTEEALAAAA 
                 cancer, leukemia 
                 Jurkat 
                 204 
               
               
                   
                   
                   
                   
                   
                 APWEGGPVPGVDRSP 
               
               
                   
                   
                   
                   
                   
                 FAK 
               
               
                   
               
               
                 206 
                 FAM29A 
                 NP_060115.3 
                 Unknown 
                 S854 
                 KREESYLsNSQTPER 
                 cancer, cervical, 
                 HeLa 
                 205 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 207 
                 FBLIM1 
                 NP_001019386.1 
                 Unassigned 
                 T51 
                 GRPWEAPAPMKtPEA 
                 cancer, cervical, 
                 HeLa 
                 206 
               
               
                   
                   
                   
                   
                   
                 GLAGRPSPWTTPGR 
                 adenocarcinoma 
               
               
                   
               
               
                 208 
                 FBLIM1 
                 NP_001019386.1 
                 Unassigned 
                 S61 
                 GRPWEAPAPMKTPEA 
                 cancer, cervical, 
                 HeLa 
                 207 
               
               
                   
                   
                   
                   
                   
                 GLAGRPsPWTTPGR 
                 adenocarcinoma 
               
               
                   
               
               
                 209 
                 FBLIM1 
                 NP_001019386.1 
                 Unassigned 
                 T64 
                 GRPWEAPAPMKTPEA 
                 cancer, cervical, 
                 HeLa 
                 208 
               
               
                   
                   
                   
                   
                   
                 GLAGRPSPWtTPGR 
                 adenocarcinoma 
               
               
                   
               
               
                 210 
                 FBP1 
                 NP_003893.2 
                 Transcriptional 
                 T318 
                 IQFKPDDGTtPER 
                 cancer, cervical, 
                 HeLa 
                 209 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 211 
                 FBP3 
                 NP_003925.1 
                 Transcriptional 
                 T130 
                 IQIASESSGIPERPCVL 
                 cancer, cervical, 
                 HeLa 
                 210 
               
               
                   
                   
                   
                 regulator 
                   
                 TGtPESIEQAK 
                 adenocarcinoma 
               
               
                   
               
               
                 212 
                 FBP3 
                 NP_003925.1 
                 Transcriptional 
                 S439 
                 VGGTNLGAPGAFGQs 
                 cancer, cervical, 
                 HeLa 
                 211 
               
               
                   
                   
                   
                 regulator 
                   
                 PFSQPPAPPHQNTFP 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 PR 
               
               
                   
               
               
                 213 
                 FBXL19 
                 NP_001093254.2 
                 Unknown 
                 T225 
                 EAGNEPPtPR 
                 cancer, 
                 K562 
                 212 
               
               
                   
                   
                   
                 function 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 214 
                 FBXW9 
                 NP_115677.2 
                 Unassigned 
                 S22 
                 TWDDDSDPEsETDPD 
                 cancer, cervical, 
                 HeLa 
                 213 
               
               
                   
                   
                   
                   
                   
                 AQAK 
                 adenocarcinoma 
               
               
                   
               
               
                 215 
                 FBXW9 
                 NP_115677.2 
                 Unassigned 
                 S59 
                 SGLAFSRPSQLSTPAA 
                 cancer, cervical, 
                 HeLa 
                 214 
               
               
                   
                   
                   
                   
                   
                 sPSASEPR 
                 adenocarcinoma 
               
               
                   
               
               
                 216 
                 FIP1L1 
                 NP_112179.2 
                 RNA 
                 T591 
                 EAGSEPAPEQESTEAt 
                 cancer, lung, 
                 H1703 
                 215 
               
               
                   
                   
                   
                 processing 
                   
                 PAE 
                 non-small cell 
               
               
                   
               
               
                 217 
                 FLI1 
                 NP_002008.2 
                 Transcriptional 
                 S241 
                 GAWGNNMNSGLNKsP 
                 cancer, leukemia 
                 Jurkat 
                 216 
               
               
                   
                   
                   
                 regulator 
                   
                 PLGGAQTISK 
               
               
                   
               
               
                 218 
                 FLJ21908 
                 Q9H6T3.2 
                 Unknown 
                 T491 
                 NSSQDDLFPTSDtPR 
                 cancer, cervical, 
                 HeLa 
                 217 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 219 
                 FLJ23518 
                 NP_079001.2 
                 Unknown 
                 S219 
                 RVVEDEGsSVEMEQK 
                 cancer, cervical, 
                 HeLa 
                 218 
               
               
                   
                   
                   
                 function 
                   
                 TPEK 
                 adenocarcinoma 
               
               
                   
               
               
                 220 
                 FLJ23518 
                 NP_079001.2 
                 Unknown 
                 S220 
                 RVVEDEGSsVEMEQK 
                 cancer, cervical, 
                 HeLa 
                 219 
               
               
                   
                   
                   
                 function 
                   
                 TPEK 
                 adenocarcinoma 
               
               
                   
               
               
                 221 
                 FLJ23518 
                 NP_079001.2 
                 Unknown 
                 T227 
                 RVVEDEGSSVEMEQK 
                 cancer, leukemia 
                 Jurkat 
                 220 
               
               
                   
                   
                   
                 function 
                   
                 tPEK 
               
               
                   
               
               
                 222 
                 FLNA 
                 NP_001447.2 
                 Transcriptional 
                 S1055 
                 EEGPYEVEVTYDGVP 
                 cancer, leukemia 
                 Jurkat 
                 221 
               
               
                   
                   
                   
                 regulator 
                   
                 VPGsPFPLEAVAPTKP 
               
               
                   
                   
                   
                   
                   
                 SK 
               
               
                   
               
               
                 223 
                 FLNA 
                 NP_001447.2 
                 Transcriptional 
                 S1342 
                 VEYTPYEEGLHSVDVT 
                 cancer, cervical, 
                 HeLa 
                 222 
               
               
                   
                   
                   
                 regulator 
                   
                 YDGSPVPsSPFQVPVT 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 EGCDPSR 
               
               
                   
               
               
                 224 
                 FLNA 
                 NP_001447.2 
                 Transcriptional 
                 S1522 
                 EGPYSIsVLYGDEEVP 
                 cancer, cervical, 
                 HeLa 
                 223 
               
               
                   
                   
                   
                 regulator 
                   
                 RSPFK 
                 adenocarcinoma 
               
               
                   
               
               
                 225 
                 FLNA 
                 NP_001447.2 
                 Transcriptional 
                 S1726 
                 FGGEHVPNsPFQVTAL 
                   
                 SCLCT3 
                 224 
               
               
                   
                   
                   
                 regulator 
                   
                 AGDQPSVQPPLR 
               
               
                   
               
               
                 226 
                 FLNA 
                 NP_034357.2 
                 Transcriptional 
                 S2120 
                 YNEQHVPGsPFTAR 
                   
                 mouse 
                 225 
               
               
                   
                   
                   
                 regulator 
                   
                   
                   
                 heart 
               
               
                   
               
               
                 227 
                 FLNB 
                 NP_001448.2 
                 Cytoskeletal 
                 S730 
                 HTIAVVWGGVNIPHsP 
                 cancer, cervical, 
                 HeLa 
                 226 
               
               
                   
                   
                   
                 protein 
                   
                 YR 
                 adenocarcinoma 
               
               
                   
               
               
                 228 
                 FLNB 
                 NP_001448.2 
                 Cytoskeletal 
                 S833 
                 VLFASQEIPAsPFR 
                 cancer, 
                 K562 
                 227 
               
               
                   
                   
                   
                 protein 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 229 
                 FLNB 
                 NP_001448.2 
                 Cytoskeletal 
                 S1409 
                 DGSCSAEYIPFAPGDY 
                 cancer, cervical, 
                 HeLa 
                 228 
               
               
                   
                   
                   
                 protein 
                   
                 DVNITYGGAHIPGsPF 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 RVPVK 
               
               
                   
               
               
                 230 
                 FLNB 
                 NP_001448.2 
                 Cytoskeletal 
                 S2369 
                 FNGSHVVGsPFK 
                 cancer, cervical, 
                 HeLa 
                 229 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 231 
                 FLNB 
                 NP_001448.2 
                 Cytoskeletal 
                 S2465 
                 YGGPNHIVGsPFK 
                 cancer, cervical, 
                 HeLa 
                 230 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 232 
                 FNBP4 
                 Q8N3X1.2 
                 Unassigned 
                 S492 
                 TGRDTPENGETAIGAE 
                 cancer, cervical, 
                 HeLa 
                 231 
               
               
                   
                   
                   
                   
                   
                 NsEKIDENSDKEMEVE 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 ESPEK 
               
               
                   
               
               
                 233 
                 FOXC1 
                 NP_001444.2 
                 Transcriptional 
                 T68 
                 AYGPYtPQPQPK 
                 cancer, cervical, 
                 HeLa 
                 232 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 234 
                 FOXK1 
                 NP_001032242.1 
                 Transcriptional 
                 S431 
                 sGGLQTPECLSREGS 
                 cancer, leukemia 
                 Jurkat 
                 233 
               
               
                   
                   
                   
                 regulator 
                   
                 PIPHDPEFGSK 
               
               
                   
               
               
                 235 
                 FOXK2 
                 NP_004505.2 
                 Transcriptional 
                 S385 
                 SAPASPNHAGVLSAH 
                 cancer, cervical, 
                 HeLa 
                 234 
               
               
                   
                   
                   
                 regulator 
                   
                 SsGAQTPESLSR 
                 adenocarcinoma 
               
               
                   
               
               
                 236 
                 FRS2 
                 NP_001036020.1 
                 Adaptor/ 
                 T457 
                 TPtTPLPQTPTRR 
                 cancer, cervical, 
                 HeLa 
                 235 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 237 
                 FRS2 
                 NP_001036020.1 
                 Adaptor/ 
                 T458 
                 TPTtPLPQTPTR 
                 cancer, cervical, 
                 HeLa 
                 236 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 238 
                 FRS2 
                 NP_001036020.1 
                 Adaptor/ 
                 T463 
                 TPTTPLPQtPTR 
                 cancer, 
                 MV4- 
                 237 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 leukemia, acute 
                 11 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 239 
                 FRS2 
                 NP_001036020.1 
                 Adaptor/ 
                 T465 
                 TPTTPLPQTPtRR 
                 cancer, 
                 MV4- 
                 238 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 leukemia, acute 
                 11 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 240 
                 GAS2L3 
                 NP_777602.1 
                 Unknown 
                 S376 
                 SKLPNsPAASSHPK 
                 cancer, lung, 
                 H128 
                 239 
               
               
                   
                   
                   
                 function 
                   
                   
                 small-cell 
               
               
                   
               
               
                 241 
                 GEMIN5 
                 NP_056280.2 
                 Transcriptional 
                 T51 
                 VGPGAGESPGtPPFR 
                 cancer, lung, 
                 H1703 
                 240 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 242 
                 GLUD1 
                 NP_005262.1 
                 Enzyme, misc. 
                 T410 
                 IIAEGANGPTtPEADKIF 
                 cancer, 
                 SEM 
                 241 
               
               
                   
                   
                   
                   
                   
                 LER 
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 243 
                 GLUD2 
                 NP_036216.2 
                 Unassigned 
                 T410 
                 IIAEGANGPTtPEADKIF 
                 cancer, 
                 SEM 
                 242 
               
               
                   
                   
                   
                   
                   
                 LER 
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 244 
                 GNL1 
                 NP_005266.2 
                 Unknown 
                 S55 
                 REEQTDTSDGEsVTH 
                 cancer, lung, 
                 H1703 
                 243 
               
               
                   
                   
                   
                 function 
                   
                 HIR 
                 non-small cell 
               
               
                   
               
               
                 245 
                 GPBP1L1 
                 NP_067652.1 
                 Unassigned 
                 T354 
                 DCDKLEDLEDNStPEPK 
                 cancer, cervical, 
                 HeLa 
                 244 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 246 
                 GRAMD1B 
                 NP_065767.1 
                 Unknown 
                 S53 
                 GSDHSSDKsPSTPEQ 
                 cancer, cervical, 
                 HeLa 
                 245 
               
               
                   
                   
                   
                 function 
                   
                 GVQR 
                 adenocarcinoma 
               
               
                   
               
               
                 247 
                 GRAMD1B 
                 NP_065767.1 
                 Unknown 
                 T56 
                 GSDHSSDKSPStPEQ 
                   
                 Adult 
                 246 
               
               
                   
                   
                   
                 function 
                   
                 GVQR 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 248 
                 GRAMD1B 
                 NP_065767.1 
                 Unknown 
                 T587 
                 VPHLEEVMSPVTTPtD 
                   
                 Embryo 
                 247 
               
               
                   
                   
                   
                 function 
                   
                 EDVGHR 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 249 
                 GRAMD3 
                 NP_080516.2 
                 Unassigned 
                 S242 
                 ADRPSsLPLDFNDEFS 
                   
                 mouse 
                 248 
               
               
                   
                   
                   
                   
                   
                 DLDGVVQQR 
                   
                 liver 
               
               
                   
               
               
                 250 
                 Haspin 
                 NP_114171.2 
                 Protein kinase, 
                 S108 
                 ARPsLTVTPR 
                 cancer, leukemia 
                 Jurkat 
                 249 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 251 
                 Haspin 
                 NP_114171.2 
                 Protein kinase, 
                 T112 
                 ARPSLTVtPR 
                 cancer, leukemia 
                 Jurkat 
                 250 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 252 
                 Haspin 
                 NP_114171.2 
                 Protein kinase, 
                 T128 
                 CStPCGPLR 
                 cancer, cervical, 
                 HeLa 
                 251 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 253 
                 HBS1 
                 NP_062676.2 
                 Transcriptional 
                 S228 
                 SANPPHTIQASEEQSs 
                   
                 mouse 
                 252 
               
               
                   
                   
                   
                 regulator 
                   
                 TPAPVKK 
                   
                 liver 
               
               
                   
               
               
                 254 
                 HDAC7 
                 NP_001091886.1 
                 Enzyme, misc. 
                 T513 
                 VLSSSEtPAR 
                 cancer, cervical, 
                 HeLa 
                 253 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 255 
                 HEBP2 
                 NP_055135.1 
                 Unassigned 
                 S181 
                 VYYTAGYNsPVK 
                 cancer, leukemia 
                 Jurkat 
                 254 
               
               
                   
               
               
                 256 
                 HEG1 
                 NP_065784.1 
                 Unknown 
                 S1293 
                 SGDFQMsPYAEYPKN 
                 cancer, cervical, 
                 HeLa 
                 255 
               
               
                   
                   
                   
                 function 
                   
                 PR 
                 adenocarcinoma 
               
               
                   
               
               
                 257 
                 Hic-5 
                 NP_001035919.1 
                 Transcriptional 
                 S137 
                 KRPsLPSSPSPGLPK 
                   
                 SCLCT3 
                 256 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 258 
                 Hic-5 
                 NP_001035919.1 
                 Transcriptional 
                 S140 
                 KRPSLPsSPSPGLPK 
                 cancer, cervical, 
                 HeLa 
                 257 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 259 
                 Hic-5 
                 NP_001035919.1 
                 Transcriptional 
                 S143 
                 KRPSLPSSPsPGLPK 
                   
                 SCLCT3 
                 258 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 260 
                 HMOX1 
                 NP_002124.1 
                 Enzyme, misc. 
                 T252 
                 VQDSAPVEtPR 
                 cancer, cervical, 
                 HeLa 
                 259 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 261 
                 HN1L 
                 NP_653171.1 
                 Unknown 
                 S75 
                 GSGIFDEsTPVQTR 
                 cancer, lung, 
                 H1703 
                 260 
               
               
                   
                   
                   
                 function 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 262 
                 hnRNP A3 
                 NP_919223.1 
                 RNA, 
                 S370 
                 SSGSPYGGGYGSGG 
                 cancer, 
                 K562 
                 261 
               
               
                   
                   
                   
                 processing 
                   
                 GsGGYGSR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 263 
                 hnRNP L 
                 NP_001524.2 
                 RNA 
                 T487 
                 FStPEQAAK 
                 cancer, leukemia 
                 Jurkat 
                 262 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 264 
                 HOMEZ 
                 NP_065885.2 
                 Unassigned 
                 S351 
                 VGPTEYLsPDMQR 
                 cancer, leukemia 
                 Jurkat 
                 263 
               
               
                   
               
               
                 265 
                 HPCA 
                 NP_002134.2 
                 Cytoskeletal 
                 T144 
                 MPEDEStPEKR 
                   
                 Adult 
                 264 
               
               
                   
                   
                   
                 protein 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 266 
                 HPCAL1 
                 NP_002140.2 
                 Calcium- 
                 T144 
                 MPEDEStPEKR 
                   
                 Adult 
                 265 
               
               
                   
                   
                   
                 binding protein 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 267 
                 HRBL 
                 NP_006067.3 
                 Unknown 
                 T163 
                 GSAStPVQGSIPEGKP 
                 cancer, cervical, 
                 HeLa 
                 266 
               
               
                   
                   
                   
                 function 
                   
                 LR 
                 adenocarcinoma 
               
               
                   
               
               
                 268 
                 HRBL 
                 NP_006067.3 
                 Unknown 
                 S468 
                 LGQRPLSQPAGISTNP 
                 cancer, leukemia 
                 Jurkat 
                 267 
               
               
                   
                   
                   
                 function 
                   
                 FMTGPSSsPFASKPPT 
               
               
                   
                   
                   
                   
                   
                 TNPFL 
               
               
                   
               
               
                 269 
                 HYD 
                 NP_056986.2 
                 Transcriptional 
                 T637 
                 RStPAPKEEEKVNEEQ 
                 cancer, leukemia 
                 Jurkat 
                 268 
               
               
                   
                   
                   
                 regulator 
                   
                 WSLR 
               
               
                   
               
               
                 270 
                 ILK 
                 NP_001014795.1 
                 Protein kinase, 
                 T172 
                 IPYKDTFWKGtTR 
                   
                 mouse 
                 269 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                   
                 heart 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 271 
                 IMPA1 
                 NP_005527.1 
                 Unassigned 
                 T168 
                 SLLVTELGSSRtPETVR 
                 cancer, cervical, 
                 HeLa 
                 270 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 272 
                 ING5 
                 NP_115705.2 
                 Tumor 
                 S123 
                 DKMEGSDFESsGGR 
                 cancer, cervical, 
                 HeLa 
                 271 
               
               
                   
                   
                   
                 suppressor 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 273 
                 IP3R1 
                 NP_002213.4 
                 Receptor, 
                 T931 
                 GGGFLPMtPMAAAPE 
                 cancer, 
                 MV4- 
                 272 
               
               
                   
                   
                   
                 channel, 
                   
                 GNVK 
                 leukemia, acute 
                 11 
               
               
                   
                   
                   
                 transporter or 
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                 cell surface 
                   
                   
                 (AML) 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 274 
                 JIP4 
                 NP_003962.3 
                 Adaptor/ 
                 S349 
                 GsSTPTKGIENK 
                   
                 Adult 
                 273 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 275 
                 JIP4 
                 NP_003962.3 
                 Adaptor/ 
                 T351 
                 GSStPTKGIENK 
                   
                 Adult 
                 274 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 276 
                 JIP4 
                 NP_003962.3 
                 Adaptor/ 
                 T353 
                 GSSTPtKGIENK 
                   
                 Adult 
                 275 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 277 
                 KAB1 
                 NP_001035863.1 
                 Cell cycle 
                 T174 
                 GtPLYGQPSWWGDDE 
                 cancer, leukemia 
                 Jurkat 
                 276 
               
               
                   
                   
                   
                 regulation 
                   
                 VDEKR 
               
               
                   
               
               
                 278 
                 KAB1 
                 NP_001035863.1 
                 Cell cycle 
                 T1278 
                 KIPPLVHSKtPEGNNGR 
                 cancer, cervical, 
                 HeLa 
                 277 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 279 
                 kanadaptin 
                 NP_060628.2 
                 Adaptor/ 
                 S82 
                 KPALPVsPAAR 
                 cancer, lung, 
                 H1703 
                 278 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 280 
                 KATNA1 
                 NP_008975.1 
                 Enzyme, misc. 
                 T81 
                 LDStPLK 
                 cancer, cervical, 
                 HeLa 
                 279 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 281 
                 KATNB1 
                 NP_005877.2 
                 Cytoskeletal 
                 T395 
                 SRtPPR 
                 cancer, leukemia 
                 Jurkat 
                 280 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 282 
                 KCNJ12 
                 NP_066292.2 
                 Unassigned 
                 S353 
                 TYEVPsTPR 
                 cancer, cervical, 
                 HeLa 
                 281 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 283 
                 KCTD16 
                 NP_065819.1 
                 Unknown 
                 S137 
                 QSPDEFCHsDFEDAS 
                 cancer, cervical, 
                 HeLa 
                 282 
               
               
                   
                   
                   
                 function 
                   
                 QGSDTR 
                 adenocarcinoma 
               
               
                   
               
               
                 284 
                 KI-67 
                 NP_002408.3 
                 Cell cycle 
                 S235 
                 KNEsPFWK 
                 cancer, cervical, 
                 HeLa 
                 283 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 285 
                 KIAA0284 
                 NP_055820.1 
                 Cytoskeletal 
                 S1042 
                 sNSLSTPRPTR 
                   
                 mouse 
                 284 
               
               
                   
                   
                   
                 protein 
                   
                   
                   
                 heart 
               
               
                   
               
               
                 286 
                 KIAA0284 
                 NP_055820.1 
                 Cytoskeletal 
                 T1047 
                 SNSLStPRPTR 
                   
                 mouse 
                 285 
               
               
                   
                   
                   
                 protein 
                   
                   
                   
                 heart 
               
               
                   
               
               
                 287 
                 KIAA0284 
                 NP_055820.1 
                 Cytoskeletal 
                 T1177 
                 QPFSRARSGSARYTSt 
                 cancer, brain, 
                 M059K 
                 286 
               
               
                   
                 iso2 
                   
                 protein 
                   
                 TQTPR 
                 glioblastoma 
               
               
                   
               
               
                 288 
                 KIAA0284 
                 NP_055820.1 
                 Cytoskeletal 
                 T1178 
                 QPFSRARSGSARYTS 
                 cancer, cervical, 
                 HeLa 
                 287 
               
               
                   
                 iso2 
                   
                 protein 
                   
                 TtQTPR 
                 adenocarcinoma 
               
               
                   
               
               
                 289 
                 KIAA0284 
                 NP_055820.1 
                 Cytoskeletal 
                 T1180 
                 QPFSRARSGSARYTS 
                 cancer, cervical, 
                 HeLa 
                 288 
               
               
                   
                 iso2 
                   
                 protein 
                   
                 TTQtPR 
                 adenocarcinoma 
               
               
                   
               
               
                 290 
                 KIAA0310 
                 NP_055681.1 
                 Unknown 
                 S29 
                 SVFWASsPYR 
                 cancer, leukemia 
                 Jurkat 
                 289 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 291 
                 KIAA0310 
                 NP_055681.1 
                 Unknown 
                 T65 
                 QALQStPLGSSSK 
                 cancer, cervical, 
                 HeLa 
                 290 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 292 
                 KIAA0310 
                 NP_055681.1 
                 Unknown 
                 S125 
                 AHASPFsGALTPSAPP 
                 cancer, cervical, 
                 HeLa 
                 291 
               
               
                   
                   
                   
                 function 
                   
                 GPEMNR 
                 adenocarcinoma 
               
               
                   
               
               
                 293 
                 KIAA0310 
                 NP_055681.1 
                 Unknown 
                 T129 
                 AHASPFSGALtPSAPP 
                 cancer, cervical, 
                 HeLa 
                 292 
               
               
                   
                   
                   
                 function 
                   
                 GPEMNR 
                 adenocarcinoma 
               
               
                   
               
               
                 294 
                 KIAA0430 
                 NP_055462.2 
                 Vesicle protein 
                 T687 
                 LVVPTHGNSSAAVStPK 
                 cancer, cervical, 
                 HeLa 
                 293 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 295 
                 KIAA0443 
                 NP_612446.1 
                 Unknown 
                 S512 
                 STsPFGIPEEASEMLE 
                 cancer, cervical, 
                 HeLa 
                 294 
               
               
                   
                   
                   
                 function 
                   
                 AKPK 
                 adenocarcinoma 
               
               
                   
               
               
                 296 
                 KIAA0460 
                 Q5VT52.1 
                 Unknown 
                 S761 
                 IISPGsSTPSSTRSPPP 
                 cancer, lung, 
                 H1703 
                 295 
               
               
                   
                   
                   
                 function 
                   
                 GRDESYPR 
                 non-small cell 
               
               
                   
               
               
                 297 
                 KIAA0460 
                 Q5VT52.1 
                 Unknown 
                 S765 
                 IISPGSSTPsSTRSPPP 
                 cancer, cervical, 
                 HeLa 
                 296 
               
               
                   
                   
                   
                 function 
                   
                 GRDESYPR 
                 adenocarcinoma 
               
               
                   
               
               
                 298 
                 KIAA0460 
                 Q5VT52.1 
                 Unknown 
                 S766 
                 IISPGSSTPSsTRSPPP 
                 cancer, leukemia 
                 Jurkat 
                 297 
               
               
                   
                   
                   
                 function 
                   
                 GRDESYPR 
               
               
                   
               
               
                 299 
                 KIAA0460 
                 Q5VT52.1 
                 Unknown 
                 T767 
                 IISPGSSTPSStRSPPP 
                 cancer, lung, 
                 H1703 
                 298 
               
               
                   
                   
                   
                 function 
                   
                 GRDESYPR 
                 non-small cell 
               
               
                   
               
               
                 300 
                 KIAA0674 
                 NP_056073.1 
                 Unknown 
                 T1203 
                 GRPPPtPLFGDDDDDD 
                 cancer, lung, 
                 H1703 
                 299 
               
               
                   
                   
                   
                 function 
                   
                 DIDWLG 
                 non-small cell 
               
               
                   
               
               
                 301 
                 KIAA0819 
                 O94909.2 
                 Enzyme, misc. 
                 S442 
                 TSTPLAPLPVQSQsDT 
                 cancer, cervical, 
                 HeLa 
                 300 
               
               
                   
                   
                   
                   
                   
                 KDR 
                 adenocarcinoma 
               
               
                   
               
               
                 302 
                 KIAA0819 
                 O94909.2 
                 Enzyme, misc. 
                 S546 
                 LGLPKPEGEPLSLPTP 
                 cancer, 
                 Kyse140 
                 301 
               
               
                   
                   
                   
                   
                   
                 RsPSDR 
                 esophageal 
               
               
                   
                   
                   
                   
                   
                   
                 carcinoma 
               
               
                   
               
               
                 303 
                 KIAA0819 
                 O94909.2 
                 Enzyme, misc. 
                 S899 
                 KADDKsCPSTPSSGAT 
                 cancer, lung, 
                 H1703 
                 302 
               
               
                   
                   
                   
                   
                   
                 VDSGK 
                 non-small cell 
               
               
                   
               
               
                 304 
                 KIAA0947 
                 NP_056140.1 
                 Unknown 
                 S958 
                 LsFSPENILIQNQDIVR 
                 cancer, cervical, 
                 HeLa 
                 303 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 305 
                 KIAA1043 
                 NP_001138890.1 
                 Unknown 
                 S2293 
                 LKYPSsPYSAHISKSPR 
                 cancer, lung, 
                 H446 
                 304 
               
               
                   
                   
                   
                 function 
                   
                   
                 small-cell 
               
               
                   
               
               
                 306 
                 KIAA1043 
                 NP_001138890.1 
                 Unknown 
                 S2302 
                 LKYPSSPYSAHISKsPR 
                 cancer, leukemia 
                 Jurkat 
                 305 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 307 
                 KIAA1064 
                 NP_055983.1 
                 Unknown 
                 S1267 
                 TGsGSPFAGNSPARE 
                 cancer, leukemia 
                 Jurkat 
                 306 
               
               
                   
                   
                   
                 function 
                   
                 GEQDAASLK 
               
               
                   
               
               
                 308 
                 KIAA1217 
                 NP_062536.2 
                 Unknown 
                 T1633 
                 SQPEDtPENTVR 
                 cancer, cervical, 
                 HeLa 
                 307 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 309 
                 KIAA1228 
                 NP_065779.1 
                 Unknown 
                 S676 
                 SHMSGSPGPGGSNTA 
                 cancer, lung, 
                 H1703 
                 308 
               
               
                   
                   
                   
                 function 
                   
                 PsTPVIGGSDKPGMEEK 
                 non-small cell 
               
               
                   
               
               
                 310 
                 KIAA1433 
                 NP_061174.1 
                 Unknown 
                 T340 
                 MTNTGLPGPAtPAYSY 
                 cancer, 
                 HT29 
                 309 
               
               
                   
                   
                   
                 function 
                   
                 AK 
                 colorectal 
               
               
                   
                   
                   
                   
                   
                   
                 carcinoma 
               
               
                   
               
               
                 311 
                 KIAA1458 
                 NP_065897.1 
                 Unknown 
                 S134 
                 LSGWEEEEESWLYSs 
                 cancer, leukemia 
                 Jurkat 
                 310 
               
               
                   
                   
                   
                 function 
                   
                 PK 
               
               
                   
               
               
                 312 
                 KIAA1602 
                 NP_001001884.1 
                 Unknown 
                 S177 
                 EVCWEQQLRPGGPG 
                   
                 Embryo 
                 311 
               
               
                   
                   
                   
                 function 
                   
                 PPAAPPPALDALsPFLR 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 313 
                 KIAA1602 
                 NP_001032895.2 
                 Unknown 
                 S658 
                 RPGDPGsTPLR 
                 cancer, cervical, 
                 HeLa 
                 312 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 314 
                 KIAA1671 
                 Q9BY89.2 
                 Unknown 
                 T600 
                 GGSSVEAPCPSDVtPE 
                 cancer, cervical, 
                 HeLa 
                 313 
               
               
                   
                   
                   
                 function 
                   
                 DDRSFQTVWATVFEH 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 HVER 
               
               
                   
               
               
                 315 
                 KIAA1671 
                 Q9BY89.2 
                 Unknown 
                 S981 
                 TDYVsPTASALR 
                 cancer, cervical, 
                 HeLa 
                 314 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 316 
                 KIAA1856 
                 O15417.3 
                 Unknown 
                 T2146 
                 GGAVERPLtPAPR 
                 cancer, cervical, 
                 HeLa 
                 315 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 317 
                 KIF14 
                 NP_055690.1 
                 Cytoskeletal 
                 T81 
                 TADMPLtPNPVGR 
                 cancer, cervical, 
                 HeLa 
                 316 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 318 
                 KIF14 
                 NP_055690.1 
                 Cytoskeletal 
                 S1632 
                 VYELHGSsPAVSSEEC 
                 cancer, cervical, 
                 HeLa 
                 317 
               
               
                   
                   
                   
                 protein 
                   
                 TPSR 
                 adenocarcinoma 
               
               
                   
               
               
                 319 
                 KIF1B 
                 NP_055889.2 
                 Cytoskeletal 
                 T1604 
                 SNSLDQKtPEANSR 
                 cancer, leukemia 
                 Jurkat 
                 318 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 320 
                 KIF1B 
                 NP_055889.2 
                 Cytoskeletal 
                 S1609 
                 SNSLDQKTPEANsR 
                 cancer, cervical, 
                 HeLa 
                 319 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 321 
                 KIF20A 
                 NP_005724.1 
                 Cytoskeletal 
                 S863 
                 TPTCQSsTDCSPYAR 
                 cancer, 
                 HT29 
                 320 
               
               
                   
                   
                   
                 protein 
                   
                   
                 colorectal 
               
               
                   
                   
                   
                   
                   
                   
                 carcinoma 
               
               
                   
               
               
                 322 
                 Kizuna 
                 NP_060944.3 
                 Cell cycle 
                 S283 
                 ERLsPENR 
                 cancer, cervical, 
                 HeLa 
                 321 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 323 
                 LAP2A 
                 NP_003267.1 
                 Unassigned 
                 T154 
                 EQGtESRSSTPLPTISS 
                 cancer, lung, 
                 H1703 
                 322 
               
               
                   
                   
                   
                   
                   
                 SAENTR 
                 non-small cell 
               
               
                   
               
               
                 324 
                 LAP2A 
                 NP_003267.1 
                 Unassigned 
                 S168 
                 SSTPLPTISSsAENTR 
                 cancer, lung, 
                 H1703 
                 323 
               
               
                   
                   
                   
                   
                   
                   
                 non-small cell 
               
               
                   
               
               
                 325 
                 LAP2A 
                 NP_003267.1 
                 Unassigned 
                 T671 
                 LAStPFKGGTLFGGEV 
                 cancer, cervical, 
                 HeLa 
                 324 
               
               
                   
                   
                   
                   
                   
                 CK 
                 adenocarcinoma 
               
               
                   
               
               
                 326 
                 LARP 
                 NP_056130.2 
                 RNA 
                 T703 
                 NtRTPRTPRTPQLK 
                 cancer, lung, 
                 H1703 
                 325 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 327 
                 LARP 
                 NP_056130.2 
                 RNA 
                 T705 
                 NTRtPRTPRTPQLK 
                 cancer, lung, 
                 H1703 
                 326 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 328 
                 LARP5 
                 NP_055970.1 
                 RNA 
                 S701 
                 YREPPALKsTPGAPR 
                 cancer, brain, 
                 M059J 
                 327 
               
               
                   
                   
                   
                 processing 
                   
                   
                 glioblastoma 
               
               
                   
               
               
                 329 
                 LEMD2 
                 NP_851853.1 
                 Unknown 
                 T147 
                 ASVRGSSEEDEDARtP 
                 cancer, lung, 
                 H1703 
                 328 
               
               
                   
                   
                   
                 function 
                   
                 DR 
                 non-small cell 
               
               
                   
               
               
                 330 
                 LEREPO4 
                 NP_060941.2 
                 Unknown 
                 S360 
                 FSTYTsDKDENK 
                 cancer, leukemia 
                 Jurkat 
                 329 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 331 
                 LILRA4 
                 NP_036408.3 
                 Unassigned 
                 T124 
                 PtLSALPSPVVTSGVN 
                 cancer, cervical, 
                 HeLa 
                 330 
               
               
                   
                   
                   
                   
                   
                 VTLR 
                 adenocarcinoma 
               
               
                   
               
               
                 332 
                 LILRA4 
                 NP_036408.3 
                 Unassigned 
                 S126 
                 PTLsALPSPVVTSGVN 
                 cancer, cervical, 
                 HeLa 
                 331 
               
               
                   
                   
                   
                   
                   
                 VTLR 
                 adenocarcinoma 
               
               
                   
               
               
                 333 
                 LILRA4 
                 NP_036408.3 
                 Unassigned 
                 S130 
                 PTLSALPsPVVTSGVN 
                 cancer, cervical, 
                 HeLa 
                 332 
               
               
                   
                   
                   
                   
                   
                 VTLR 
                 adenocarcinoma 
               
               
                   
               
               
                 334 
                 LIMCH1 
                 Q9UPQ0.3 
                 Unknown 
                 T317 
                 YGPRtPVSDDAESTSM 
                 cancer, cervical, 
                 HeLa 
                 333 
               
               
                   
                   
                   
                 function 
                   
                 FDMR 
                 adenocarcinoma 
               
               
                   
               
               
                 335 
                 LIN9 
                 NP_775106.2 
                 Transcriptional 
                 T55 
                 YSSLQKtPVWK 
                 cancer, lung, 
                 H1703 
                 334 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 336 
                 LMO7 
                 NP_056667.2 
                 Adaptor/ 
                 S683 
                 TPNNVVSTPAPSPDAS 
                 cancer, cervical, 
                 HeLa 
                 335 
               
               
                   
                   
                   
                 scaffold 
                   
                 QLAsSLSSQK 
                 adenocarcinoma 
               
               
                   
               
               
                 337 
                 LMO7 
                 NP_056667.2 
                 Adaptor/ 
                 T1303 
                 TSTTGVATTQSPtPR 
                 cancer, cervical, 
                 HeLa 
                 336 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 338 
                 LOC100129899 
                 XP_001715056.1 
                 Unassigned 
                 S333 
                 VsPFGLR 
                 cancer, cervical, 
                 HeLa 
                 337 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 339 
                 LOC100132561 
                 XP_001714024.1 
                 Unassigned 
                 T367 
                 GNPTDMDPtLEDPTAP 
                 cancer, cervical, 
                 HeLa 
                 338 
               
               
                   
                   
                   
                   
                   
                 KCKMRRCSSCSPK 
                 adenocarcinoma 
               
               
                   
               
               
                 340 
                 LOC100132561 
                 XP_001714024.1 
                 Unassigned 
                 S385 
                 GNPTDMDPTLEDPTA 
                 cancer, cervical, 
                 HeLa 
                 339 
               
               
                   
                   
                   
                   
                   
                 PKCKMRRCSSCsPK 
                 adenocarcinoma 
               
               
                   
               
               
                 341 
                 LOC100133063 
                 XP_001716809.1 
                 Unassigned 
                 S182 
                 AQQGLYQVPGPSPQF 
                 cancer, cervical, 
                 HeLa 
                 340 
               
               
                   
                   
                   
                   
                   
                 QsPPAK 
                 adenocarcinoma 
               
               
                   
               
               
                 342 
                 LOC100133510 
                 XP_001719668.1 
                 Unassigned 
                 T19 
                 YIASVQGStPSPR 
                 cancer, lung, 
                 H1703 
                 341 
               
               
                   
                   
                   
                   
                   
                   
                 non-small cell 
               
               
                   
               
               
                 343 
                 LOC100133510 
                 XP_001719668.1 
                 Unassigned 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 342 
               
               
                   
               
               
                 344 
                 LOC100133510 
                 XP_001719668.1 
                 Unassigned 
                 T783 
                 RSTPSPtRYSLSPSK 
                 cancer, cervical, 
                 HeLa 
                 343 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 345 
                 LOC284058 
                 NP_056258.1 
                 Unknown 
                 S1021 
                 CsTPELGLDEQSVQP 
                 cancer, cervical, 
                 HeLa 
                 344 
               
               
                   
                   
                   
                 function 
                   
                 WER 
                 adenocarcinoma 
               
               
                   
               
               
                 346 
                 LOC284861 
                 XP_001715957.1 
                 Unknown 
                 T381 
                 tPPRASPKRTPPTASP 
                 cancer, 
                 K562 
                 345 
               
               
                   
                 iso4 
                   
                 function 
                   
                 TR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 347 
                 LOC284861 
                 XP_001715957.1 
                 Unknown 
                 S395 
                 TPPRASPKRTPPTAsP 
                 cancer, leukemia 
                 Jurkat 
                 346 
               
               
                   
                 iso4 
                   
                 function 
                   
                 TR 
               
               
                   
               
               
                 348 
                 LOC339287 
                 NP_001012241.1 
                 Unknown 
                 T133 
                 SSVDtPPR 
                 cancer, leukemia 
                 Jurkat 
                 347 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 349 
                 LOC339287 
                 NP_001012241.1 
                 Unknown 
                 T139 
                 LStPQKGPSTHPK 
                 cancer, leukemia 
                 Jurkat 
                 348 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 350 
                 LOC435684 
                 NP_612365.2 
                 Unknown 
                 S238 
                 VIKDLPWPPPVGQLDS 
                 cancer, cervical, 
                 HeLa 
                 349 
               
               
                   
                   
                   
                 function 
                   
                 sPSLPDGDR 
                 adenocarcinoma 
               
               
                   
               
               
                 351 
                 LOC642044 
                 XP_001716539.1 
                 Unassigned 
                 S72 
                 HLLsPPR 
                 cancer, cervical, 
                 HeLa 
                 350 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 352 
                 LOC642075 
                 XP_001717549.1 
                 Unassigned 
                 S72 
                 HLLsPPR 
                 cancer, cervical, 
                 HeLa 
                 351 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 353 
                 LOC646079 
                 XP_001716006.1 
                 Unassigned 
                 S182 
                 AQQGLYQVPGPSPQF 
                 cancer, cervical, 
                 HeLa 
                 352 
               
               
                   
                   
                   
                   
                   
                 QsPPAK 
                 adenocarcinoma 
               
               
                   
               
               
                 354 
                 LOC646720 
                 XP_938936.1 
                 Unassigned 
                 S72 
                 HLLsPPR 
                 cancer, cervical, 
                 HeLa 
                 353 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 355 
                 LY6K 
                 AAI17143.1 
                 Unassigned 
                 S23 
                 GGRGsPYRPDPGR 
                 cancer, cervical, 
                 HeLa 
                 354 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 356 
                 MAP1B 
                 NP_005900.2 
                 Cytoskeletal 
                 T744 
                 SStPLSEAK 
                 cancer, cervical, 
                 HeLa 
                 355 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 357 
                 MAP1B 
                 NP_005900.2 
                 Cytoskeletal 
                 S747 
                 SSTPLsEAK 
                 cancer, cervical, 
                 HeLa 
                 356 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 358 
                 MAP1B 
                 NP_005900.2 
                 Cytoskeletal 
                 S1254 
                 DSISAVSSEKVSPsKS 
                 cancer, 
                 K562 
                 357 
               
               
                   
                   
                   
                 protein 
                   
                 PSLSPSPPSPLEK 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 359 
                 MAP1B 
                 NP_005900.2 
                 Cytoskeletal 
                 T1341 
                 TLEVVSPSQSVTGSA 
                 cancer, lung, 
                 H1703 
                 358 
               
               
                   
                   
                   
                 protein 
                   
                 GHTPYYQSPtDEK 
                 non-small cell 
               
               
                   
               
               
                 360 
                 MAP1B 
                 NP_005900.2 
                 Cytoskeletal 
                 T1853 
                 DLStPGLEK 
                 cancer, cervical, 
                 HeLa 
                 359 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 361 
                 MAP1B 
                 NP_005900.2 
                 Cytoskeletal 
                 S1960 
                 TTRTPEEGGYSYDIsEK 
                 cancer, cervical, 
                 HeLa 
                 360 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 362 
                 MAP4 iso4 
                 NP_112146.2 
                 Cytoskeletal 
                 T340 
                 ILEtPQK 
                 cancer, cervical, 
                 HeLa 
                 361 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 363 
                 MBD1 
                 NP_056723.2 
                 Transcriptional 
                 S37 
                 SDTYYQsPTGDR 
                 cancer, cervical, 
                 HeLa 
                 362 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 364 
                 MCPH1 
                 NP_078872.2 
                 Cell cycle 
                 T120 
                 DFNFKtPENDKR 
                 cancer, cervical, 
                 HeLa 
                 363 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 365 
                 MDC1 
                 NP_055456.2 
                 Cell cycle 
                 T150 
                 GPLTVEEtPR 
                 cancer, cervical, 
                 HeLa 
                 364 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 366 
                 MELK 
                 NP_055606.1 
                 Protein kinase, 
                 T459 
                 EILtTPNRYTTPSK 
                 cancer, leukemia 
                 Jurkat 
                 365 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 367 
                 MELK 
                 NP_055606.1 
                 Protein kinase, 
                 T466 
                 EILTTPNRYTtPSK 
                 cancer, leukemia 
                 Jurkat 
                 366 
               
               
                   
                   
                   
                 Ser/Thr (non- 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 368 
                 MGC35274 
                 NP_699205.1 
                 Unknown 
                 S206 
                 DEEsPYATSLYHS 
                 cancer, cervical, 
                 HeLa 
                 367 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 369 
                 MGC5509 
                 NP_076998.1 
                 Unknown 
                 S184 
                 KSPsGPVKSPPLSPVG 
                   
                 Embryo 
                 368 
               
               
                   
                   
                   
                 function 
                   
                 TTPVK 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 370 
                 MgcRacGAP 
                 NP_037409.2 
                 G protein or 
                 S593 
                 VSLLGPVTTPEHQLLK 
                 cancer, cervical, 
                 HeLa 
                 369 
               
               
                   
                   
                   
                 regulator 
                   
                 TPSSSsLSQR 
                 adenocarcinoma 
               
               
                   
               
               
                 371 
                 MICB 
                 Q29980.1 
                 Receptor, 
                 T99 
                 RtLTHIKDQKGGLHSL 
                 cancer, lung, 
                 H1703 
                 370 
               
               
                   
                   
                   
                 channel, 
                   
                 QEIR 
                 non-small cell 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 372 
                 MICB 
                 Q29980.1 
                 Receptor, 
                 S112 
                 RTLTHIKDQKGGLHsL 
                 cancer, lung, 
                 H1703 
                 371 
               
               
                   
                   
                   
                 channel, 
                   
                 QEIR 
                 non-small cell 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 373 
                 MIRab13 
                 NP_203744.1 
                 Unassigned 
                 S311 
                 KASEsTTPAPPTPRPR 
                 cancer, cervical, 
                 HeLa 
                 372 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 374 
                 MKK3 
                 NP_659731.1 
                 Protein kinase, 
                 T39 
                 ISCMSKPPAPNPtPPR 
                 cancer, cervical, 
                 HeLa 
                 373 
               
               
                   
                   
                   
                 dual-specificity 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 375 
                 MKK7 
                 NP_660186.1 
                 Protein kinase, 
                 T83 
                 HMLGLPSTLFtPR 
                 cancer, cervical, 
                 HeLa 
                 374 
               
               
                   
                   
                   
                 dual-specificity 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 376 
                 MKL1 
                 NP_065882.1 
                 Transcriptional 
                 S446 
                 FGsTGSTPPVSPTPSER 
                 cancer, cervical, 
                 HeLa 
                 375 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 377 
                 MLH1 
                 NP_000240.1 
                 Chromatin, 
                 T495 
                 EMTAACtPR 
                 cancer, leukemia 
                 Jurkat 
                 376 
               
               
                   
                   
                   
                 DNA-binding, 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 378 
                 MLL 
                 NP_005924.2 
                 Transcriptional 
                 S3026 
                 NsSTPGLQVPVSPTVP 
                 cancer, cervical, 
                 HeLa 
                 377 
               
               
                   
                   
                   
                 regulator 
                   
                 IQNQK 
                 adenocarcinoma 
               
               
                   
               
               
                 379 
                 MORC2 
                 NP_055756.1 
                 Unknown 
                 T588 
                 KAPVISStPK 
                 cancer, cervical, 
                 HeLa 
                 378 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 380 
                 MRCKb 
                 NP_006026.3 
                 Protein kinase, 
                 S1677 
                 HsTPSNSSNPSGPPSP 
                 cancer, cervical, 
                 HeLa 
                 379 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 NSPHR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 381 
                 MRCKb 
                 NP_006026.3 
                 Protein kinase, 
                 T1678 
                 HStPSNSSNPSGPPSP 
                   
                 Adult 
                 380 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 NSPHR 
                   
                 mouse 
               
               
                   
                   
                   
                 receptor) 
                   
                   
                   
                 brain 
               
               
                   
               
               
                 382 
                 MYO19 
                 NP_079385.2 
                 Unassigned 
                 S485 
                 RLHPCTSSGPDsPYPAK 
                 cancer, leukemia 
                 Jurkat 
                 381 
               
               
                   
               
               
                 383 
                 MYO9b 
                 NP_004136.2 
                 Motor or 
                 S1926 
                 LGFSsPYEGVLNKSPK 
                 cancer, cervical, 
                 HeLa 
                 382 
               
               
                   
                   
                   
                 contractile 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 384 
                 MYO9b 
                 NP_004136.2 
                 Motor or 
                 S1935 
                 LGFSSPYEGVLNKsPK 
                 cancer, cervical, 
                 HeLa 
                 383 
               
               
                   
                   
                   
                 contractile 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 385 
                 myoferlin 
                 NP_579899.1 
                 Receptor, 
                 T1768 
                 SLGPPGPPFNItPR 
                 cancer, cervical, 
                 HeLa 
                 384 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 386 
                 MYOZ3 
                 NP_588612.2 
                 Adaptor/ 
                 T197 
                 tPVPFGGPLVGGTFPR 
                 cancer, cervical, 
                 HeLa 
                 385 
               
               
                   
                   
                   
                 scaffold 
                   
                 PGTPFIPEPLSGLELLR 
                 adenocarcinoma 
               
               
                   
               
               
                 387 
                 MYST3 
                 NP_001092882.1 
                 Enzyme, misc. 
                 T1144 
                 NSPLEPDTStPLKK 
                 cancer, leukemia 
                 Jurkat 
                 386 
               
               
                   
               
               
                 388 
                 N4BP1 
                 XP_993549.1 
                 Unknown 
                 T645 
                 GVYSSTNELTTDStPK 
                   
                 Embryo 
                 387 
               
               
                   
                   
                   
                 function 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 389 
                 NACA 
                 NP_005585.1 
                 Transcriptional 
                 S114 
                 NILFVITKPDVYKsPAS 
                 cancer, leukemia 
                 Jurkat 
                 388 
               
               
                   
                   
                   
                 regulator 
                   
                 DTYIVFGEAK 
               
               
                   
               
               
                 390 
                 NAV1 
                 NP_065176.2 
                 Adhesion or 
                 T342 
                 SEGtPAWYMHGER 
                 cancer, cervical, 
                 HeLa 
                 389 
               
               
                   
                   
                   
                 extracellular 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 matrix protein 
               
               
                   
               
               
                 391 
                 NAV1 
                 NP_065176.2 
                 Adhesion or 
                 S1366 
                 VAPGPSSGsTPGQVP 
                 cancer, cervical, 
                 HeLa 
                 390 
               
               
                   
                   
                   
                 extracellular 
                   
                 GSSALSSPRR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 matrix protein 
               
               
                   
               
               
                 392 
                 NAV1 
                 NP_065176.2 
                 Adhesion or 
                 S1378 
                 VAPGPSSGSTPGQVP 
                 cancer, cervical, 
                 HeLa 
                 391 
               
               
                   
                   
                   
                 extracellular 
                   
                 GSSALsSPRR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 matrix protein 
               
               
                   
               
               
                 393 
                 NCALD 
                 NP_114430.2 
                 Unassigned 
                 T144 
                 MPEDEStPEKR 
                   
                 Adult 
                 392 
               
               
                   
                   
                   
                   
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 394 
                 NCoA7 
                 NP_861447.3 
                 Transcriptional 
                 S500 
                 QDIMPEVDKQsGSPESR 
                 cancer, cervical, 
                 HeLa 
                 393 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 395 
                 N-CoR1 
                 NP_006302.2 
                 Transcriptional 
                 T1300 
                 TVLSGSIMQGtPR 
                 cancer, leukemia 
                 Jurkat 
                 394 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 396 
                 Nedd4-BP2 
                 NP_060647.2 
                 Kinase (non- 
                 T1210 
                 AVtPENHESMTSIFPSA 
                 cancer, leukemia 
                 Jurkat 
                 395 
               
               
                   
                   
                   
                 protein) 
                   
                 AVGLK 
               
               
                   
               
               
                 397 
                 NEK6 
                 NP_055212.2 
                 Protein kinase, 
                 S215 
                 TTAAHSLVGTPYYMsP 
                 cancer, leukemia 
                 Jurkat 
                 396 
               
               
                   
                   
                   
                 Tyr (non- 
                   
                 ERIHENGYNFK 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 398 
                 NF1 
                 NP_000258.1 
                 G protein or 
                 T2544 
                 RQEMESGITtPPK 
                 cancer, leukemia 
                 Jurkat 
                 397 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 399 
                 NFAT3 
                 NP_004545.2 
                 Transcriptional 
                 S221 
                 AsPRPWTPEDPWSLY 
                 cancer, cervical, 
                 HeLa 
                 398 
               
               
                   
                   
                   
                 regulator 
                   
                 GPSPGGR 
                 adenocarcinoma 
               
               
                   
               
               
                 400 
                 NFAT3 
                 NP_004545.2 
                 Transcriptional 
                 T226 
                 ASPRPWtPEDPWSLY 
                 cancer, cervical, 
                 HeLa 
                 399 
               
               
                   
                   
                   
                 regulator 
                   
                 GPSPGGR 
                 adenocarcinoma 
               
               
                   
               
               
                 401 
                 NFAT90 
                 NP_036350.2 
                 Transcriptional 
                 S762 
                 KQPHGGQQKPSYGS 
                 cancer, leukemia 
                 Jurkat 
                 400 
               
               
                   
                   
                   
                 regulator 
                   
                 GYQSHQGQQQSYNQ 
               
               
                   
                   
                   
                   
                   
                 sPYSNYGPPQGK 
               
               
                   
               
               
                 402 
                 NFAT90 
                 NP_036350.2 
                 Transcriptional 
                 S860 
                 QGGYSQSNYNsPGSG 
                 cancer, leukemia 
                 Jurkat 
                 401 
               
               
                   
                   
                   
                 regulator 
                   
                 QNYSGPPSSYQSSQG 
               
               
                   
                   
                   
                   
                   
                 GYGR 
               
               
                   
               
               
                 403 
                 NFRKB 
                 NP_006156.2 
                 Transcriptional 
                 T1060 
                 ASSASAPSStPTGTTV 
                 cancer, cervical, 
                 HeLa 
                 402 
               
               
                   
                   
                   
                 regulator 
                   
                 VK 
                 adenocarcinoma 
               
               
                   
               
               
                 404 
                 NHSL1 
                 NP_001137532.1 
                 Unknown 
                 S1404 
                 QVGsIQRSIRKSSTSS 
                 cancer, lung, 
                 H1703 
                 403 
               
               
                   
                   
                   
                 function 
                   
                 DNFKALLLK 
                 non-small cell 
               
               
                   
               
               
                 405 
                 NHSL1 
                 NP_001137532.1 
                 Unknown 
                 S1412 
                 QVGSIQRSIRKsSTSS 
                 cancer, lung, 
                 H1703 
                 404 
               
               
                   
                   
                   
                 function 
                   
                 DNFKALLLK 
                 non-small cell 
               
               
                   
               
               
                 406 
                 NIPBL 
                 NP_597677.2 
                 Chromatin, 
                 S588 
                 QCNDAPVSVLQEDIVG 
                 cancer, cervical, 
                 HeLa 
                 405 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 sLKSTPENHPETPKKK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 407 
                 NIPBL 
                 NP_597677.2 
                 Chromatin, 
                 S591 
                 QCNDAPVSVLQEDIVG 
                 cancer, lung, 
                 H1703 
                 406 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SLKsTPENHPETPK 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 408 
                 NIPBL 
                 NP_597677.2 
                 Chromatin, 
                 T599 
                 QCNDAPVSVLQEDIVG 
                 cancer, lung, 
                 H1703 
                 407 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SLKSTPENHPEtPK 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 409 
                 NIPBL 
                 NP_597677.2 
                 Chromatin, 
                 T914 
                 SDKLGFKSPtSK 
                 cancer, cervical, 
                 HeLa 
                 408 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 410 
                 NPM 
                 NP_002511.1 
                 RNA 
                 S217 
                 DSKPsSTPR 
                 cancer, leukemia 
                 Jurkat 
                 409 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 411 
                 NPM 
                 NP_002511.1 
                 RNA 
                 S218 
                 DSKPSsTPR 
                 cancer, 
                 K562 
                 410 
               
               
                   
                   
                   
                 processing 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 412 
                 NR2C2 
                 NP_003289.2 
                 Receptor, 
                 S370 
                 DQsTPIIEVEGPLLSDT 
                 cancer, leukemia 
                 Jurkat 
                 411 
               
               
                   
                   
                   
                 channel, 
                   
                 HVTFK 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 413 
                 NUDCD3 
                 NP_056147.2 
                 Unknown 
                 S340 
                 KGWDAEGsPFR 
                 cancer, cervical, 
                 HeLa 
                 412 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 414 
                 NUDT9 
                 NP_932155.1 
                 Unassigned 
                 S18 
                 ARTsPYPGSKVER 
                 cancer, 
                 K562 
                 413 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 415 
                 NuMA-1 
                 NP_006176.2 
                 Cell cycle 
                 S77 
                 KHPSsPECLVSAQK 
                 cancer, leukemia 
                 Jurkat 
                 414 
               
               
                   
                   
                   
                 regulation 
               
               
                   
               
               
                 416 
                 NuMA-1 
                 NP_006176.2 
                 Cell cycle 
                 T2015 
                 ATSCFPRPMtPR 
                 cancer, 
                 SEM 
                 415 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 417 
                 NUP153 
                 NP_005115.2 
                 Receptor, 
                 T699 
                 QTGIEtPNK 
                 cancer, leukemia 
                 Jurkat 
                 416 
               
               
                   
                   
                   
                 channel, 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 418 
                 NUP35 
                 NP_612142.2 
                 Receptor, 
                 T109 
                 SIYDDISSPGLGSTPLt 
                 cancer, cervical, 
                 HeLa 
                 417 
               
               
                   
                   
                   
                 channel, 
                   
                 SR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 419 
                 NUP35 
                 NP_612142.2 
                 Receptor, 
                 T270 
                 tLGTPTQPGSTPR 
                 cancer, cervical, 
                 HeLa 
                 418 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 420 
                 NUP50 
                 NP_009103.2 
                 Receptor, 
                 T246 
                 LQQESTFLFHGNKTED 
                 cancer, cervical, 
                 HeLa 
                 419 
               
               
                   
                   
                   
                 channel, 
                   
                 tPDKK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 421 
                 NUP98 
                 NP_005378.4 
                 Receptor, 
                 T553 
                 ALTTPTHYKLtPR 
                 cancer, leukemia 
                 Jurkat 
                 420 
               
               
                   
                   
                   
                 channel, 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 422 
                 NUP98 
                 NP_005378.4 
                 Receptor, 
                 T670 
                 PIPQtPESAGNK 
                 cancer, leukemia 
                 Jurkat 
                 421 
               
               
                   
                   
                   
                 channel, 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 423 
                 NUSAP1 
                 NP_060924.4 
                 Cell cycle 
                 T299 
                 SLTKtPAR 
                 cancer, cervical, 
                 HeLa 
                 422 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 424 
                 OAS3 
                 NP_006178.2 
                 Enzyme, misc. 
                 T365 
                 AGCSGLGHPIQLDPN 
                 cancer, cervical, 
                 HeLa 
                 423 
               
               
                   
                   
                   
                   
                   
                 QKtPENSK 
                 adenocarcinoma 
               
               
                   
               
               
                 425 
                 OFD1 
                 NP_003602.1 
                 Cell cycle 
                 S735 
                 RLsSTPLPK 
                 cancer, lung, 
                 H3255 
                 424 
               
               
                   
                   
                   
                 regulation 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 426 
                 P18SRP 
                 NP_776190.1 
                 RNA 
                 S150 
                 HSSTPNSsEFSR 
                 cancer, cervical, 
                 HeLa 
                 425 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 427 
                 p57Kip2 
                 NP_000067.1 
                 Transcriptional 
                 S299 
                 SSGDVPAPCPSPsAAP 
                 cancer, cervical, 
                 HeLa 
                 426 
               
               
                   
                   
                   
                 regulator 
                   
                 GVGSVEQTPR 
                 adenocarcinoma 
               
               
                   
               
               
                 428 
                 PACS-1 
                 NP_060496.2 
                 Adaptor/ 
                 T321 
                 TRRKLTStSAITRQPNIK 
                 cancer, lung, 
                 H1703 
                 427 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 429 
                 PARD3 
                 NP_062565.2 
                 Adaptor/ 
                 S1139 
                 NSKPsPVDSNRSTPSN 
                 cancer, cervical, 
                 HeLa 
                 428 
               
               
                   
                   
                   
                 scaffold 
                   
                 HDR 
                 adenocarcinoma 
               
               
                   
               
               
                 430 
                 PARD3 
                 NP_062565.2 
                 Adaptor/ 
                 T1147 
                 NSKPSPVDSNRStPSN 
                 cancer, cervical, 
                 HeLa 
                 429 
               
               
                   
                   
                   
                 scaffold 
                   
                 HDR 
                 adenocarcinoma 
               
               
                   
               
               
                 431 
                 PARG 
                 NP_003622.2 
                 Unassigned 
                 T945 
                 NCStPGPDIK 
                 cancer, cervical, 
                 HeLa 
                 430 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 432 
                 PCM-1 
                 NP_006188.3 
                 Cell cycle 
                 S537 
                 KDEETEESEYDsEHEN 
                 cancer, cervical, 
                 HeLa 
                 431 
               
               
                   
                   
                   
                 regulation 
                   
                 SEPVTNIR 
                 adenocarcinoma 
               
               
                   
               
               
                 433 
                 PCNT 
                 NP_006022.3 
                 Unassigned 
                 T191 
                 GMFTVSDHtPEQR 
                 cancer, leukemia 
                 Jurkat 
                 432 
               
               
                   
               
               
                 434 
                 PCNXL3 
                 NP_115599.2 
                 Unknown 
                 S128 
                 VSsTPPVR 
                 cancer, cervical, 
                 HeLa 
                 433 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 435 
                 PCNXL3 
                 NP_115599.2 
                 Unknown 
                 T129 
                 VSStPPVR 
                 cancer, cervical, 
                 HeLa 
                 434 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 436 
                 PDCD7 
                 NP_005698.1 
                 Unassigned 
                 T153 
                 QWLEAVFGtPR 
                 cancer, cervical, 
                 HeLa 
                 435 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 437 
                 PDE3B 
                 NP_000913.2 
                 Enzyme, misc. 
                 T561 
                 SLGNAPNtPDFYQQLR 
                 cancer, leukemia 
                 Jurkat 
                 436 
               
               
                   
               
               
                 438 
                 PDE4B 
                 NP_002591.2 
                 Enzyme, misc. 
                 S140 
                 SDsDYDLSPK 
                   
                 mouse 
                 437 
               
               
                   
                   
                   
                   
                   
                   
                   
                 heart 
               
               
                   
               
               
                 439 
                 PDLIM3 
                 NP_001107579.1 
                 Cytoskeletal 
                 S145 
                 QVVSASYNsPIGLYST 
                 cancer, cervical, 
                 HeLa 
                 438 
               
               
                   
                 iso2 
                   
                 protein 
                   
                 SNIQDALHGQLR 
                 adenocarcinoma 
               
               
                   
               
               
                 440 
                 PDLIM7 
                 NP_005442.2 
                 Cytoskeletal 
                 S203 
                 TEAPAPAsSTPQEPW 
                 cancer, cervical, 
                 HeLa 
                 439 
               
               
                   
                   
                   
                 protein 
                   
                 PGPTAPSPTSRPPWA 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 VDPAFAER 
               
               
                   
               
               
                 441 
                 peregrin 
                 NP_004625.2 
                 Unknown 
                 S880 
                 GLGPNMSsTPAHEVGR 
                 cancer, cervical, 
                 HeLa 
                 440 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 442 
                 PEX14 
                 NP_004556.1 
                 Adaptor/ 
                 S232 
                 QFPPsPSAPK 
                 cancer, 
                 K562 
                 441 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 443 
                 PEX14 
                 NP_004556.1 
                 Adaptor/ 
                 S234 
                 QFPPSPsAPK 
                   
                 Embryo 
                 442 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 444 
                 PHACTR4 
                 NP_076412.3 
                 Phosphatase 
                 T368 
                 SPSPPLPtHIPPEPPRT 
                 cancer, lung, 
                 H1703 
                 443 
               
               
                   
                   
                   
                   
                   
                 PPFPAK 
                 non-small cell 
               
               
                   
               
               
                 445 
                 PHLPP 
                 O60346.3 
                 Phosphatase 
                 T451 
                 AAAAVAPGGLQStPGR 
                 cancer, cervical, 
                 HeLa 
                 444 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 446 
                 PIMT 
                 NP_079107.6 
                 Transcriptional 
                 S405 
                 DRPHAsGTDGDESEE 
                 cancer, lung, 
                 H1703 
                 445 
               
               
                   
                   
                   
                 regulator 
                   
                 DPPEHKPSK 
                 non-small cell 
               
               
                   
               
               
                 447 
                 PIMT 
                 NP_079107.6 
                 Transcriptional 
                 T407 
                 DRPHASGtDGDESEE 
                 cancer, leukemia 
                 Jurkat 
                 446 
               
               
                   
                   
                   
                 regulator 
                   
                 DPPEHKPSK 
               
               
                   
               
               
                 448 
                 PIMT 
                 NP_079107.6 
                 Transcriptional 
                 S412 
                 DRPHASGTDGDEsEE 
                 cancer, lung, 
                 H1703 
                 447 
               
               
                   
                   
                   
                 regulator 
                   
                 DPPEHKPSK 
                 non-small cell 
               
               
                   
               
               
                 449 
                 PKHD1L1 
                 NP_803875.2 
                 Unassigned 
                 S3568 
                 SPRsPSGGR 
                 cancer, cervical, 
                 HeLa 
                 448 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 450 
                 plakophilin 3 
                 NP_009114.1 
                 Adhesion or 
                 S115 
                 PAYsPASWSSR 
                 cancer, 
                 K562 
                 449 
               
               
                   
                   
                   
                 extracellular 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                 matrix protein 
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 451 
                 PLCL2 
                 Q9UPR0.2 
                 Lipid binding 
                 S17 
                 GGAAGGALPTsPGPA 
                 cancer, leukemia 
                 Jurkat 
                 450 
               
               
                   
                   
                   
                 protein 
                   
                 LGAK 
               
               
                   
               
               
                 452 
                 PLEKHA2 
                 NP_067636.1 
                 Unassigned 
                 T358 
                 APSVASSWQPWtPVP 
                 cancer, cervical, 
                 HeLa 
                 451 
               
               
                   
                   
                   
                   
                   
                 QAGEK 
                 adenocarcinoma 
               
               
                   
               
               
                 453 
                 PLEKHC1 
                 NP_006823.1 
                 Cytoskeletal 
                 S339 
                 LSIMTSENHLNNsDKE 
                 cancer, cervical, 
                 HeLa 
                 452 
               
               
                   
                   
                   
                 protein 
                   
                 VDEVDAALSDLEITLE 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 GGK 
               
               
                   
               
               
                 454 
                 PMCA4 
                 NP_001675.3 
                 Receptor, 
                 T1145 
                 SIHSFMTHPEFAIEEEL 
                 cancer, leukemia 
                 Jurkat 
                 453 
               
               
                   
                   
                   
                 channel, 
                   
                 PRtPLLDEEEEENPDK 
               
               
                   
                   
                   
                 transporter or 
                   
                 ASK 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 455 
                 POLA2 
                 NP_002680.2 
                 Chromatin, 
                 T133 
                 AISTPETPLtKR 
                 cancer, cervical, 
                 HeLa 
                 454 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 456 
                 POLS 
                 NP_008930.1 
                 Chromatin, 
                 S337 
                 IATCNGEQTQNREPEs 
                 cancer, leukemia 
                 Jurkat 
                 455 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 PYGQR 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 457 
                 polybromo 1 
                 NP_060783.3 
                 Chromatin, 
                 S27 
                 ATSPSSSVSGDFDDG 
                 cancer, lung, 
                 H1703 
                 456 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 HHSVsTPGPSR 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 458 
                 POM121 
                 A8CG34.2 
                 Receptor, 
                 S95 
                 TLFAsPPAK 
                 cancer, cervical, 
                 HeLa 
                 457 
               
               
                   
                 iso3 
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 459 
                 PPARBP 
                 NP_004765.2 
                 Transcriptional 
                 S1439 
                 NYGSPLISGsTPK 
                 cancer, 
                 K562 
                 458 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 460 
                 PPP1CC 
                 NP_002701.1 
                 Phosphatase 
                 T311 
                 KKPNATRPVtPPR 
                 cancer, leukemia 
                 Jurkat 
                 459 
               
               
                   
               
               
                 461 
                 PPP1R13L 
                 NP_006654.2 
                 Transcriptional 
                 T241 
                 AQDDLtLR 
                 cancer, cervical, 
                 HeLa 
                 460 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 462 
                 PPP2R5D 
                 NP_851307.1 
                 Phosphatase 
                 T63 
                 RPSNStPPPTQLSK 
                 cancer, cervical, 
                 HeLa 
                 461 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 463 
                 PPP4R2 
                 NP_777567.1 
                 Unassigned 
                 T173 
                 SNINGPGtPRPLNRPK 
                 cancer, leukemia 
                 Jurkat 
                 462 
               
               
                   
               
               
                 464 
                 PRC1 
                 NP_003972.1 
                 Cell cycle 
                 S521 
                 LPPsGSKPVAASTCSG 
                 cancer, cervical, 
                 HeLa 
                 463 
               
               
                   
                   
                   
                 regulation 
                   
                 KKTPR 
                 adenocarcinoma 
               
               
                   
               
               
                 465 
                 PRC1 
                 NP_003972.1 
                 Cell cycle 
                 S529 
                 LPPSGSKPVAAsTCSG 
                 cancer, cervical, 
                 HeLa 
                 464 
               
               
                   
                   
                   
                 regulation 
                   
                 KKTPR 
                 adenocarcinoma 
               
               
                   
               
               
                 466 
                 PRC1 
                 NP_003972.1 
                 Cell cycle 
                 S532 
                 LPPSGSKPVAASTCsG 
                 cancer, cervical, 
                 HeLa 
                 465 
               
               
                   
                   
                   
                 regulation 
                   
                 KKTPR 
                 adenocarcinoma 
               
               
                   
               
               
                 467 
                 PRC1 
                 NP_003972.1 
                 Cell cycle 
                 T536 
                 LPPSGSKPVAASTCS 
                 cancer, cervical, 
                 HeLa 
                 466 
               
               
                   
                   
                   
                 regulation 
                   
                 GKKtPR 
                 adenocarcinoma 
               
               
                   
               
               
                 468 
                 PRR12 
                 NP_065770.1 
                 Chromatin, 
                 T224 
                 LAGGGVLGPAGLGPA 
                 cancer, lung, 
                 H1703 
                 467 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 QtPPYRPGPPDPPPPPR 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 469 
                 PRR12 
                 NP_065770.1 
                 Chromatin, 
                 T738 
                 GGEtPEGLATSVVHYG 
                   
                 Adult 
                 468 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 AGAK 
                   
                 mouse 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                   
                 brain 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 470 
                 PRR12 
                 NP_065770.1 
                 Chromatin, 
                 S1191 
                 IRPLEVPTTAGPASAsT 
                 cancer, cervical, 
                 HeLa 
                 469 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 PTDGAK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 471 
                 PSF 
                 NP_005057.1 
                 Transcriptional 
                 T226 
                 MPGGPKPGGGPGLSt 
                 cancer, cervical, 
                 HeLa 
                 470 
               
               
                   
                   
                   
                 regulator 
                   
                 PGGHPKPPHR 
                 adenocarcinoma 
               
               
                   
               
               
                 472 
                 PSF 
                 NP_005057.1 
                 Transcriptional 
                 S379 
                 NLsPYVSNELLEEAFS 
                 cancer, cervical, 
                 HeLa 
                 471 
               
               
                   
                   
                   
                 regulator 
                   
                 QFGPIER 
                 adenocarcinoma 
               
               
                   
               
               
                 473 
                 PSMB5 
                 NP_002788.1 
                 Protease 
                 T262 
                 VSSDNVADLHEKYSG 
                 cancer, leukemia 
                 Jurkat 
                 472 
               
               
                   
                   
                   
                   
                   
                 StP 
               
               
                   
               
               
                 474 
                 PSMD8 
                 NP_002803.2 
                 Protease 
                 S106 
                 GEWNRKsPNLSK 
                 cancer, cervical, 
                 HeLa 
                 473 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 475 
                 PSRC1 
                 NP_116025.1 
                 Tumor 
                 T138 
                 StPSPSSLTPR 
                 cancer, cervical, 
                 HeLa 
                 474 
               
               
                   
                   
                   
                 suppressor 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 476 
                 PTPRK 
                 NP_002835.2 
                 Phosphatase 
                 S857 
                 YLCEGTEsPYQTGQLH 
                 cancer, leukemia 
                 Jurkat 
                 475 
               
               
                   
                   
                   
                   
                   
                 PAIR 
               
               
                   
               
               
                 477 
                 PWWP2 
                 NP_001092107.1 
                 Unknown 
                 T259 
                 ISYStPQGK 
                 cancer, 
                 SEM 
                 476 
               
               
                   
                   
                   
                 function 
                   
                   
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 478 
                 Rab11FIP5 
                 NP_056285.1 
                 Cytoskeletal 
                 S188 
                 DKPRsPFSK 
                 cancer, leukemia 
                 Jurkat 
                 477 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 479 
                 Rab3IL1 
                 NP_037533.2 
                 G protein or 
                 T165 
                 TLVITStPASPNRELHP 
                 cancer, 
                 HEL 
                 478 
               
               
                   
                   
                   
                 regulator 
                   
                 QLLSPTK 
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 480 
                 RABEP2 
                 NP_079092.2 
                 G protein or 
                 S66 
                 AELAGALAEMETMKA 
                 cancer, 
                 K562 
                 479 
               
               
                   
                   
                   
                 regulator 
                   
                 VAEVSEsTK 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 481 
                 RAD54L 
                 NP_003570.2 
                 Chromatin, 
                 T31 
                 SCDDEDWQPGLVtPR 
                 cancer, 
                 K562 
                 480 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                 chronic 
               
               
                   
                   
                   
                 DNA replication 
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                 protein 
                   
                   
                 (CML) 
               
               
                   
               
               
                 482 
                 RAI1 
                 NP_109590.3 
                 Transcriptional 
                 S470 
                 NLVsRTPEQHK 
                   
                 Adult 
                 481 
               
               
                   
                   
                   
                 regulator 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 483 
                 RAI1 
                 NP_109590.3 
                 Transcriptional 
                 T472 
                 NLVSRtPEQHK 
                 cancer, leukemia 
                 Jurkat 
                 482 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 484 
                 RAI1 
                 NP_109590.3 
                 Transcriptional 
                 T1476 
                 RPYLGPALLLtPR 
                 cancer, leukemia 
                 Jurkat 
                 483 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 485 
                 RAI14 
                 Q9P0K7.2 
                 Adaptor/ 
                 S296 
                 SITsTPLSGK 
                 cancer, cervical, 
                 HeLa 
                 484 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 486 
                 RALGPS2 
                 NP_689876.2 
                 G protein or 
                 T290 
                 IEPGTStPR 
                 cancer, cervical, 
                 HeLa 
                 485 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 487 
                 RAMP 
                 Q9NZJ0.2 
                 Adaptor/ 
                 S416 
                 EsRPGLVTVTSSQSTP 
                 cancer, cervical, 
                 HeLa 
                 486 
               
               
                   
                   
                   
                 scaffold 
                   
                 AKAPR 
                 adenocarcinoma 
               
               
                   
               
               
                 488 
                 RAMP 
                 Q9NZJ0.2 
                 Adaptor/ 
                 S425 
                 ESRPGLVTVTsSQSTP 
                 cancer, leukemia 
                 Jurkat 
                 487 
               
               
                   
                   
                   
                 scaffold 
                   
                 AKAPR 
               
               
                   
               
               
                 489 
                 RAMP 
                 Q9NZJ0.2 
                 Adaptor/ 
                 S428 
                 ESRPGLVTVTSSQsTP 
                 cancer, lung, 
                 H1703 
                 488 
               
               
                   
                   
                   
                 scaffold 
                   
                 AKAPR 
                 non-small cell 
               
               
                   
               
               
                 490 
                 RAMP 
                 Q9NZJ0.2 
                 Adaptor/ 
                 S656 
                 ENSsPENKNWLLAMA 
                 cancer, cervical, 
                 HeLa 
                 489 
               
               
                   
                   
                   
                 scaffold 
                   
                 AK 
                 adenocarcinoma 
               
               
                   
               
               
                 491 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 490 
               
               
                   
                   
                   
                 scaffold 
               
               
                   
               
               
                 492 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 S773 
                 NADsEIKHSTPSPTR 
                 cancer, cervical, 
                 HeLa 
                 491 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 493 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 S778 
                 NADSEIKHsTPSPTR 
                 cancer, cervical, 
                 HeLa 
                 492 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 494 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 T1393 
                 ELVGPPLAEtVFTPKTS 
                 cancer, cervical, 
                 HeLa 
                 493 
               
               
                   
                   
                   
                 scaffold 
                   
                 PENVQDR 
                 adenocarcinoma 
               
               
                   
               
               
                 495 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 S1640 
                 QNQTTsAVSTPASSET 
                 cancer, lung, 
                 H1703 
                 494 
               
               
                   
                   
                   
                 scaffold 
                   
                 SK 
                 non-small cell 
               
               
                   
               
               
                 496 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 S1699 
                 QNQTTsAVSTPASSET 
                 cancer, lung, 
                 H1703 
                 495 
               
               
                   
                   
                   
                 scaffold 
                   
                 SK 
                 non-small cell 
               
               
                   
               
               
                 497 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 T1703 
                 QNQTTSAVStPASSET 
                 cancer, lung, 
                 H1703 
                 496 
               
               
                   
                   
                   
                 scaffold 
                   
                 SK 
                 non-small cell 
               
               
                   
               
               
                 498 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 T1761 
                 QNQTTAIStPASSEISK 
                 cancer, cervical, 
                 HeLa 
                 497 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 499 
                 RanBP2 
                 NP_006258.3 
                 Adaptor/ 
                 T2458 
                 DSLITPHVSRSStPR 
                 cancer, 
                 K562 
                 498 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 500 
                 RANBP9 
                 NP_005484.2 
                 Adaptor/ 
                 S489 
                 SQDSYPVSPRPFSSP 
                 cancer, lung, 
                 H524 
                 499 
               
               
                   
                   
                   
                 scaffold 
                   
                 SMSPsHGMNIHNLAS 
                 small-cell 
               
               
                   
                   
                   
                   
                   
                 GK 
               
               
                   
               
               
                 501 
                 RAP140 
                 NP_001106207.1 
                 Unknown 
                 S979 
                 SSDYQFPSsPFTDTLK 
                 cancer, cervical, 
                 HeLa 
                 500 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 502 
                 RASAL2 
                 NP_004832.1 
                 G protein or 
                 S758 
                 ETQSTPQsAPQVR 
                 cancer, lung, 
                 H1703 
                 501 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 503 
                 RAVER1 
                 Q8IY67.1 
                 Unassigned 
                 T594 
                 AAMWAStPR 
                 cancer, cervical, 
                 HeLa 
                 502 
               
               
                   
                 iso1 
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 504 
                 Rb 
                 NP_000312.2 
                 Transcriptional 
                 T601 
                 DREGPTDHLESACPL 
                 cancer, leukemia 
                 Jurkat 
                 503 
               
               
                   
                   
                   
                 regulator 
                   
                 NLPLQNNHtAADMYLS 
               
               
                   
                   
                   
                   
                   
                 PVRSPK 
               
               
                   
               
               
                 505 
                 RbBP6 
                 NP_061173.1 
                 Cell cycle 
                 S654 
                 LKEESKsPYSGSSYSR 
                 cancer, leukemia 
                 Jurkat 
                 504 
               
               
                   
                 iso2 
                   
                 regulation 
               
               
                   
               
               
                 506 
                 RBM12B 
                 NP_976324.2 
                 RNA 
                 S839 
                 SPQEEDFRCPsDEDFR 
                 cancer, cervical, 
                 HeLa 
                 505 
               
               
                   
                 iso4 
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 507 
                 RBM22 
                 NP_060517.1 
                 RNA 
                 T154 
                 TtPYYK 
                 cancer, cervical, 
                 HeLa 
                 506 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 508 
                 RBM23 
                 NP_060577.3 
                 Unassigned 
                 S112 
                 VHYRsPPLATGYR 
                 cancer, leukemia 
                 Jurkat 
                 507 
               
               
                   
               
               
                 509 
                 RBM27 
                 Q9P2N5.2 
                 RNA 
                 S883 
                 TsSAVSTPSKVK 
                 cancer, lung, 
                 H1703 
                 508 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 510 
                 RBM27 
                 Q9P2N5.2 
                 RNA 
                 S887 
                 TSSAVsTPSKVK 
                 cancer, lung, 
                 H1703 
                 509 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 511 
                 RBM27 
                 Q9P2N5.2 
                 RNA 
                 S890 
                 TSSAVSTPsKVK 
                 cancer, cervical, 
                 HeLa 
                 510 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 512 
                 RBM41 
                 NP_060771.2 
                 Unassigned 
                 T113 
                 LRAtPEAIQNR 
                 cancer, cervical, 
                 HeLa 
                 511 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 513 
                 RBM5 
                 NP_005769.1 
                 RNA 
                 S72 
                 RNSDRsEDGYHSDGD 
                 cancer, lung, 
                 H1703 
                 512 
               
               
                   
                   
                   
                 processing 
                   
                 YGEHDYR 
                 non-small cell 
               
               
                   
               
               
                 514 
                 RBM9 iso6 
                 NP_001076047.1 
                 Unassigned 
                 T67 
                 TEEAAADGGGGMQN 
                 cancer, cervical, 
                 HeLa 
                 513 
               
               
                   
                   
                   
                   
                   
                 EPLtPGYHGFPAR 
                 adenocarcinoma 
               
               
                   
               
               
                 515 
                 RBMS3 
                 NP_055298.2 
                 Unassigned 
                 S111 
                 GYGFVDFDsPAAAQK 
                 cancer, cervical, 
                 HeLa 
                 514 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 516 
                 RBMS3 
                 NP_055298.2 
                 Unassigned 
                 S268 
                 EGEAGMALTYDPTAAI 
                 cancer, cervical, 
                 HeLa 
                 515 
               
               
                   
                   
                   
                   
                   
                 QNGFYSsPYSIATNR 
                 adenocarcinoma 
               
               
                   
               
               
                 517 
                 RCOR3 
                 NP_060724.1 
                 Unknown 
                 S156 
                 HNQGDsDDDVEETHP 
                 cancer, cervical, 
                 HeLa 
                 516 
               
               
                   
                   
                   
                 function 
                   
                 MDGNDSDYDPKK 
                 adenocarcinoma 
               
               
                   
               
               
                 518 
                 RCOR3 
                 NP_060724.1 
                 Unknown 
                 S171 
                 HNQGDSDDDVEETHP 
                 cancer, cervical, 
                 HeLa 
                 517 
               
               
                   
                   
                   
                 function 
                   
                 MDGNDsDYDPKK 
                 adenocarcinoma 
               
               
                   
               
               
                 519 
                 RED1 
                 NP_001103.1 
                 Unassigned 
                 T32 
                 DGStPGPGEGSQLSN 
                 cancer, cervical, 
                 HeLa 
                 518 
               
               
                   
                   
                   
                   
                   
                 GGGGGPGR 
                 adenocarcinoma 
               
               
                   
               
               
                 520 
                 restin 
                 NP_002947.1 
                 Cytoskeletal 
                 S43 
                 AsSTPSSETQEEFVDD 
                 cancer, cervical, 
                 HeLa 
                 519 
               
               
                   
                   
                   
                 protein 
                   
                 FR 
                 adenocarcinoma 
               
               
                   
               
               
                 521 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 S127 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 520 
               
               
                   
               
               
                 522 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 S795 
                 SYKYsPKTPPR 
                 cancer, leukemia 
                 Jurkat 
                 521 
               
               
                   
               
               
                 523 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 T798 
                 YSPKtPPR 
                 cancer, leukemia 
                 Jurkat 
                 522 
               
               
                   
               
               
                 524 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 T1310 
                 LNQSGTSVGtDEESDV 
                 cancer, lung, 
                 H1703 
                 523 
               
               
                   
                   
                   
                   
                   
                 TQEEER 
                 non-small cell 
               
               
                   
               
               
                 525 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 T1467 
                 DSLItPHVSRSSTPR 
                 cancer, 
                 K562 
                 524 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 526 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 S1474 
                 DSLITPHVSRSsTPR 
                 cancer, 
                 K562 
                 525 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 527 
                 RGPD1 
                 NP_001019628.2 
                 Unassigned 
                 T1475 
                 DSLITPHVSRSStPR 
                 cancer, 
                 K562 
                 526 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 528 
                 RGPD2 
                 P0C839.1 
                 Unassigned 
                 S52 
                 SYKYsPKTPPR 
                 cancer, leukemia 
                 Jurkat 
                 527 
               
               
                   
               
               
                 529 
                 RGPD2 
                 P0C839.1 
                 Unassigned 
                 T55 
                 YSPKtPPR 
                 cancer, leukemia 
                 Jurkat 
                 528 
               
               
                   
               
               
                 530 
                 RGPD2 
                 P0C839.1 
                 Unassigned 
                 T567 
                 LNQSGTSVGtDEESDV 
                 cancer, lung, 
                 H1703 
                 529 
               
               
                   
                   
                   
                   
                   
                 TQEEER 
                 non-small cell 
               
               
                   
               
               
                 531 
                 RGPD2 
                 P0C839.1 
                 Unassigned 
                 T724 
                 DSLItPHVSRSSTPR 
                 cancer, 
                 K562 
                 530 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 532 
                 RGPD2 
                 P0C839.1 
                 Unassigned 
                 S731 
                 DSLITPHVSRSsTPR 
                 cancer, 
                 K562 
                 531 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 533 
                 RGPD2 
                 P0C839.1 
                 Unassigned 
                 T732 
                 DSLITPHVSRSStPR 
                 cancer, 
                 K562 
                 532 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 534 
                 RGPD3 
                 A6NKT7.1 
                 Unassigned 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 533 
               
               
                   
               
               
                 535 
                 RGPD3 
                 A6NKT7.1 
                 Unassigned 
                 T1318 
                 LNQSGTSVGtDEESDV 
                 cancer, lung, 
                 H1703 
                 534 
               
               
                   
                   
                   
                   
                   
                 TQEEER 
                 non-small cell 
               
               
                   
               
               
                 536 
                 RGPD3 
                 A6NKT7.1 
                 Unassigned 
                 T1475 
                 DSLItPHVSRSSTPR 
                 cancer, 
                 K562 
                 535 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 537 
                 RGPD3 
                 A6NKT7.1 
                 Unassigned 
                 S1482 
                 DSLITPHVSRSsTPR 
                 cancer, 
                 K562 
                 536 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 538 
                 RGPD3 
                 A6NKT7.1 
                 Unassigned 
                 T1483 
                 DSLITPHVSRSStPR 
                 cancer, 
                 K562 
                 537 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 539 
                 RGPD4 
                 NP_872394.2 
                 Unassigned 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 538 
               
               
                   
               
               
                 540 
                 RGPD4 
                 NP_872394.2 
                 Unassigned 
                 T1318 
                 LNQSGTSVGtDEESDV 
                 cancer, lung, 
                 H1703 
                 539 
               
               
                   
                   
                   
                   
                   
                 TQEEER 
                 non-small cell 
               
               
                   
               
               
                 541 
                 RGPD4 
                 NP_872394.2 
                 Unassigned 
                 T1475 
                 DSLItPHVSRSSTPR 
                 cancer, 
                 K562 
                 540 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 542 
                 RGPD4 
                 NP_872394.2 
                 Unassigned 
                 S1482 
                 DSLITPHVSRSsTPR 
                 cancer, 
                 K562 
                 541 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 543 
                 RGPD4 
                 NP_872394.2 
                 Unassigned 
                 T1483 
                 DSLITPHVSRSStPR 
                 cancer, 
                 K562 
                 542 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 544 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 543 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 545 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 S773 
                 NADsEIKHSTPSPTR 
                 cancer, leukemia 
                 Jurkat 
                 544 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 546 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 S778 
                 NADSEIKHsTPSPTR 
                 cancer, leukemia 
                 Jurkat 
                 545 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 547 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 T779 
                 NADSEIKHStPSPTR 
                   
                 Embryo 
                 546 
               
               
                   
                   
                   
                 function 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 548 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 S781 
                 NADSEIKHSTPsPTR 
                   
                 Embryo 
                 547 
               
               
                   
                   
                   
                 function 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 549 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 T1474 
                 DSLItPHVSRSSTPR 
                 cancer, leukemia 
                 Jurkat 
                 548 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 550 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 S1481 
                 DSLITPHVSRSsTPR 
                 cancer, leukemia 
                 Jurkat 
                 549 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 551 
                 RGPD5 
                 Q53T03.1 
                 Unknown 
                 T1482 
                 DSLITPHVSRSStPR 
                 cancer, leukemia 
                 Jurkat 
                 550 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 552 
                 RGPD6 
                 NP_001116835.1 
                 Unknown 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 551 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 553 
                 RGPD6 
                 NP_001116835.1 
                 Unknown 
                 S1481 
                 DSLITPHVSRSsTPR 
                 cancer, leukemia 
                 Jurkat 
                 552 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 554 
                 RGPD6 
                 NP_001116835.1 
                 Unknown 
                 T1482 
                 DSLITPHVSRSStPR 
                 cancer, leukemia 
                 Jurkat 
                 553 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 555 
                 RGPD7 
                 NP_001032955.1 
                 Unassigned 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 554 
               
               
                   
               
               
                 556 
                 RGPD8 
                 XP_001722331.1 
                 Unassigned 
                 S128 
                 LFPGsPAIYK 
                 cancer, leukemia 
                 Jurkat 
                 555 
               
               
                   
               
               
                 557 
                 RGPD8 
                 XP_001722331.1 
                 Unassigned 
                 T1474 
                 DSLItPHVSRSSTPR 
                 cancer, 
                 K562 
                 556 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 558 
                 RGPD8 
                 XP_001722331.1 
                 Unassigned 
                 S1481 
                 DSLITPHVSRSsTPR 
                 cancer, 
                 K562 
                 557 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 559 
                 RGPD8 
                 XP_001722331.1 
                 Unassigned 
                 T1482 
                 DSLITPHVSRSStPR 
                 cancer, 
                 K562 
                 558 
               
               
                   
                   
                   
                   
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 560 
                 RIN2 
                 NP_061866.1 
                 G protein or 
                 T332 
                 LARTETQtSMPETVNH 
                 cancer, lung, 
                 H1703 
                 559 
               
               
                   
                   
                   
                 regulator 
                   
                 NK 
                 non-small cell 
               
               
                   
               
               
                 561 
                 RIN2 
                 NP_061866.1 
                 G protein or 
                 T337 
                 LARTETQTSMPEtVNH 
                 cancer, lung, 
                 H1703 
                 560 
               
               
                   
                   
                   
                 regulator 
                   
                 NK 
                 non-small cell 
               
               
                   
               
               
                 562 
                 RNF123 
                 NP_071347.2 
                 Ubiquitin 
                 T694 
                 FLSTAAVSLMtPR 
                 cancer, cervical, 
                 HeLa 
                 561 
               
               
                   
                   
                   
                 conjugating 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 system 
               
               
                   
               
               
                 563 
                 RNF4 
                 NP_002929.1 
                 Transcriptional 
                 T112 
                 DVYVTTHtPR 
                 cancer, cervical, 
                 HeLa 
                 562 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 564 
                 RNF40 
                 NP_055586.1 
                 Ubiquitin 
                 S556 
                 AQASGSAHSTPNLGH 
                 cancer, leukemia 
                 Jurkat 
                 563 
               
               
                   
                   
                   
                 conjugating 
                   
                 PEDSGVSAPAPGKEE 
               
               
                   
                   
                   
                 system 
                   
                 GGPGPVsTPDNR 
               
               
                   
               
               
                 565 
                 RNF40 
                 NP_055586.1 
                 Ubiquitin 
                 T557 
                 AQASGSAHSTPNLGH 
                 cancer, leukemia 
                 Jurkat 
                 564 
               
               
                   
                   
                   
                 conjugating 
                   
                 PEDSGVSAPAPGKEE 
               
               
                   
                   
                   
                 system 
                   
                 GGPGPVStPDNRK 
               
               
                   
               
               
                 566 
                 RNUT1 
                 NP_005692.1 
                 RNA 
                 T341 
                 ASENGHYELEHLStPK 
                 cancer, cervical, 
                 HeLa 
                 565 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 567 
                 RNUXA 
                 NP_115553.2 
                 RNA 
                 T358 
                 SLNFQEDDDTSRETFA 
                 cancer, leukemia 
                 Jurkat 
                 566 
               
               
                   
                   
                   
                 processing 
                   
                 SDtNEALASLDESQEG 
               
               
                   
                   
                   
                   
                   
                 HAEAK 
               
               
                   
               
               
                 568 
                 ROS 
                 NP_002935.2 
                 Protein kinase, 
                 S1273 
                 NsTIISFSVYPLLSR 
                 cancer, lung, 
                 H1703 
                 567 
               
               
                   
                   
                   
                 Tyr (receptor) 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 569 
                 RoXaN 
                 NP_060060.3 
                 Chromatin, 
                 S217 
                 GsPALLPSTPTMPLFP 
                 cancer, lung, 
                 H1703 
                 568 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 HVLDLLAPLDSSR 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 570 
                 RoXaN 
                 NP_060060.3 
                 Chromatin, 
                 S223 
                 GSPALLPsTPTMPLFP 
                 cancer, leukemia 
                 Jurkat 
                 569 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 HVLDLLAPLDSSR 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 571 
                 RP1 
                 NP_055083.1 
                 Cytoskeletal 
                 T217 
                 SSPAAKPGStPSRPSS 
                 cancer, leukemia 
                 Jurkat 
                 570 
               
               
                   
                   
                   
                 protein 
                   
                 AK 
               
               
                   
               
               
                 572 
                 RP1 
                 NP_055083.1 
                 Cytoskeletal 
                 S222 
                 SSPAAKPGSTPSRPsS 
                 cancer, cervical, 
                 HeLa 
                 571 
               
               
                   
                   
                   
                 protein 
                   
                 AK 
                 adenocarcinoma 
               
               
                   
               
               
                 573 
                 RP11- 
                 NP_078873.2 
                 Unknown 
                 S499 
                 WSsSPENACGLPSPIS 
                 cancer, cervical, 
                 HeLa 
                 572 
               
               
                   
                 535K18.3 
                   
                 function 
                   
                 TNR 
                 adenocarcinoma 
               
               
                   
               
               
                 574 
                 RP11- 
                 NP_078873.2 
                 Unknown 
                 S509 
                 WSSSPENACGLPsPIS 
                 cancer, cervical, 
                 HeLa 
                 573 
               
               
                   
                 535K18.3 
                   
                 function 
                   
                 TNR 
                 adenocarcinoma 
               
               
                   
               
               
                 575 
                 RPRC1 
                 NP_060537.3 
                 Unknown 
                 S469 
                 ARPSsPSTSWHRPAS 
                 cancer, lung, 
                 H128 
                 574 
               
               
                   
                   
                   
                 function 
                   
                 PCPSPGPGHTLPPKP 
                 small-cell 
               
               
                   
                   
                   
                   
                   
                 PSPR 
               
               
                   
               
               
                 576 
                 RPRC1 
                 NP_060537.3 
                 Unknown 
                 S496 
                 ARPSSPSTSWHRPAS 
                 cancer, lung, 
                 H128 
                 575 
               
               
                   
                   
                   
                 function 
                   
                 PCPSPGPGHTLPPKP 
                 small-cell 
               
               
                   
                   
                   
                   
                   
                 PsPR 
               
               
                   
               
               
                 577 
                 RPS9 
                 NP_001004.2 
                 Translation 
                 T15 
                 KTYVtPR 
                 cancer, leukemia 
                 Jurkat 
                 576 
               
               
                   
               
               
                 578 
                 RTN3 
                 NP_958831.1 
                 Endoplasmic 
                 T377 
                 TPVCSIDGStPITK 
                 cancer, cervical, 
                 HeLa 
                 577 
               
               
                   
                   
                   
                 reticulum or 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 golgi 
               
               
                   
               
               
                 579 
                 S6 
                 NP_001001.2 
                 Translation 
                 T181 
                 RLVtPR 
                 cancer, cervical, 
                 HeLa 
                 578 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 580 
                 Sam68 
                 NP_006550.1 
                 RNA 
                 T33 
                 SGSMDPSGAHPSVRQ 
                 cancer, lung, 
                 H1703 
                 579 
               
               
                   
                   
                   
                 processing 
                   
                 tPSR 
                 non-small cell 
               
               
                   
               
               
                 581 
                 SAMD4 
                 NP_056404.2 
                 RNA 
                 S421 
                 AYSSPsTTPEAR 
                 cancer, cervical, 
                 HeLa 
                 580 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 582 
                 SART3 
                 NP_055521.1 
                 Transcriptional 
                 S778 
                 PMFVsPCVDK 
                 cancer, cervical, 
                 HeLa 
                 581 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 583 
                 Sec24B 
                 NP_006314.2 
                 Vesicle protein 
                 S311 
                 SsPVVSTVLSGSSGSS 
                 cancer, cervical, 
                 HeLa 
                 582 
               
               
                   
                   
                   
                   
                   
                 STR 
                 adenocarcinoma 
               
               
                   
               
               
                 584 
                 Sec24B 
                 NP_006314.2 
                 Vesicle protein 
                 S321 
                 SSPVVSTVLSGsSGSS 
                 cancer, cervical, 
                 HeLa 
                 583 
               
               
                   
                   
                   
                   
                   
                 STR 
                 adenocarcinoma 
               
               
                   
               
               
                 585 
                 Sec5 
                 NP_060773.3 
                 Vesicle protein 
                 S431 
                 GsSFQSGRDDTWR 
                 cancer, leukemia 
                 Jurkat 
                 584 
               
               
                   
               
               
                 586 
                 SEC62 
                 NP_081292.1 
                 Receptor, 
                 S341 
                 VGPGNHGTEGSGGE 
                   
                 mouse 
                 585 
               
               
                   
                   
                   
                 channel, 
                   
                 RHsDTDSDRR 
                   
                 liver 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 587 
                 SENP1 
                 NP_055369.1 
                 Transcriptional 
                 T102 
                 NStPSSSSSLQK 
                 cancer, leukemia 
                 Jurkat 
                 586 
               
               
                   
                   
                   
                 regulator 
               
               
                   
               
               
                 588 
                 SENP3 
                 NP_056485.2 
                 Protease 
                 S26 
                 MKETIQGTGSWGPEP 
                 cancer, leukemia 
                 Jurkat 
                 587 
               
               
                   
                   
                   
                   
                   
                 PGPGIPPAYSsPRR 
               
               
                   
               
               
                 589 
                 SEPT2 
                 NP_004395.1 
                 Cell cycle 
                 T14 
                 QQPTQFINPEtPGYVG 
                 cancer, 
                 HT29 
                 588 
               
               
                   
                   
                   
                 regulation 
                   
                 FANLPNQVHR 
                 colorectal 
               
               
                   
                   
                   
                   
                   
                   
                 carcinoma 
               
               
                   
               
               
                 590 
                 SEPT9 
                 NP_006631.2 
                 Cell cycle 
                 T237 
                 SQEATEAAPSCVGDM 
                 cancer, 
                 K562 
                 589 
               
               
                   
                   
                   
                 regulation 
                   
                 ADtPR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 591 
                 SF3B1 
                 NP_036565.2 
                 RNA 
                 T426 
                 VLPPPAGYVPIRtPAR 
                 cancer, lung, 
                 H1703 
                 590 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 592 
                 SFRS12 
                 NP_631907.1 
                 RNA 
                 T363 
                 SRtPPR 
                 cancer, cervical, 
                 HeLa 
                 591 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 593 
                 SgK269 
                 NP_079052.2 
                 Protein kinase, 
                 S389 
                 EIEPNYEsPSSNNQDK 
                 cancer, cervical, 
                 HeLa 
                 592 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                 DSSQASK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 594 
                 SH3D19 
                 Q5HYK7.2 
                 Unassigned 
                 S369 
                 SSsDMDLQKK 
                 cancer, cervical, 
                 HeLa 
                 593 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 595 
                 SHARP 
                 NP_055816.2 
                 Transcriptional 
                 S1622 
                 EVEKQEDTENHPKTP 
                 cancer, cervical, 
                 HeLa 
                 594 
               
               
                   
                   
                   
                 regulator 
                   
                 EsAPENK 
                 adenocarcinoma 
               
               
                   
               
               
                 596 
                 SHARP 
                 NP_055816.2 
                 Transcriptional 
                 T1946 
                 ELQEAAAVPtTPR 
                 cancer, cervical, 
                 HeLa 
                 595 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 597 
                 SHARP 
                 NP_055816.2 
                 Transcriptional 
                 T1947 
                 ELQEAAAVPTtPR 
                 cancer, cervical, 
                 HeLa 
                 596 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 598 
                 Sin3A 
                 NP_056292.1 
                 Transcriptional 
                 S274 
                 VSKPSQLQAHTPASQ 
                 cancer, leukemia 
                 Jurkat 
                 597 
               
               
                   
                   
                   
                 regulator 
                   
                 QTPPLPPYAsPR 
               
               
                   
               
               
                 599 
                 SIPA1L1 
                 NP_056371.1 
                 G protein or 
                 T1405 
                 SQAGStPLTR 
                 cancer, cervical, 
                 HeLa 
                 598 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 600 
                 SLBP 
                 NP_006518.1 
                 RNA 
                 S59 
                 RPEsFTTPEGPKPR 
                 cancer, leukemia 
                 Jurkat 
                 599 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 601 
                 SLC16A3 
                 NP_004198.1 
                 Receptor, 
                 T463 
                 AEPEKNGEVVHTPEtSV 
                 cancer, cervical, 
                 HeLa 
                 600 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 602 
                 SLC19A1 
                 NP_919231.1 
                 Receptor, 
                 S225 
                 CETSAsELER 
                 cancer, lung, 
                 H1703 
                 601 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 non-small cell 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 603 
                 SLC4A2 
                 NP_003031.3 
                 Receptor, 
                 T169 
                 tSPSSPAPLPHQEATPR 
                 cancer, cervical, 
                 HeLa 
                 602 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 604 
                 slingshot 2 
                 NP_203747.2 
                 Cytoskeletal 
                 T795 
                 AQtPENKPGHMEQDE 
                 cancer, leukemia 
                 Jurkat 
                 603 
               
               
                   
                   
                   
                 protein 
                   
                 DSCTAQPELAK 
               
               
                   
               
               
                 605 
                 SMARCAD1 
                 Q9H4L7.1 
                 Adaptor/ 
                 T71 
                 TEDSSVPEtPDNER 
                 cancer, leukemia 
                 Jurkat 
                 604 
               
               
                   
                   
                   
                 scaffold 
               
               
                   
               
               
                 606 
                 SMARCAL1 
                 NP_001120679.1 
                 Unassigned 
                 T215 
                 ASPSGQNISYIHSSSE 
                 cancer, cervical, 
                 HeLa 
                 605 
               
               
                   
                   
                   
                   
                   
                 SVtPR 
                 adenocarcinoma 
               
               
                   
               
               
                 607 
                 smoothelin 
                 NP_008863.3 
                 Cytoskeletal 
                 S314 
                 EsTPLASGPSSFQR 
                 cancer, cervical, 
                 HeLa 
                 606 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 608 
                 SMRT iso4 
                 NP_006303.3 
                 Transcriptional 
                 S1900 
                 GIITAVEPsTPTVLR 
                 cancer, cervical, 
                 HeLa 
                 607 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 609 
                 SMRT iso4 
                 NP_006303.3 
                 Transcriptional 
                 T1901 
                 GIITAVEPStPTVLR 
                 cancer, cervical, 
                 HeLa 
                 608 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 610 
                 SNIP 
                 NP_079524.2 
                 Cytoskeletal 
                 T997 
                 YRtEKPSKSPPPPPPR 
                 cancer, cervical, 
                 HeLa 
                 609 
               
               
                   
                   
                   
                 protein 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 611 
                 SNIP 
                 NP_079524.2 
                 Cytoskeletal 
                 S1003 
                 YRTEKPSKsPPPPPPR 
                   
                 Embryo 
                 610 
               
               
                   
                   
                   
                 protein 
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 612 
                 SNX4 
                 NP_003785.1 
                 Unassigned 
                 T367 
                 LFGQEtPEQR 
                 cancer, cervical, 
                 HeLa 
                 611 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 613 
                 SOLO 
                 XP_341310.3 
                 Unknown 
                 T1201 
                 GPDGPWGVGtPR 
                   
                 mouse 
                 612 
               
               
                   
                   
                   
                 function 
                   
                   
                   
                 brain 
               
               
                   
               
               
                 614 
                 SP110 
                 Q9HB58.4 
                 Chromatin, 
                 S256 
                 DNsPEPNDPEEPQEV 
                 cancer, lung, 
                 H1703 
                 613 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SSTPSDKK 
                 non-small cell 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 615 
                 SP110 
                 Q9HB58.4 
                 Chromatin, 
                 S270 
                 DNSPEPNDPEEPQEV 
                 cancer, cervical, 
                 HeLa 
                 614 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SsTPSDKK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 616 
                 SP110 
                 Q9HB58.4 
                 Chromatin, 
                 T271 
                 DNSPEPNDPEEPQEV 
                 cancer, cervical, 
                 HeLa 
                 615 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 SStPSDKK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 617 
                 SPECC1 
                 NP_001028725.1 
                 Unknown 
                 S241 
                 ELsDLEEENR 
                 cancer, cervical, 
                 HeLa 
                 616 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 618 
                 SPT5 
                 NP_003160.2 
                 Transcriptional 
                 S780 
                 TPMYGSQTPMYGsGS 
                 cancer, leukemia 
                 Jurkat 
                 617 
               
               
                   
                   
                   
                 regulator 
                   
                 RTPMYGSQTPLQDGSR 
               
               
                   
               
               
                 619 
                 SPTAN1 
                 NP_003118.2 
                 Adaptor/ 
                 S1413 
                 AGTFQAFEQFGQQLL 
                 cancer, cervical, 
                 HeLa 
                 618 
               
               
                   
                   
                   
                 scaffold 
                   
                 AHGHYAsPEIK 
                 adenocarcinoma 
               
               
                   
               
               
                 620 
                 SR-A1 
                 Q9H7N4.2 
                 Unknown 
                 S975 
                 VPsTPPPK 
                 cancer, leukemia 
                 Jurkat 
                 619 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 621 
                 SRm300 
                 NP_057417.3 
                 RNA 
                 S1042 
                 SsTPPGESYFGVSSLQ 
                 cancer, lung, 
                 H1703 
                 620 
               
               
                   
                   
                   
                 processing 
                   
                 LK 
                 non-small cell 
               
               
                   
               
               
                 622 
                 SRm300 
                 NP_057417.3 
                 RNA 
                 T1680 
                 tKSRTPPR 
                 cancer, cervical, 
                 HeLa 
                 621 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 623 
                 SRm300 
                 NP_057417.3 
                 RNA 
                 T1720 
                 SRtPPR 
                 cancer, cervical, 
                 HeLa 
                 622 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 624 
                 SRp46 
                 NP_115285.1 
                 RNA 
                 S158 
                 YSRsPYSR 
                 cancer, leukemia 
                 Jurkat 
                 623 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 625 
                 SRp46 
                 NP_115285.1 
                 RNA 
                 S163 
                 YSRsPYSR 
                 cancer, leukemia 
                 Jurkat 
                 624 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 626 
                 SRp46 
                 NP_115285.1 
                 RNA 
                 S173 
                 YSRsPYSR 
                 cancer, lung, 
                 N06CS91 
                 625 
               
               
                   
                   
                   
                 processing 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 627 
                 SSBP2 
                 NP_036578.2 
                 Chromatin, 
                 T333 
                 NSPNNMSLSNQPGtPR 
                 cancer, leukemia 
                 Jurkat 
                 626 
               
               
                   
                   
                   
                 DNA-binding, 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 628 
                 SSFA2 
                 NP_006742.2 
                 Cytoskeletal 
                 S883 
                 TLSTHSVPNISGATCS 
                 cancer, cervical, 
                 HeLa 
                 627 
               
               
                   
                   
                   
                 protein 
                   
                 AFAsPFGCPYSHR 
                 adenocarcinoma 
               
               
                   
               
               
                 629 
                 supervillin 
                 NP_068506.2 
                 Transcriptional 
                 S86 
                 SKYCTETSGVHGDsP 
                 cancer, cervical, 
                 HeLa 
                 628 
               
               
                   
                   
                   
                 regulator 
                   
                 YGSGTMDTHSLESK 
                 adenocarcinoma 
               
               
                   
               
               
                 630 
                 SURF6 
                 NP_006744.2 
                 Unassigned 
                 T184 
                 KAEEATEAQEVVEAtP 
                 cancer, leukemia 
                 Jurkat 
                 629 
               
               
                   
                   
                   
                   
                   
                 EGACTEPR 
               
               
                   
               
               
                 631 
                 SYNE2 
                 NP_878918.2 
                 Adaptor/ 
                 T6365 
                 LTSCTPGLEDEKEASE 
                 cancer, leukemia 
                 Jurkat 
                 630 
               
               
                   
                   
                   
                 scaffold 
                   
                 NEtDMEDPR 
               
               
                   
               
               
                 632 
                 synergin, 
                 NP_542117.2 
                 Adaptor/ 
                 S644 
                 SVsTPQSTGSAATMTA 
                 cancer, leukemia 
                 Jurkat 
                 631 
               
               
                   
                 gamma 
                   
                 scaffold 
                   
                 LAATK 
               
               
                   
               
               
                 633 
                 TACC3 
                 NP_006333.1 
                 Cell cycle 
                 T59 
                 VTFQtPLRDPQTHR 
                 cancer, leukemia 
                 Jurkat 
                 632 
               
               
                   
                   
                   
                 regulation 
               
               
                   
               
               
                 634 
                 TAFII31 
                 NP_081415.1 
                 Transcriptional 
                 S152 
                 LSVGsVTSRPSTPTLG 
                   
                 Embryo 
                 633 
               
               
                   
                   
                   
                 regulator 
                   
                 TPTPQTMSVSTK 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 635 
                 talin 1 
                 NP_006280.3 
                 Cytoskeletal 
                 T144 
                 KEEITGtLRK 
                 cancer, leukemia 
                 Jurkat 
                 634 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 636 
                 talin 1 
                 NP_006280.3 
                 Cytoskeletal 
                 S2162 
                 QELAVFCsPEPPAK 
                 cancer, leukemia 
                 Jurkat 
                 635 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 637 
                 TANC2 
                 NP_851416.2 
                 Unassigned 
                 S425 
                 ELPLTQPPSAHSsITSG 
                   
                 Embryo 
                 636 
               
               
                   
                   
                   
                   
                   
                 SCPGTPEMR 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 638 
                 TAO3 
                 NP_057365.3 
                 Protein kinase, 
                 T573 
                 IKEEMNEDHStPK 
                 cancer, cervical, 
                 HeLa 
                 637 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 639 
                 TBC1D16 
                 NP_061893.2 
                 G protein or 
                 T99 
                 YItPESSPVR 
                 cancer, lung, 
                 H1703 
                 638 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 640 
                 TBC1D23 
                 Q9NUY8.2 
                 G protein or 
                 T562 
                 GVKPVFSIGDEEEYDt 
                 cancer, cervical, 
                 HeLa 
                 639 
               
               
                   
                   
                   
                 regulator 
                   
                 DEIDSSSMSDDDRK 
                 adenocarcinoma 
               
               
                   
               
               
                 641 
                 TBC1D23 
                 Q9NUY8.2 
                 G protein or 
                 S571 
                 GVKPVFSIGDEEEYDT 
                 cancer, lung, 
                 H1703 
                 640 
               
               
                   
                   
                   
                 regulator 
                   
                 DEIDSSSMsDDDRK 
                 non-small cell 
               
               
                   
               
               
                 642 
                 TBC1D24 
                 NP_775278.2 
                 G protein or 
                 S476 
                 HPELTKPPPLMAAEPT 
                   
                 mouse 
                 641 
               
               
                   
                   
                   
                 regulator 
                   
                 APLSHSASSDPADRLs 
                   
                 heart 
               
               
                   
                   
                   
                   
                   
                 PFLAAR 
               
               
                   
               
               
                 643 
                 TBC1D4 
                 NP_055647.2 
                 G protein or 
                 T766 
                 TSSTCSNESLSVGGTS 
                 cancer, leukemia 
                 Jurkat 
                 642 
               
               
                   
                   
                   
                 regulator 
                   
                 VtPR 
               
               
                   
               
               
                 644 
                 TCF20 
                 NP_852469.1 
                 Transcriptional 
                 S1760 
                 SASNGsKTDTEEEEEQ 
                 cancer, lung, 
                 H1703 
                 643 
               
               
                   
                   
                   
                 regulator 
                   
                 QQQQK 
                 non-small cell 
               
               
                   
               
               
                 645 
                 TCF7L1 
                 NP_112573.1 
                 Unassigned 
                 T511 
                 PEtRAQLALHSAAFLS 
                 cancer, lung, 
                 H1703 
                 644 
               
               
                   
                   
                   
                   
                   
                 AK 
                 non-small cell 
               
               
                   
               
               
                 646 
                 TCF7L1 
                 NP_112573.1 
                 Unassigned 
                 S519 
                 PETRAQLALHsAAFLS 
                 cancer, lung, 
                 H1703 
                 645 
               
               
                   
                   
                   
                   
                   
                 AK 
                 non-small cell 
               
               
                   
               
               
                 647 
                 TCF8 
                 P37275.2 
                 Transcriptional 
                 T151 
                 QGtPEASGHDENGTP 
                 cancer, cervical, 
                 HeLa 
                 646 
               
               
                   
                   
                   
                 regulator 
                   
                 DAFSQLLTCPYCDR 
                 adenocarcinoma 
               
               
                   
               
               
                 648 
                 TFIIF-alpha 
                 NP_002087.2 
                 Transcriptional 
                 T427 
                 LDtGPQSLSGKSTPQP 
                 cancer, leukemia 
                 Jurkat 
                 647 
               
               
                   
                   
                   
                 regulator 
                   
                 PSGK 
               
               
                   
               
               
                 649 
                 THAP4 
                 NP_057047.3 
                 Unassigned 
                 T154 
                 QAALQGEAtPR 
                 cancer, cervical, 
                 HeLa 
                 648 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 650 
                 THOC2 
                 NP_065182.1 
                 RNA 
                 T1173 
                 EKTPAtTPEAR 
                 cancer, leukemia 
                 Jurkat 
                 649 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 651 
                 THOC2 
                 NP_065182.1 
                 RNA 
                 S1405 
                 SESPCEsPYPNEKDKEK 
                 cancer, leukemia 
                 Jurkat 
                 650 
               
               
                   
                   
                   
                 processing 
               
               
                   
               
               
                 652 
                 TIPIN 
                 NP_060328.2 
                 Unassigned 
                 T233 
                 LLSNSQTLGNDMLMNt 
                 cancer, leukemia 
                 Jurkat 
                 651 
               
               
                   
                   
                   
                   
                   
                 PR 
               
               
                   
               
               
                 653 
                 TLE1 
                 NP_005068.2 
                 Transcriptional 
                 T312 
                 AStPVLK 
                 cancer, cervical, 
                 HeLa 
                 652 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 654 
                 TNRC6B 
                 NP_055903.2 
                 Unknown 
                 S1345 
                 GGSPYNQFDIIPGDTL 
                 cancer, leukemia 
                 Jurkat 
                 653 
               
               
                   
                   
                   
                 function 
                   
                 GGHTGPAGDsWLPAK 
               
               
                   
                   
                   
                   
                   
                 SPPTNK 
               
               
                   
               
               
                 655 
                 TOP2B 
                 NP_001059.2 
                 Chromatin, 
                 T1595 
                 KTSFDQDSDVDIFPSD 
                 cancer, cervical, 
                 HeLa 
                 654 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 FPTEPPSLPRtGR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 656 
                 TOR1AIP1 
                 NP_056417.2 
                 Receptor, 
                 T20 
                 EGWGVYVtPR 
                 cancer, cervical, 
                 HeLa 
                 655 
               
               
                   
                   
                   
                 channel, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 657 
                 TPR 
                 NP_598541.2 
                 Receptor, 
                 S640 
                 ILLSQTTGVAIPLHASS 
                   
                 Embryo 
                 656 
               
               
                   
                   
                   
                 channel, 
                   
                 LDDVSLAsTPK 
                   
                 mouse 
               
               
                   
                   
                   
                 transporter or 
                   
                   
                   
                 brain 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 658 
                 TPR 
                 NP_003283.2 
                 Receptor, 
                 S2136 
                 TVPsTPTLVVPHRTDG 
                 cancer, lung, 
                 H1703 
                 657 
               
               
                   
                   
                   
                 channel, 
                   
                 FAEAIHSPQVAGVPR 
                 non-small cell 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 659 
                 treacle 
                 NP_000347.2 
                 Transcriptional 
                 T1098 
                 SAHTLGPtPSR 
                 cancer, cervical, 
                 HeLa 
                 658 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 660 
                 TRPS1 
                 NP_054831.2 
                 Unassigned 
                 T764 
                 VYNLLtPDSK 
                 cancer, cervical, 
                 HeLa 
                 659 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 661 
                 Tsc22d4 
                 NP_112197.1 
                 Unknown 
                 S49 
                 LPNGEPsPDPGGKGT 
                 cancer, 
                 K562 
                 660 
               
               
                   
                   
                   
                 function 
                   
                 PR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 662 
                 Tsc22d4 
                 NP_112197.1 
                 Unknown 
                 T57 
                 LPNGEPSPDPGGKGtPR 
                 cancer, 
                 K562 
                 661 
               
               
                   
                   
                   
                 function 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 663 
                 UBA3 
                 NP_937838.1 
                 Transcriptional 
                 S385 
                 LQEVLDYLTNSASLQM 
                 cancer, cervical, 
                 HeLa 
                 662 
               
               
                   
                   
                   
                 regulator 
                   
                 KsPAITATLEGK 
                 adenocarcinoma 
               
               
                   
               
               
                 664 
                 UBAP2 
                 NP_060919.2 
                 Unknown 
                 S630 
                 IPYQsPVSSSESAPGTI 
                 cancer, leukemia 
                 Jurkat 
                 663 
               
               
                   
                   
                   
                 function 
                   
                 MNGHGGGR 
               
               
                   
               
               
                 665 
                 UBAP2 
                 NP_060919.2 
                 Unknown 
                 S1114 
                 SQASKPAYGNsPYWTN 
                 cancer, cervical, 
                 HeLa 
                 664 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 666 
                 UBE2I 
                 NP_919235.1 
                 Transcriptional 
                 S71 
                 DDYPSsPPK 
                 cancer, cervical, 
                 HeLa 
                 665 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 667 
                 UBP1 
                 NP_001121633.1 
                 Unassigned 
                 T194 
                 TSAFIQVHCISTEFtPR 
                 cancer, leukemia 
                 Jurkat 
                 666 
               
               
                   
               
               
                 668 
                 UBR4 
                 NP_065816.2 
                 Ubiquitin 
                 S1762 
                 ISESLVRHASTsSPADK 
                 cancer, leukemia 
                 Jurkat 
                 667 
               
               
                   
                   
                   
                 conjugating 
               
               
                   
                   
                   
                 system 
               
               
                   
               
               
                 669 
                 UCK2 
                 NP_036606.2 
                 Unassigned 
                 T246 
                 QTNGCLNGYtPSR 
                 cancer, leukemia 
                 Jurkat 
                 668 
               
               
                   
               
               
                 670 
                 UKp68 
                 NP_079100.2 
                 Chromatin, 
                 S527 
                 FIVTLDGVPsPPGYMS 
                 cancer, cervical, 
                 HeLa 
                 669 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 DQEEDMCFEGMKPVN 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
                   
                 QTAASNK 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 671 
                 UKp68 
                 NP_079100.2 
                 Chromatin, 
                 S533 
                 FIVTLDGVPSPPGYMs 
                 cancer, cervical, 
                 HeLa 
                 670 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 DQEEDMCFEGMKPVN 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
                   
                 QTAASNK 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 672 
                 UPF3B 
                 NP_075386.1 
                 RNA 
                 S176 
                 MTsTPETLLEEIEAK 
                 cancer, cervical, 
                 HeLa 
                 671 
               
               
                   
                   
                   
                 processing 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 673 
                 USF2 
                 NP_003358.1 
                 Unassigned 
                 T230 
                 IDGTRtPRDER 
                 cancer, leukemia 
                 Jurkat 
                 672 
               
               
                   
               
               
                 674 
                 USP24 
                 NP_056121.1 
                 Protease 
                 T1129 
                 QMSLCGtPEK 
                 cancer, leukemia 
                 Jurkat 
                 673 
               
               
                   
               
               
                 675 
                 USP32 
                 NP_115971.2 
                 Ubiquitin 
                 T1326 
                 DPALCQHKPLtPQGDE 
                 cancer, 
                 HEL 
                 674 
               
               
                   
                   
                   
                 conjugating 
                   
                 LSEPR 
                 leukemia, acute 
               
               
                   
                   
                   
                 system 
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 676 
                 USP35 
                 NP_065849.1 
                 Ubiquitin 
                 S982 
                 AAYISALPTsPHWGR 
                 cancer, 
                 Kyse140 
                 675 
               
               
                   
                   
                   
                 conjugating 
                   
                   
                 esophageal 
               
               
                   
                   
                   
                 system 
                   
                   
                 carcinoma 
               
               
                   
               
               
                 677 
                 USP37 
                 Q86T82.1 
                 Ubiquitin 
                 S630 
                 ASQMVNSCITSPsTPS 
                 cancer, cervical, 
                 HeLa 
                 676 
               
               
                   
                   
                   
                 conjugating 
                   
                 KK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 system 
               
               
                   
               
               
                 678 
                 USP54 
                 NP_689799.3 
                 Ubiquitin 
                 T442 
                 DTGHLtDSECNQK 
                 cancer, cervical, 
                 HeLa 
                 677 
               
               
                   
                   
                   
                 conjugating 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 system 
               
               
                   
               
               
                 679 
                 VASP 
                 NP_003361.1 
                 Cytoskeletal 
                 T335 
                 SSSSVTTSETQPCtPS 
                 cancer, leukemia 
                 Jurkat 
                 678 
               
               
                   
                   
                   
                 protein 
                   
                 SSDYSDLQR 
               
               
                   
               
               
                 680 
                 VGLL4 
                 Q14135.4 
                 Transcriptional 
                 S276 
                 RGQPASPsAHMVSHS 
                 cancer, 
                 HEL 
                 679 
               
               
                   
                   
                   
                 regulator 
                   
                 HSPSVVS 
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (AML) 
               
               
                   
               
               
                 681 
                 VPRBP 
                 NP_055518.1 
                 Ubiquitin 
                 T891 
                 EADLPMTAASHSSAFT 
                 cancer, cervical, 
                 HeLa 
                 680 
               
               
                   
                   
                   
                 conjugating 
                   
                 PVtAAASPVSLPRTPR 
                 adenocarcinoma 
               
               
                   
                   
                   
                 system 
               
               
                   
               
               
                 682 
                 WAC 
                 NP_057712.2 
                 Adaptor/ 
                 S62 
                 RsDSPENKYSDSTGH 
                 cancer, leukemia 
                 Jurkat 
                 681 
               
               
                   
                   
                   
                 scaffold 
                   
                 SK 
               
               
                   
               
               
                 683 
                 WAC 
                 NP_057712.2 
                 Adaptor/ 
                 S64 
                 SDsPENKYSDSTGHSK 
                 cancer, leukemia 
                 Jurkat 
                 682 
               
               
                   
                   
                   
                 scaffold 
               
               
                   
               
               
                 684 
                 WDR11 
                 NP_060404.3 
                 Adaptor/ 
                 T1482 
                 SESSTSAFSTPtR 
                 cancer, cervical, 
                 HeLa 
                 683 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 685 
                 WDR12 
                 Q9GZL7.2 
                 Unassigned 
                 T221 
                 IWSTVPtDEEDEMEES 
                 cancer, leukemia 
                 Jurkat 
                 684 
               
               
                   
                   
                   
                   
                   
                 TNRPR 
               
               
                   
               
               
                 686 
                 WDR43 
                 NP_055946.1 
                 Unknown 
                 S666 
                 ELNGDsDLDPENESEEE 
                 cancer, cervical, 
                 HeLa 
                 685 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 687 
                 WDR43 
                 NP_055946.1 
                 Unknown 
                 S674 
                 ELNGDSDLDPENEsEEE 
                 cancer, cervical, 
                 HeLa 
                 686 
               
               
                   
                   
                   
                 function 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 688 
                 WDR75 
                 NP_115544.1 
                 Unknown 
                 T692 
                 QLLAEESLPtTPFYFIL 
                 cancer, 
                 SEM 
                 687 
               
               
                   
                   
                   
                 function 
                   
                 GK 
                 leukemia, acute 
               
               
                   
                   
                   
                   
                   
                   
                 lymphocytic 
               
               
                   
                   
                   
                   
                   
                   
                 (ALL) 
               
               
                   
               
               
                 689 
                 WDR9 
                 NP_061836.2 
                 Transcriptional 
                 S1703 
                 DENQLLPVsSSHTAQS 
                 cancer, cervical, 
                 HeLa 
                 688 
               
               
                   
                   
                   
                 regulator 
                   
                 NVDESENRDSESESD 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 LRVARK 
               
               
                   
               
               
                 690 
                 WDR9 
                 NP_061836.2 
                 Transcriptional 
                 S1715 
                 DENQLLPVSSSHTAQ 
                 cancer, cervical, 
                 HeLa 
                 689 
               
               
                   
                   
                   
                 regulator 
                   
                 SNVDEsENRDSESES 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 DLRVARK 
               
               
                   
               
               
                 691 
                 WDR9 
                 NP_061836.2 
                 Transcriptional 
                 S1720 
                 DENQLLPVSSSHTAQ 
                 cancer, cervical, 
                 HeLa 
                 690 
               
               
                   
                   
                   
                 regulator 
                   
                 SNVDESENRDsESES 
                 adenocarcinoma 
               
               
                   
                   
                   
                   
                   
                 DLRVARK 
               
               
                   
               
               
                 692 
                 WHSC1 
                 NP_001074571.1 
                 Enzyme, misc. 
                 S401 
                 LCSSAETLESHPDIGK 
                   
                 Embryo 
                 691 
               
               
                   
                   
                   
                   
                   
                 sTPQK 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 693 
                 WHSC1 
                 NP_001074571.1 
                 Enzyme, misc. 
                 T402 
                 LCSSAETLESHPDIGK 
                   
                 Embryo 
                 692 
               
               
                   
                   
                   
                   
                   
                 StPQK 
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 694 
                 WHSC1L1 
                 NP_060248.2 
                 Chromatin, 
                 T547 
                 LIIStPNQR 
                 cancer, cervical, 
                 HeLa 
                 693 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 695 
                 WHSC2 
                 NP_005654.3 
                 Transcriptional 
                 T223 
                 KMDTTtPLK 
                 cancer, cervical, 
                 HeLa 
                 694 
               
               
                   
                   
                   
                 regulator 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 696 
                 WHSC2 
                 NP_005654.3 
                 Transcriptional 
                 T238 
                 QAPFRSPtAPSVFSPT 
                 cancer, 
                 K562 
                 695 
               
               
                   
                   
                   
                 regulator 
                   
                 GNRTPIPPSR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 697 
                 XRCC1 
                 P18887.1 
                 Chromatin, 
                 T440 
                 TKPtQAAGPSSPQKPP 
                 cancer, cervical, 
                 HeLa 
                 696 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 TPEETK 
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 698 
                 ZAK 
                 NP_057737.2 
                 Protein kinase, 
                 S700 
                 GRYSGKsQHSTPSRGR 
                 cancer, cervical, 
                 HeLa 
                 697 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 699 
                 ZAK 
                 NP_057737.2 
                 Protein kinase, 
                 S703 
                 GRYSGKSQHsTPSRGR 
                 cancer, cervical, 
                 HeLa 
                 698 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 700 
                 ZAK 
                 NP_057737.2 
                 Protein kinase, 
                 S706 
                 GRYSGKSQHSTPsRGR 
                 cancer, cervical, 
                 HeLa 
                 699 
               
               
                   
                   
                   
                 Ser/Thr (non- 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 receptor) 
               
               
                   
               
               
                 701 
                 ZBBX iso2 
                 NP_078963.2 
                 Unknown 
                 T624 
                 ItLAGQKSQRPSTANF 
                 cancer, gastric 
                 MKN- 
                 700 
               
               
                   
                   
                   
                 function 
                   
                 PLSNSVKE 
                   
                 45 
               
               
                   
               
               
                 702 
                 ZBBX iso2 
                 NP_078963.2 
                 Unknown 
                 S630 
                 ITLAGQKsQRPSTANF 
                 cancer, gastric 
                 MKN- 
                 701 
               
               
                   
                   
                   
                 function 
                   
                 PLSNSVKE 
                   
                 45 
               
               
                   
               
               
                 703 
                 ZBBX iso2 
                 NP_078963.2 
                 Unknown 
                 T635 
                 ITLAGQKSQRPStANF 
                 cancer, gastric 
                 MKN- 
                 702 
               
               
                   
                   
                   
                 function 
                   
                 PLSNSVKE 
                   
                 45 
               
               
                   
               
               
                 704 
                 ZBTB17 
                 Q13105.3 
                 Unassigned 
                 S156 
                 LEQAGRsTPIGPSR 
                 cancer, leukemia 
                 Jurkat 
                 703 
               
               
                   
               
               
                 705 
                 ZBTB2 
                 NP_065912.1 
                 Unassigned 
                 T459 
                 TFStPNEVVK 
                 cancer, cervical, 
                 HeLa 
                 704 
               
               
                   
                   
                   
                   
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 706 
                 ZC3H7A 
                 NP_054872.2 
                 Unknown 
                 T210 
                 ALNHSVEDIEPDLLtPR 
                 cancer, 
                 K562 
                 705 
               
               
                   
                   
                   
                 function 
                   
                   
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 707 
                 ZCCHC8 
                 NP_060082.2 
                 Unassigned 
                 T374 
                 LVNYPGFNIStPR 
                 cancer, leukemia 
                 Jurkat 
                 706 
               
               
                   
               
               
                 708 
                 ZFP161 
                 NP_003400.2 
                 Transcriptional 
                 T225 
                 KVNCYGQEVESMEtP 
                 cancer, leukemia 
                 Jurkat 
                 707 
               
               
                   
                   
                   
                 regulator 
                   
                 ESK 
               
               
                   
               
               
                 709 
                 ZNF174 
                 NP_003441.1 
                 Transcriptional 
                 T165 
                 TGSQLGEQELPDFQP 
                 cancer, 
                 K562 
                 708 
               
               
                   
                   
                   
                 regulator 
                   
                 QtPR 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 710 
                 ZNF185 
                 NP_009081.2 
                 Chromatin, 
                 S446 
                 GGQGDPAVPAQQPA 
                 cancer, 
                 HT29 
                 709 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 DPsTPER 
                 colorectal 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                 carcinoma 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 711 
                 ZNF185 
                 NP_009081.2 
                 Chromatin, 
                 S452 
                 GGQGDPAVPAQQPA 
                 cancer, 
                 HT29 
                 710 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 DPSTPERQsSPSGSE 
                 colorectal 
               
               
                   
                   
                   
                 DNA repair or 
                   
                 QLVR 
                 carcinoma 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 712 
                 ZNF185 
                 NP_009081.2 
                 Chromatin, 
                 S519 
                 GGQGDPAVPTQQPAD 
                 cancer, 
                 HT29 
                 711 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 PSTPEQQNsPSGSEQ 
                 colorectal 
               
               
                   
                   
                   
                 DNA repair or 
                   
                 FVR 
                 carcinoma 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 713 
                 ZNF185 
                 NP_009081.2 
                 Chromatin, 
                 S617 
                 KPPCGsTPYSER 
                 cancer, cervical, 
                 HeLa 
                 712 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 714 
                 ZNF185 
                 NP_009081.2 
                 Chromatin, 
                 T618 
                 KPPCGStPYSER 
                 cancer, cervical, 
                 HeLa 
                 713 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                   
                 adenocarcinoma 
               
               
                   
                   
                   
                 DNA repair or 
               
               
                   
                   
                   
                 DNA replication 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 715 
                 ZNF262 
                 NP_005086.2 
                 Chromatin, 
                 T217 
                 AANQVEETLHTHLPQt 
                 cancer, 
                 HEL 
                 714 
               
               
                   
                   
                   
                 DNA-binding, 
                   
                 PETNFR 
                 leukemia, acute 
               
               
                   
                   
                   
                 DNA repair or 
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                 DNA replication 
                   
                   
                 (AML) 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
               
                 716 
                 ZNF318 
                 NP_055160.2 
                 Transcriptional 
                 S40 
                 RSsPPPPPSGSSSRTP 
                 cancer, cervical, 
                 HeLa 
                 715 
               
               
                   
                   
                   
                 regulator 
                   
                 AR 
                 adenocarcinoma 
               
               
                   
               
               
                 717 
                 ZNF318 
                 NP_055160.2 
                 Transcriptional 
                 T52 
                 RSSPPPPPSGSSSRtP 
                 cancer, cervical, 
                 HeLa 
                 716 
               
               
                   
                   
                   
                 regulator 
                   
                 AR 
                 adenocarcinoma 
               
               
                   
               
               
                 718 
                 ZNF503 
                 NP_116161.2 
                 Unassigned 
                 T223 
                 VPSATCQPFtPR 
                   
                 Embryo 
                 717 
               
               
                   
                   
                   
                   
                   
                   
                   
                 mouse 
               
               
                   
                   
                   
                   
                   
                   
                   
                 brain 
               
               
                   
               
               
                 719 
                 ZNF609 
                 NP_055857.1 
                 Unknown 
                 S361 
                 FCDSPTsDLEMR 
                 cancer, lung, 
                 H1703 
                 718 
               
               
                   
                   
                   
                 function 
                   
                   
                 non-small cell 
               
               
                   
               
               
                 720 
                 ZNF609 
                 NP_055857.1 
                 Unknown 
                 S758 
                 AEEGKsPFRESSGDG 
                 cancer, 
                 K562 
                 719 
               
               
                   
                   
                   
                 function 
                   
                 MK 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 721 
                 ZNF609 
                 NP_055857.1 
                 Unknown 
                 T817 
                 LENTtPTQPLTPLHVVT 
                 cancer, 
                 K562 
                 720 
               
               
                   
                   
                   
                 function 
                   
                 QNGAEASSVK 
                 leukemia, 
               
               
                   
                   
                   
                   
                   
                   
                 chronic 
               
               
                   
                   
                   
                   
                   
                   
                 myelogenous 
               
               
                   
                   
                   
                   
                   
                   
                 (CML) 
               
               
                   
               
               
                 722 
                 ZNF609 
                 NP_055857.1 
                 Unknown 
                 S1311 
                 sKSPTISDKTSQER 
                 cancer, leukemia 
                 Jurkat 
                 721 
               
               
                   
                   
                   
                 function 
               
               
                   
               
               
                 723 
                 ZO1 
                 NP_003248.3 
                 Adaptor/ 
                 T1521 
                 TVtPAYNR 
                 cancer, cervical, 
                 HeLa 
                 722 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 724 
                 ZO2 
                 NP_004808.2 
                 Adaptor/ 
                 T445 
                 ERPSSREDtPSR 
                 cancer, cervical, 
                 HeLa 
                 723 
               
               
                   
                   
                   
                 scaffold 
                   
                   
                 adenocarcinoma 
               
               
                   
               
               
                 725 
                 ZXDC 
                 NP_079388.3 
                 Unassigned 
                 S171 
                 APQASGPsTPGYR 
                   
                   
                 724 
               
               
                   
               
               
                 726 
                 ZXDC 
                 NP_079388.3 
                 Unassigned 
                 T172 
                 APQASGPStPGYR 
                   
                   
                 725 
               
               
                   
               
               
                 727 
                 4ET 
                 NP_062817.1 
                 Receptor, 
                 S259 
                 RTRRRTAsVKEGIVE 
                   
                   
                 726 
               
               
                   
                   
                   
                 channel, 
               
               
                   
                   
                   
                 transporter or 
               
               
                   
                   
                   
                 cell surface 
               
               
                   
                   
                   
                 protein 
               
               
                   
               
            
           
         
       
     
     The invention also provides peptides comprising a novel phosphorylation site of the invention. In one particular embodiment, the peptides comprise any one of the amino acid sequences as set forth in SEQ ID NOs: 1-726, which are trypsin-digested peptide fragments of the parent proteins. Alternatively, a parent signaling protein listed in Table 1 may be digested with another protease, and the sequence of a peptide fragment comprising a phosphorylation site can be obtained in a similar way. Suitable proteases include, but are not limited to, serine and threonine proteases (e.g. hepsin), metallo proteases (e.g. PUMP1), chymotrypsin, cathepsin, pepsin, thermolysin, carboxypeptidases, etc. 
     The invention also provides proteins and peptides that are mutated to eliminate a novel phosphorylation site of the invention. Such proteins and peptides are particular useful as research tools to understand complex signaling transduction pathways of cancer cells, for example, to identify new upstream kinase(s) or phosphatase(s) or other proteins that regulates the activity of a signaling protein; to identify downstream effector molecules that interact with a signaling protein, etc. 
     Various methods that are well known in the art can be used to eliminate a phosphorylation site. For example, the phosphorylatable serine or threonine may be mutated into a non-phosphorylatable residue, such as phenylalanine. A “phosphorylatable” amino acid refers to an amino acid that is capable of being modified by addition of a phosphate group (any includes both phosphorylated form and unphosphorylated form). Alternatively, the serine or threonine may be deleted. Residues other than the serine or threonine may also be modified (e.g., delete or mutated) if such modification inhibits the phosphorylation of the serine or threonine residue. For example, residues flanking the serine or threonine may be deleted or mutated, so that a kinase cannot recognize/phosphorylate the mutated protein or the peptide. Standard mutagenesis and molecular cloning techniques can be used to create amino acid substitutions or deletions. 
     2. Modulators of the Phosphorylation Sites 
     In another aspect, the invention provides a modulator that modulates serine or threonine phosphorylation at a novel phosphorylation site of the invention, including small molecules, peptides comprising a novel phosphorylation site, and binding molecules that specifically bind at a novel phosphorylation site, including but not limited to antibodies or antigen-binding fragments thereof. 
     Modulators of a phosphorylation site include any molecules that directly or indirectly counteract, reduce, antagonize or inhibit serine or threonine phosphorylation of the site. The modulators may compete or block the binding of the phosphorylation site to its upstream kinase(s) or phosphatase(s), or to its downstream signaling transduction molecule(s). 
     The modulators may directly interact with a phosphorylation site. The modulator may also be a molecule that does not directly interact with a phosphorylation site. For example, the modulators can be dominant negative mutants, i.e., proteins and peptides that are mutated to eliminate the phosphorylation site. Such mutated proteins or peptides could retain the binding ability to a downstream signaling molecule but lose the ability to trigger downstream signaling transduction of the wild type parent signaling protein. 
     The modulators include small molecules that modulate the serine or threonine phosphorylation at a novel phosphorylation site of the invention. Chemical agents, referred to in the art as “small molecule” compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, less than 5,000, less than 1,000, or less than 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of a phosphorylation site of the invention or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries. Methods for generating and obtaining compounds are well known in the art (Schreiber S L, Science 151: 1964-1969 (2000); Radmann J. and Gunther J., Science 151: 1947-1948 (2000)). 
     The modulators also include peptidomimetics, small protein-like chains designed to mimic peptides. Peptidomimetics may be analogues of a peptide comprising a phosphorylation site of the invention. Peptidomimetics may also be analogues of a modified peptide that are mutated to eliminate a phosphorylation site of the invention. Peptidomimetics (both peptide and non-peptidyl analogues) may have improved properties (e.g., decreased proteolysis, increased retention or increased bioavailability). Peptidomimetics generally have improved oral availability, which makes them especially suited to treatment of disorders in a human or animal. 
     In certain embodiments, the modulators are peptides comprising a novel phosphorylation site of the invention. In certain embodiments, the modulators are antibodies or antigen-binding fragments thereof that specifically bind a novel phosphorylation site of the invention. 
     3. Heavy-Isotope Labeled Peptides (AQUA Peptides). 
     In another aspect, the invention provides peptides comprising a novel phosphorylation site of the invention. In a particular embodiment, the invention provides Heavy-Isotype Labeled Peptides (AQUA peptides) comprising a novel phosphorylation site. Such peptides are useful to generate phosphorylation site-specific antibodies for a novel phosphorylation site. Such peptides are also useful as potential diagnostic tools for screening for diseases such as carcinoma or leukemia, or as potential therapeutic agents for treating diseases such as carcinoma or leukemia. 
     The peptides may be of any length, typically six to fifteen amino acids. The novel serine or threonine phosphorylation site can occur at any position in the peptide; if the peptide will be used as an immunogen, it preferably is from seven to twenty amino acids in length. In some embodiments, the peptide is labeled with a detectable marker. 
     “Heavy-isotope labeled peptide” (used interchangeably with AQUA peptide) refers to a peptide comprising at least one heavy-isotope label, as described in WO/03016861, “Absolute Quantification of Proteins and Modified Forms Thereof by Multistage Mass Spectrometry” (Gygi et al.) (the teachings of which are hereby incorporated herein by reference, in their entirety). The amino acid sequence of an AQUA peptide is identical to the sequence of a proteolytic fragment of the parent protein in which the novel phosphorylation site occurs. AQUA peptides of the invention are highly useful for detecting, quantitating or modulating a phosphorylation site of the invention (both in phosphorylated and unphosphorylated forms) in a biological sample. 
     A peptide of the invention, including an AQUA peptides comprises any novel phosphorylation site. Preferably, the peptide or AQUA peptide comprises a novel phosphorylation site of a protein in Table 1 that is an adaptor/scaffold protein, kinase/protease/phosphatase/enzyme proteins, protein kinase, cytoskeletal protein, ubiquitan conjugating system protein, chromatin or DNA binding/repair protein, g protein or regulator protein, receptor/channel/transporter/cell surface protein, transcriptional regulator and cell cycle regulation protein. 
     Particularly preferred peptides and AQUA peptides are these comprising a novel serine or threonine phosphorylation site (shown as a lower case “s” or “t” (respectively) within the sequences listed in Table 1) selected from the group consisting of SEQ ID NOs 1-726. 
     In some embodiments, the peptide or AQUA peptide comprises the amino acid sequence shown in any one of the above listed SEQ ID NOs. In some embodiments, the peptide or AQUA peptide consists of the amino acid sequence in said SEQ ID NOs. In some embodiments, the peptide or AQUA peptide comprises a fragment of the amino acid sequence in said SEQ ID NOs., wherein the fragment is six to twenty amino acid long and includes the phosphorylatable serine and/or threonine. In some embodiments, the peptide or AQUA peptide consists of a fragment of the amino acid sequence in said SEQ ID NOs., wherein the fragment is six to twenty amino acid long and includes the phosphorylatable serine and/or threonine. 
     In certain embodiments, the peptide or AQUA peptide comprises any one of SEQ ID NOs: 1-726, which are trypsin-digested peptide fragments of the parent proteins. 
     It is understood that parent protein listed in Table 1 may be digested with any suitable protease (e.g., serine proteases (e.g. trypsin, hepsin), metallo proteases (e.g. PUMP1), chymotrypsin, cathepsin, pepsin, thermolysin, carboxypeptidases, etc), and the resulting peptide sequence comprising a phosphorylated site of the invention may differ from that of trypsin-digested fragments (as set forth in Column E), depending the cleavage site of a particular enzyme. An AQUA peptide for a particular a parent protein sequence should be chosen based on the amino acid sequence of the parent protein and the particular protease for digestion; that is, the AQUA peptide should match the amino acid sequence of a proteolytic fragment of the parent protein in which the novel phosphorylation site occurs. 
     An AQUA peptide is preferably at least about 6 amino acids long. The preferred ranged is about 7 to 15 amino acids. 
     The AQUA method detects and quantifies a target protein in a sample by introducing a known quantity of at least one heavy-isotope labeled peptide standard (which has a unique signature detectable by LC-SRM chromatography) into a digested biological sample. By comparing to the peptide standard, one may readily determines the quantity of a peptide having the same sequence and protein modification(s) in the biological sample. Briefly, the AQUA methodology has two stages: (1) peptide internal standard selection and validation; method development; and (2) implementation using validated peptide internal standards to detect and quantify a target protein in a sample. The method is a powerful technique for detecting and quantifying a given peptide/protein within a complex biological mixture, such as a cell lysate, and may be used, e.g., to quantify change in protein phosphorylation as a result of drug treatment, or to quantify a protein in different biological states. 
     Generally, to develop a suitable internal standard, a particular peptide (or modified peptide) within a target protein sequence is chosen based on its amino acid sequence and a particular protease for digestion. The peptide is then generated by solid-phase peptide synthesis such that one residue is replaced with that same residue containing stable isotopes ( 13 C,  15 N). The result is a peptide that is chemically identical to its native counterpart formed by proteolysis, but is easily distinguishable by MS via a mass shift. A newly synthesized AQUA internal standard peptide is then evaluated by LC-MS/MS. This process provides qualitative information about peptide retention by reverse-phase chromatography, ionization efficiency, and fragmentation via collision-induced dissociation. Informative and abundant fragment ions for sets of native and internal standard peptides are chosen and then specifically monitored in rapid succession as a function of chromatographic retention to form a selected reaction monitoring (LC-SRM) method based on the unique profile of the peptide standard. 
     The second stage of the AQUA strategy is its implementation to measure the amount of a protein or the modified form of the protein from complex mixtures. Whole cell lysates are typically fractionated by SDS-PAGE gel electrophoresis, and regions of the gel consistent with protein migration are excised. This process is followed by in-gel proteolysis in the presence of the AQUA peptides and LC-SRM analysis. (See Gerber et al. supra.) AQUA peptides are spiked in to the complex peptide mixture obtained by digestion of the whole cell lysate with a proteolytic enzyme and subjected to immunoaffinity purification as described above. The retention time and fragmentation pattern of the native peptide formed by digestion (e.g., trypsinization) is identical to that of the AQUA internal standard peptide determined previously; thus, LC-MS/MS analysis using an SRM experiment results in the highly specific and sensitive measurement of both internal standard and analyte directly from extremely complex peptide mixtures. Because an absolute amount of the AQUA peptide is added (e.g. 250 fmol), the ratio of the areas under the curve can be used to determine the precise expression levels of a protein or phosphorylated form of a protein in the original cell lysate. In addition, the internal standard is present during in-gel digestion as native peptides are formed, such that peptide extraction efficiency from gel pieces, absolute losses during sample handling (including vacuum centrifugation), and variability during introduction into the LC-MS system do not affect the determined ratio of native and AQUA peptide abundances. 
     An AQUA peptide standard may be developed for a known phosphorylation site previously identified by the IAP-LC-MS/MS method within a target protein. One AQUA peptide incorporating the phosphorylated form of the site, and a second AQUA peptide incorporating the unphosphorylated form of site may be developed. In this way, the two standards may be used to detect and quantify both the phosphorylated and unphosphorylated forms of the site in a biological sample. 
     Peptide internal standards may also be generated by examining the primary amino acid sequence of a protein and determining the boundaries of peptides produced by protease cleavage. Alternatively, a protein may actually be digested with a protease and a particular peptide fragment produced can then sequenced. Suitable proteases include, but are not limited to, serine proteases (e.g. trypsin, hepsin), metallo proteases (e.g. PUMP1), chymotrypsin, cathepsin, pepsin, thermolysin, carboxypeptidases, etc. 
     A peptide sequence within a target protein is selected according to one or more criteria to optimize the use of the peptide as an internal standard. Preferably, the size of the peptide is selected to minimize the chances that the peptide sequence will be repeated elsewhere in other non-target proteins. Thus, a peptide is preferably at least about 6 amino acids. The size of the peptide is also optimized to maximize ionization frequency. Thus, peptides longer than about 20 amino acids are not preferred. The preferred ranged is about 7 to 15 amino acids. A peptide sequence is also selected that is not likely to be chemically reactive during mass spectrometry, thus sequences comprising cysteine, tryptophan, or methionine are avoided. 
     A peptide sequence that is outside a phosphorylation site may be selected as internal standard to determine the quantity of all forms of the target protein. Alternatively, a peptide encompassing a phosphorylated site may be selected as internal standard to detect and quantify only the phosphorylated form of the target protein. Peptide standards for both phosphorylated form and unphosphorylated form can be used together, to determine the extent of phosphorylation in a particular sample. 
     The peptide is labeled using one or more labeled amino acids (i.e. the label is an actual part of the peptide) or less preferably, labels may be attached after synthesis according to standard methods. Preferably, the label is a mass-altering label selected based on the following considerations: The mass should be unique to shift fragment masses produced by MS analysis to regions of the spectrum with low background; the ion mass signature component is the portion of the labeling moiety that preferably exhibits a unique ion mass signature in MS analysis; the sum of the masses of the constituent atoms of the label is preferably uniquely different than the fragments of all the possible amino acids. As a result, the labeled amino acids and peptides are readily distinguished from unlabeled ones by the ion/mass pattern in the resulting mass spectrum. Preferably, the ion mass signature component imparts a mass to a protein fragment that does not match the residue mass for any of the 20 natural amino acids. 
     The label should be robust under the fragmentation conditions of MS and not undergo unfavorable fragmentation. Labeling chemistry should be efficient under a range of conditions, particularly denaturing conditions, and the labeled tag preferably remains soluble in the MS buffer system of choice. The label preferably does not suppress the ionization efficiency of the protein and is not chemically reactive. The label may contain a mixture of two or more isotopically distinct species to generate a unique mass spectrometric pattern at each labeled fragment position. Stable isotopes, such as  13 C,  15 N,  17 O,  18 O, or  34 S, are among preferred labels. Pairs of peptide internal standards that incorporate a different isotope label may also be prepared. Preferred amino acid residues into which a heavy isotope label may be incorporated include leucine, proline, valine, and phenylalanine. 
     Peptide internal standards are characterized according to their mass-to-charge (m/z) ratio, and preferably, also according to their retention time on a chromatographic column (e.g. an HPLC column). Internal standards that co-elute with unlabeled peptides of identical sequence are selected as optimal internal standards. The internal standard is then analyzed by fragmenting the peptide by any suitable means, for example by collision-induced dissociation (CID) using, e.g., argon or helium as a collision gas. The fragments are then analyzed, for example by multi-stage mass spectrometry (MS″) to obtain a fragment ion spectrum, to obtain a peptide fragmentation signature. Preferably, peptide fragments have significant differences in m/z ratios to enable peaks corresponding to each fragment to be well separated, and a signature that is unique for the target peptide is obtained. If a suitable fragment signature is not obtained at the first stage, additional stages of MS are performed until a unique signature is obtained. 
     Fragment ions in the MS/MS and MS 3  spectra are typically highly specific for the peptide of interest, and, in conjunction with LC methods, allow a highly selective means of detecting and quantifying a target peptide/protein in a complex protein mixture, such as a cell lysate, containing many thousands or tens of thousands of proteins. Any biological sample potentially containing a target protein/peptide of interest may be assayed. Crude or partially purified cell extracts are preferably used. Generally, the sample has at least 0.01 mg of protein, typically a concentration of 0.1-10 mg/mL, and may be adjusted to a desired buffer concentration and pH. 
     A known amount of a labeled peptide internal standard, preferably about 10 femtomoles, corresponding to a target protein to be detected/quantified is then added to a biological sample, such as a cell lysate. The spiked sample is then digested with one or more protease(s) for a suitable time period to allow digestion. A separation is then performed (e.g., by HPLC, reverse-phase HPLC, capillary electrophoresis, ion exchange chromatography, etc.) to isolate the labeled internal standard and its corresponding target peptide from other peptides in the sample. Microcapillary LC is a preferred method. 
     Each isolated peptide is then examined by monitoring of a selected reaction in the MS. This involves using the prior knowledge gained by the characterization of the peptide internal standard and then requiring the MS to continuously monitor a specific ion in the MS/MS or MS n  spectrum for both the peptide of interest and the internal standard. After elution, the area under the curve (AUC) for both peptide standard and target peptide peaks are calculated. The ratio of the two areas provides the absolute quantification that can be normalized for the number of cells used in the analysis and the protein&#39;s molecular weight, to provide the precise number of copies of the protein per cell. Further details of the AQUA methodology are described in Gygi et al., and Gerber et al. supra. 
     Accordingly, AQUA internal peptide standards (heavy-isotope labeled peptides) may be produced, as described above, for any of the 726 novel phosphorylation sites of the invention (see Table 1). For example, peptide standards for a given phosphorylation site (e.g., an AQUA peptide having the sequence RTRRRRTAsVKEGIVE (SEQ ID NO: 726), wherein “s” corresponds to phosphorylatable serine 259 of 4ET (which is sometimes numbered as serine 258 of 4ET)) may be produced for both the phosphorylated and unphosphorylated forms of the sequence. Such standards may be used to detect and quantify both phosphorylated form and unphosphorylated form of the parent signaling protein (e.g., 4ET) in a biological sample. 
     Heavy-isotope labeled equivalents of a phosphorylation site of the invention, both in phosphorylated and unphosphorylated form, can be readily synthesized and their unique MS and LC-SRM signature determined, so that the peptides are validated as AQUA peptides and ready for use in quantification. 
     The novel phosphorylation sites of the invention are particularly well suited for development of corresponding AQUA peptides, since the IAP method by which they were identified (see Part A above and Example 1) inherently confirmed that such peptides are in fact produced by enzymatic digestion (e.g., trypsinization) and are in fact suitably fractionated/ionized in MS/MS. Thus, heavy-isotope labeled equivalents of these peptides (both in phosphorylated and unphosphorylated form) can be readily synthesized and their unique MS and LC-SRM signature determined, so that the peptides are validated as AQUA peptides and ready for use in quantification experiments. 
     Accordingly, the invention provides heavy-isotope labeled peptides (AQUA peptides) that may be used for detecting, quantitating, or modulating any of the phosphorylation sites of the invention (Table 1). For example, an AQUA peptide having the sequence RTRRRRTAsVKEGIVE (SEQ ID NO: 726), wherein y (Ser 259) is phosphotyrosine, and wherein V=labeled valine (e.g.,  14 C)) is provided for the quantification of phosphorylated (or unphosphorylated) form of 4ET (a transcriptional regulator) in a biological sample. 
     Example 4 is provided to further illustrate the construction and use, by standard methods described above, of exemplary AQUA peptides provided by the invention. For example, AQUA peptides corresponding to both the phosphorylated and unphosphorylated forms of SEQ ID NO: 1 (a trypsin-digested fragment of 2′PDE, with a Serine 222 phosphorylation site) may be used to quantify the amount of phosphorylated 2′PDE in a biological sample, e.g., a tumor cell sample or a sample before or after treatment with a therapeutic agent. 
     Peptides and AQUA peptides provided by the invention will be highly useful in the further study of signal transduction anomalies underlying cancer, including carcinomas and leukemias. Peptides and AQUA peptides of the invention may also be used for identifying diagnostic/bio-markers of carcinomas, identifying new potential drug targets, and/or monitoring the effects of test therapeutic agents on signaling proteins and pathways. 
     4. Phosphorylation Site-Specific Antibodies 
     In another aspect, the invention discloses phosphorylation site-specific binding molecules that specifically bind at a novel serine or threonine phosphorylation site of the invention, and that distinguish between the phosphorylated and unphosphorylated forms. In one embodiment, the binding molecule is an antibody or an antigen-binding fragment thereof. The antibody may specifically bind to an amino acid sequence comprising a phosphorylation site identified in Table 1. 
     In some embodiments, the antibody or antigen-binding fragment thereof specifically binds the phosphorylated site. In other embodiments, the antibody or antigen-binding fragment thereof specially binds the unphosphorylated site. An antibody or antigen-binding fragment thereof specially binds an amino acid sequence comprising a novel serine or threonine phosphorylation site in Table 1 when it does not significantly bind any other site in the parent protein and does not significantly bind a protein other than the parent protein. An antibody of the invention is sometimes referred to herein as a “phospho-specific” antibody. 
     An antibody or antigen-binding fragment thereof specially binds an antigen when the dissociation constant is ≦1 mM, preferably ≦100 nM, and more preferably ≦10 nM. 
     In some embodiments, the antibody or antigen-binding fragment of the invention binds an amino acid sequence that comprises a novel phosphorylation site of a protein in Table 1 that is adaptor/scaffold protein, kinase/protease/phosphatase/enzyme proteins, protein kinase, cytoskeletal protein, ubiquitan conjugating system protein, chromatin or DNA binding/repair protein, g protein or regulator protein, receptor/channel/transporter/cell surface protein, transcriptional regulator and cell cycle regulation protein. 
     In particularly preferred embodiments, an antibody or antigen-binding fragment thereof of the invention specially binds an amino acid sequence comprising a novel serine or threonine phosphorylation site shown as a lower case “y,” “s,” or “t” (respectively) in a sequence listed in Table 1 selected from the group consisting of SEQ ID NOs 1-726. 
     It shall be understood that if a given sequence disclosed herein comprises more than one amino acid that can be modified, this invention includes sequences comprising modifications at one or more of the amino acids. In one non-limiting example, where the sequence is: VCYTVINHIPHQRSSLSSNDDGYE, and the * symbol indicates the preceding amino acid is modified (e.g., a Y* indicates a modified (e.g., phosphorylated) tyrosine residues, the invention includes, without limitation, VCY*TVINHIPHQRSSLSSNDDGYE, VCYT*VINHIPHQRSSLSSNDDGYE, VCYTVINHIPHQRS*SLSSNDDGYE, VCYTVINHIPHQRSS*LSSNDDGYE, VCYTVINHIPHQRSSLS*SNDDGYE, VCYTVINHIPHQRSSLSS*NDDGYE, VCYTVINHIPHQRSSLSSNDDGY*E, as well as sequences comprising more than one modified amino acid including VCY*T*VINHIPHQRSSLSSNDDGYE, VCY*TVINHIPHQRS*SLSSNDDGYE, VCY*TVINHIPHQRSSLSSNDDGY*E, VCY*T*VINHIPHQRS*S*LS*S*NDDGY*E, etc. Thus, an antibody of the invention may specifically bind to VCY*TVINHIPHQRSSLSSNDDGYE, or may specifically bind to VCYT*VINHIPHQRSSLSSNDDGYE, or may specifically bind to VCYTVINHIPHQRS*SLSSNDDGYE, and so forth. In some embodiments, an antibody of the invention specifically binds the sequence comprising a modification at one amino acid residues in the sequence. In some embodiments, an antibody of the invention specifically binds the sequence comprising modifications at two or more amino acid residues in the sequence. 
     In some embodiments, an antibody or antigen-binding fragment thereof of the invention specifically binds an amino acid sequence comprising any one of the above listed SEQ ID NOs. In some embodiments, an antibody or antigen-binding fragment thereof of the invention especially binds an amino acid sequence comprises a fragment of one of said SEQ ID NOs., wherein the fragment is four to twenty amino acid long and includes the phosphorylatable serine and/or threonine. 
     In certain embodiments, an antibody or antigen-binding fragment thereof of the invention specially binds an amino acid sequence that comprises a peptide produced by proteolysis of the parent protein with a protease wherein said peptide comprises a novel serine or threonine phosphorylation site of the invention. In some embodiments, the peptides are produced from trypsin digestion of the parent protein. The parent protein comprising the novel serine or threonine phosphorylation site can be from any species, preferably from a mammal including but not limited to non-human primates, rabbits, mice, rats, goats, cows, sheep, and guinea pigs. In some embodiments, the parent protein is a human protein and the antibody binds an epitope comprising the novel serine or threonine phosphorylation site shown by a lower case “y,” “s” or “t” in Column E of Table 1. Such peptides include any one of SEQ ID NOs: 1-726. 
     An antibody of the invention can be an intact, four immunoglobulin chain antibody comprising two heavy chains and two light chains. The heavy chain of the antibody can be of any isotype including IgM, IgG, IgE, IgG, IgA or IgD or sub-isotype including IgG1, IgG2, IgG3, IgG4, IgE1, IgE2, etc. The light chain can be a kappa or a lambda light chain. 
     Also within the invention are antibody molecules with fewer than 4 chains, including single chain antibodies, Camelid antibodies and the like and components of the antibody, including a heavy chain or a light chain. The term “antibody” (or “antibodies”) refers to all types of immunoglobulins. The term “an antigen-binding fragment of an antibody” refers to any portion of an antibody that retains specific binding of the intact antibody. An exemplary antigen-binding fragment of an antibody is the heavy chain and/or light chain CDR, or the heavy and/or light chain variable region. The term “does not bind,” when appeared in context of an antibody&#39;s binding to one phospho-form (e.g., phosphorylated form) of a sequence, means that the antibody does not substantially react with the other phospho-form (e.g., non-phosphorylated form) of the same sequence. One of skill in the art will appreciate that the expression may be applicable in those instances when (1) a phospho-specific antibody either does not apparently bind to the non-phospho form of the antigen as ascertained in commonly used experimental detection systems (Western blotting, IHC, Immunofluorescence, etc.); (2) where there is some reactivity with the surrounding amino acid sequence, but that the phosphorylated residue is an immunodominant feature of the reaction. In cases such as these, there is an apparent difference in affinities for the two sequences. Dilutional analyses of such antibodies indicates that the antibodies apparent affinity for the phosphorylated form is at least 10-100 fold higher than for the non-phosphorylated form; or where (3) the phospho-specific antibody reacts no more than an appropriate control antibody would react under identical experimental conditions. A control antibody preparation might be, for instance, purified immunoglobulin from a pre-immune animal of the same species, an isotype- and species-matched monoclonal antibody. Tests using control antibodies to demonstrate specificity are recognized by one of skill in the art as appropriate and definitive. 
     In some embodiments an immunoglobulin chain may comprise in order from 5′ to 3′, a variable region and a constant region. The variable region may comprise three complementarity determining regions (CDRs), with interspersed framework (FR) regions for a structure FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. Also within the invention are heavy or light chain variable regions, framework regions and CDRs. An antibody of the invention may comprise a heavy chain constant region that comprises some or all of a CH1 region, hinge, CH2 and CH3 region. 
     An antibody of the invention may have an binding affinity (K D ) of 1×10 −7 M or less. In other embodiments, the antibody binds with a K D  of 1×10 −8  M, 1×10 −9  M, 1×10 −10  M, 1×10 −11  M, 1×10 −12  M or less. In certain embodiments, the K D  is 1 pM to 500 pM, between 500 pM to 1 μM, between 1 μM to 100 nM, or between 100 mM to 10 nM. 
     Antibodies of the invention can be derived from any species of animal, preferably a mammal. Non-limiting exemplary natural antibodies include antibodies derived from human, chicken, goats, and rodents (e.g., rats, mice, hamsters and rabbits), including transgenic rodents genetically engineered to produce human antibodies (see, e.g., Lonberg et al., WO93/12227; U.S. Pat. No. 5,545,806; and Kucherlapati, et al., WO91/10741; U.S. Pat. No. 6,150,584, which are herein incorporated by reference in their entirety). Natural antibodies are the antibodies produced by a host animal. “Genetically altered antibodies” refer to antibodies wherein the amino acid sequence has been varied from that of a native antibody. Because of the relevance of recombinant DNA techniques to this application, one need not be confined to the sequences of amino acids found in natural antibodies; antibodies can be redesigned to obtain desired characteristics. The possible variations are many and range from the changing of just one or a few amino acids to the complete redesign of, for example, the variable or constant region. Changes in the constant region will, in general, be made in order to improve or alter characteristics, such as complement fixation, interaction with membranes and other effector functions. Changes in the variable region will be made in order to improve the antigen binding characteristics. 
     The antibodies of the invention include antibodies of any isotype including IgM, IgG, IgD, IgA and IgE, and any sub-isotype, including IgG1, IgG2a, IgG2b, IgG3 and IgG4, IgE1, IgE2 etc. The light chains of the antibodies can either be kappa light chains or lambda light chains. 
     Antibodies disclosed in the invention may be polyclonal or monoclonal. As used herein, the term “epitope” refers to the smallest portion of a protein capable of selectively binding to the antigen binding site of an antibody. It is well accepted by those skilled in the art that the minimal size of a protein epitope capable of selectively binding to the antigen binding site of an antibody is about five or six to seven amino acids. 
     Other antibodies specifically contemplated are oligoclonal antibodies. As used herein, the phrase “oligoclonal antibodies” refers to a predetermined mixture of distinct monoclonal antibodies. See, e.g., PCT publication WO 95/20401; U.S. Pat. Nos. 5,789,208 and 6,335,163. In one embodiment, oligoclonal antibodies consisting of a predetermined mixture of antibodies against one or more epitopes are generated in a single cell. In other embodiments, oligoclonal antibodies comprise a plurality of heavy chains capable of pairing with a common light chain to generate antibodies with multiple specificities (e.g., PCT publication WO 04/009618). Oligoclonal antibodies are particularly useful when it is desired to target multiple epitopes on a single target molecule. In view of the assays and epitopes disclosed herein, those skilled in the art can generate or select antibodies or mixtures of antibodies that are applicable for an intended purpose and desired need. 
     Recombinant antibodies against the phosphorylation sites identified in the invention are also included in the present application. These recombinant antibodies have the same amino acid sequence as the natural antibodies or have altered amino acid sequences of the natural antibodies in the present application. They can be made in any expression systems including both prokaryotic and eukaryotic expression systems or using phage display methods (see, e.g., Dower et al., WO91/17271 and McCafferty et al., WO92/01047; U.S. Pat. No. 5,969,108, which are herein incorporated by reference in their entirety). 
     Antibodies can be engineered in numerous ways. They can be made as single-chain antibodies (including small modular immunopharmaceuticals or SMIPs™), Fab and F(ab′) 2  fragments, etc. Antibodies can be humanized, chimerized, deimmunized, or fully human. Numerous publications set forth the many types of antibodies and the methods of engineering such antibodies. For example, see U.S. Pat. Nos. 6,355,245; 6,180,370; 5,693,762; 6,407,213; 6,548,640; 5,565,332; 5,225,539; 6,103,889; and 5,260,203. 
     The genetically altered antibodies should be functionally equivalent to the above-mentioned natural antibodies. In certain embodiments, modified antibodies provide improved stability or/and therapeutic efficacy. Examples of modified antibodies include those with conservative substitutions of amino acid residues, and one or more deletions or additions of amino acids that do not significantly deleteriously alter the antigen binding utility. Substitutions can range from changing or modifying one or more amino acid residues to complete redesign of a region as long as the therapeutic utility is maintained. Antibodies of this application can be modified post-translationally (e.g., acetylation, and/or phosphorylation) or can be modified synthetically (e.g., the attachment of a labeling group). 
     Antibodies with engineered or variant constant or Fc regions can be useful in modulating effector functions, such as, for example, antigen-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Such antibodies with engineered or variant constant or Fc regions may be useful in instances where a parent singling protein (Table 1) is expressed in normal tissue; variant antibodies without effector function in these instances may elicit the desired therapeutic response while not damaging normal tissue. Accordingly, certain aspects and methods of the present disclosure relate to antibodies with altered effector functions that comprise one or more amino acid substitutions, insertions, and/or deletions. 
     In certain embodiments, genetically altered antibodies are chimeric antibodies and humanized antibodies. 
     The chimeric antibody is an antibody having portions derived from different antibodies. For example, a chimeric antibody may have a variable region and a constant region derived from two different antibodies. The donor antibodies may be from different species. In certain embodiments, the variable region of a chimeric antibody is non-human, e.g., murine, and the constant region is human. 
     The genetically altered antibodies used in the invention include CDR grafted humanized antibodies. In one embodiment, the humanized antibody comprises heavy and/or light chain CDRs of a non-human donor immunoglobulin and heavy chain and light chain frameworks and constant regions of a human acceptor immunoglobulin. The method of making humanized antibody is disclosed in U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,761; 5,693,762; and 6,180,370 each of which is incorporated herein by reference in its entirety. 
     Antigen-binding fragments of the antibodies of the invention, which retain the binding specificity of the intact antibody, are also included in the invention. Examples of these antigen-binding fragments include, but are not limited to, partial or full heavy chains or light chains, variable regions, or CDR regions of any phosphorylation site-specific antibodies described herein. 
     In one embodiment of the application, the antibody fragments are truncated chains (truncated at the carboxyl end). In certain embodiments, these truncated chains possess one or more immunoglobulin activities (e.g., complement fixation activity). Examples of truncated chains include, but are not limited to, Fab fragments (consisting of the VL, VH, CL and CH1 domains); Fd fragments (consisting of the VH and CH1 domains); Fv fragments (consisting of VL and VH domains of a single chain of an antibody); dAb fragments (consisting of a VH domain); isolated CDR regions; (Fab′) 2  fragments, bivalent fragments (comprising two Fab fragments linked by a disulphide bridge at the hinge region). The truncated chains can be produced by conventional biochemical techniques, such as enzyme cleavage, or recombinant DNA techniques, each of which is known in the art. These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in the vectors using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab′) 2  fragments. Single chain antibodies may be produced by joining VL- and VH-coding regions with a DNA that encodes a peptide linker connecting the VL and VH protein fragments 
     Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment of an antibody yields an F(ab′) 2  fragment that has two antigen-combining sites and is still capable of cross-linking antigen. 
     “Fv” usually refers to the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V H -V L  dimer. Collectively, the CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising three CDRs specific for an antigen) has the ability to recognize and bind antigen, although likely at a lower affinity than the entire binding site. 
     Thus, in certain embodiments, the antibodies of the application may comprise 1, 2, 3, 4, 5, 6, or more CDRs that recognize the phosphorylation sites identified in Column E of Table 1. 
     The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab′) 2  antibody fragments originally were produced as pairs of Fab′ fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known. 
     “Single-chain Fv” or “scFv” antibody fragments comprise the V H  and V L  domains of an antibody, wherein these domains are present in a single polypeptide chain. In certain embodiments, the Fv polypeptide further comprises a polypeptide linker between the V H  and V L  domains that enables the scFv to form the desired structure for antigen binding. For a review of scFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore, eds. (Springer-Verlag: New York, 1994), pp. 269-315. 
     SMIPs are a class of single-chain peptides engineered to include a target binding region and effector domain (CH2 and CH3 domains). See, e.g., U.S. Patent Application Publication No. 20050238646. The target binding region may be derived from the variable region or CDRs of an antibody, e.g., a phosphorylation site-specific antibody of the application. Alternatively, the target binding region is derived from a protein that binds a phosphorylation site. 
     Bispecific antibodies may be monoclonal, human or humanized antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the phosphorylation site, the other one is for any other antigen, such as for example, a cell-surface protein or receptor or receptor subunit. Alternatively, a therapeutic agent may be placed on one arm. The therapeutic agent can be a drug, toxin, enzyme, DNA, radionuclide, etc. 
     In some embodiments, the antigen-binding fragment can be a diabody. The term “diabody” refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) in the same polypeptide chain (V H -V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993). 
     Camelid antibodies refer to a unique type of antibodies that are devoid of light chain, initially discovered from animals of the camelid family. The heavy chains of these so-called heavy-chain antibodies bind their antigen by one single domain, the variable domain of the heavy immunoglobulin chain, referred to as VHH. VHHs show homology with the variable domain of heavy chains of the human VHIII family. The VHHs obtained from an immunized camel, dromedary, or llama have a number of advantages, such as effective production in microorganisms such as  Saccharomyces cerevisiae.    
     In certain embodiments, single chain antibodies, and chimeric, humanized or primatized (CDR-grafted) antibodies, as well as chimeric or CDR-grafted single chain antibodies, comprising portions derived from different species, are also encompassed by the present disclosure as antigen-binding fragments of an antibody. The various portions of these antibodies can be joined together chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques. For example, nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous protein. See, e.g., U.S. Pat. No. 4,816,567; U.S. Pat. No. 6,331,415; U.S. Pat. No. 7,485,291; U.S. Pat. No. 4,816,397; European Patent No. 0,120,694; WO 86/01533; European Patent No. 0,194,276 B1; U.S. Pat. No. 5,225,539; and European Patent No. 0,239,400 B1. See also, Newman et al., BioTechnology, 10: 1455-1460 (1992), regarding primatized antibody. See, e.g., Ladner et al., U.S. Pat. No. 4,946,778; and Bird et al., Science, 242: 423-426 (1988)), regarding single chain antibodies. 
     In addition, functional fragments of antibodies, including fragments of chimeric, humanized, primatized or single chain antibodies, can also be produced. Functional fragments of the subject antibodies retain at least one binding function and/or modulation function of the full-length antibody from which they are derived. 
     Since the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities, the genes of the antibody fragments may be fused to functional regions from other genes (e.g., enzymes, U.S. Pat. No. 5,004,692, which is incorporated by reference in its entirety) to produce fusion proteins or conjugates having novel properties. 
     Non-immunoglobulin binding polypeptides are also contemplated. For example, CDRs from an antibody disclosed herein may be inserted into a suitable non-immunoglobulin scaffold to create a non-immunoglobulin binding polypeptide. Suitable candidate scaffold structures may be derived from, for example, members of fibronectin type III and cadherin superfamilies. 
     Also contemplated are other equivalent non-antibody molecules, such as protein binding domains or aptamers, which bind, in a phospho-specific manner, to an amino acid sequence comprising a novel phosphorylation site of the invention. See, e.g., Neuberger et al.,  Nature  312: 604 (1984). Aptamers are oligonucleic acid or peptide molecules that bind a specific target molecule. DNA or RNA aptamers are typically short oligonucleotides, engineered through repeated rounds of selection to bind to a molecular target. Peptide aptamers typically consist of a variable peptide loop attached at both ends to a protein scaffold. This double structural constraint generally increases the binding affinity of the peptide aptamer to levels comparable to an antibody (nanomolar range). 
     The invention also discloses the use of the phosphorylation site-specific antibodies with immunotoxins. Conjugates that are immunotoxins including antibodies have been widely described in the art. The toxins may be coupled to the antibodies by conventional coupling techniques or immunotoxins containing protein toxin portions can be produced as fusion proteins. In certain embodiments, antibody conjugates may comprise stable linkers and may release cytotoxic agents inside cells (see U.S. Pat. Nos. 6,867,007 and 6,884,869). The conjugates of the present application can be used in a corresponding way to obtain such immunotoxins. Illustrative of such immunotoxins are those described by Byers et al., Seminars Cell Biol 2:59-70 (1991) and by Fanger et al., Immunol Today 12:51-54 (1991). Exemplary immunotoxins include radiotherapeutic agents, ribosome-inactivating proteins (RIPs), chemotherapeutic agents, toxic peptides, or toxic proteins. 
     The phosphorylation site-specific antibodies disclosed in the invention may be used singly or in combination. The antibodies may also be used in an array format for high throughput uses. An antibody microarray is a collection of immobolized antibodies, typically spotted and fixed on a solid surface (such as glass, plastic and silicon chip). 
     In another aspect, the antibodies of the invention modulate at least one, or all, biological activities of a parent protein identified in Column A of Table 1. The biological activities of a parent protein identified in Column A of Table 1 include: 1) ligand binding activities (for instance, these neutralizing antibodies may be capable of competing with or completely blocking the binding of a parent signaling protein to at least one, or all, of its ligands; 2) signaling transduction activities, such as receptor dimerization, or serine or threonine phosphorylation; and 3) cellular responses induced by a parent signaling protein, such as oncogenic activities (e.g., cancer cell proliferation mediated by a parent signaling protein), and/or angiogenic activities. 
     In certain embodiments, the antibodies of the invention may have at least one activity selected from the group consisting of: 1) inhibiting cancer cell growth or proliferation; 2) inhibiting cancer cell survival; 3) inhibiting angiogenesis; 4) inhibiting cancer cell metastasis, adhesion, migration or invasion; 5) inducing apoptosis of cancer cells; 6) incorporating a toxic conjugate; and 7) acting as a diagnostic marker. 
     In certain embodiments, the phosphorylation site specific antibodies disclosed in the invention are especially indicated for diagnostic and therapeutic applications as described herein. Accordingly, the antibodies may be used in therapies, including combination therapies, in the diagnosis and prognosis of disease, as well as in the monitoring of disease progression. The invention, thus, further includes compositions comprising one or more embodiments of an antibody or an antigen binding portion of the invention as described herein. The composition may further comprise a pharmaceutically acceptable carrier. The composition may comprise two or more antibodies or antigen-binding portions, each with specificity for a different novel serine or threonine phosphorylation site of the invention or two or more different antibodies or antigen-binding portions all of which are specific for the same novel serine or threonine phosphorylation site of the invention. A composition of the invention may comprise one or more antibodies or antigen-binding portions of the invention and one or more additional reagents, diagnostic agents or therapeutic agents. 
     The present application provides for the polynucleotide molecules encoding the antibodies and antibody fragments and their analogs described herein. Because of the degeneracy of the genetic code, a variety of nucleic acid sequences encode each antibody amino acid sequence. The desired nucleic acid sequences can be produced by de novo solid-phase DNA synthesis or by PCR mutagenesis of an earlier prepared variant of the desired polynucleotide. In one embodiment, the codons that are used comprise those that are typical for human or mouse (see, e.g., Nakamura, Y., Nucleic Acids Res. 28: 292 (2000)). 
     The invention also provides immortalized cell lines that produce an antibody of the invention. For example, hybridoma clones, constructed as described above, that produce monoclonal antibodies to the targeted signaling protein phosphorylation sties disclosed herein are also provided. Similarly, the invention includes recombinant cells producing an antibody of the invention, which cells may be constructed by well known techniques; for example the antigen combining site of the monoclonal antibody can be cloned by PCR and single-chain antibodies produced as phage-displayed recombinant antibodies or soluble antibodies in  E. coli  (see, e.g., A NTIBODY  E NGINEERING  P ROTOCOLS,  1995, Humana Press, Sudhir Paul editor.) 
     5. Methods of Making Phosphorylation site-Specific Antibodies 
     In another aspect, the invention provides a method for making phosphorylation site-specific antibodies. 
     Polyclonal antibodies of the invention may be produced according to standard techniques by immunizing a suitable animal (e.g., rabbit, goat, etc.) with an antigen comprising a novel serine or threonine phosphorylation site of the invention. (i.e. a phosphorylation site shown in Table 1) in either the phosphorylated or unphosphorylated state, depending upon the desired specificity of the antibody, collecting immune serum from the animal, and separating the polyclonal antibodies from the immune serum, in accordance with known procedures and screening and isolating a polyclonal antibody specific for the novel serine or threonine phosphorylation site of interest as further described below. Methods for immunizing non-human animals such as mice, rats, sheep, goats, pigs, cattle and horses are well known in the art. See, e.g., Harlow and Lane,  Antibodies: A Laboratory Manual , New York: Cold Spring Harbor Press, 1990. 
     The immunogen may be the full length protein or a peptide comprising the novel serine or threonine phosphorylation site of interest. In some embodiments the immunogen is a peptide of from 7 to 20 amino acids in length, preferably about 8 to 17 amino acids in length. In some embodiments, the peptide antigen desirably will comprise about 3 to 8 amino acids on each side of the phosphorylatable serine and/or threonine. In yet other embodiments, the peptide antigen desirably will comprise four or more amino acids flanking each side of the phosphorylatable amino acid and encompassing it. Peptide antigens suitable for producing antibodies of the invention may be designed, constructed and employed in accordance with well-known techniques. See, e.g., Antibodies: A Laboratory Manual, Chapter 5, p. 75-76, Harlow &amp; Lane Eds., Cold Spring Harbor Laboratory (1988); Czernik,  Methods In Enzymology,  201: 264-283 (1991); Merrifield,  J. Am. Chem. Soc.  85: 21-49 (1962)). 
     Suitable peptide antigens may comprise all or partial sequence of a trypsin-digested fragment as set forth in Column E of Table 1. Suitable peptide antigens may also comprise all or partial sequence of a peptide fragment produced by another protease digestion. 
     Preferred immunogens are those that comprise a novel phosphorylation site of a protein in Table 1 that is an adaptor/scaffold protein, kinase/protease/phosphatase/enzyme proteins, protein kinase, cytoskeletal protein, ubiquitan conjugating system protein, chromatin or DNA binding/repair protein, g protein or regulator protein, receptor/channel/transporter/cell surface protein, transcriptional regulator and cell cycle regulation protein. In some embodiments, the peptide immunogen is an AQUA peptide, for example, any one of SEQ ID NOS: 1-726. 
     Particularly preferred immunogens are peptides comprising any one of the novel serine or threonine phosphorylation site shown as a lower case “y,” “s” or “t” the sequences listed in Table 1 selected from the group consisting of SEQ ID NOS: 1-726 
     In some embodiments the immunogen is administered with an adjuvant. Suitable adjuvants will be well known to those of skill in the art. Exemplary adjuvants include complete or incomplete Freund&#39;s adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes). 
     For example, a peptide antigen comprising the novel transcriptional regulator protein phosphorylation site in SEQ ID NO: 36 shown by the lower case “s” in Table 1 may be used to produce antibodies that specifically bind the novel tyrosine phosphorylation site. 
     When the above-described methods are used for producing polyclonal antibodies, following immunization, the polyclonal antibodies which secreted into the bloodstream can be recovered using known techniques. Purified forms of these antibodies can, of course, be readily prepared by standard purification techniques, such as for example, affinity chromatography with Protein A, anti-immunoglobulin, or the antigen itself. In any case, in order to monitor the success of immunization, the antibody levels with respect to the antigen in serum will be monitored using standard techniques such as ELISA, RIA and the like. 
     Monoclonal antibodies of the invention may be produced by any of a number of means that are well-known in the art. In some embodiments, antibody-producing B cells are isolated from an animal immunized with a peptide antigen as described above. The B cells may be from the spleen, lymph nodes or peripheral blood. Individual B cells are isolated and screened as described below to identify cells producing an antibody specific for the novel serine or threonine phosphorylation site of interest. Identified cells are then cultured to produce a monoclonal antibody of the invention. 
     Alternatively, a monoclonal phosphorylation site-specific antibody of the invention may be produced using standard hybridoma technology, in a hybridoma cell line according to the well-known technique of Kohler and Milstein. See  Nature  265: 495-97 (1975); Kohler and Milstein,  Eur. J. Immunol.  6: 511 (1976); see also, Current Protocols in Molecular Biology, Ausubel et al. Eds. (1989). Monoclonal antibodies so produced are highly specific, and improve the selectivity and specificity of diagnostic assay methods provided by the invention. For example, a solution containing the appropriate antigen may be injected into a mouse or other species and, after a sufficient time (in keeping with conventional techniques), the animal is sacrificed and spleen cells obtained. The spleen cells are then immortalized by any of a number of standard means. Methods of immortalizing cells include, but are not limited to, transfecting them with oncogenes, infecting them with an oncogenic virus and cultivating them under conditions that select for immortalized cells, subjecting them to carcinogenic or mutating compounds, fusing them with an immortalized cell, e.g., a myeloma cell, and inactivating a tumor suppressor gene. See, e.g., Harlow and Lane, supra. If fusion with myeloma cells is used, the myeloma cells preferably do not secrete immunoglobulin polypeptides (a non-secretory cell line). Typically the antibody producing cell and the immortalized cell (such as but not limited to myeloma cells) with which it is fused are from the same species. Rabbit fusion hybridomas, for example, may be produced as described in U.S. Pat. No. 5,675,063, C. Knight, Issued Oct. 7, 1997. The immortalized antibody producing cells, such as hybridoma cells, are then grown in a suitable selection media, such as hypoxanthine-aminopterin-thymidine (HAT), and the supernatant screened for monoclonal antibodies having the desired specificity, as described below. The secreted antibody may be recovered from tissue culture supernatant by conventional methods such as precipitation, ion exchange or affinity chromatography, or the like. 
     The invention also encompasses antibody-producing cells and cell lines, such as hybridomas, as described above. 
     Polyclonal or monoclonal antibodies may also be obtained through in vitro immunization. For example, phage display techniques can be used to provide libraries containing a repertoire of antibodies with varying affinities for a particular antigen. Techniques for the identification of high affinity human antibodies from such libraries are described by Griffiths et al., (1994)  EMBO J.,  13:3245-3260; Nissim et al., ibid, pp. 692-698 and by Griffiths et al., ibid, 12:725-734, which are incorporated by reference. 
     The antibodies may be produced recombinantly using methods well known in the art for example, according to the methods disclosed in U.S. Pat. No. 4,349,893 (Reading) or U.S. Pat. No. 4,816,567 (Cabilly et al.) The antibodies may also be chemically constructed by specific antibodies made according to the method disclosed in U.S. Pat. No. 4,676,980 (Segel et al.) 
     Once a desired phosphorylation site-specific antibody is identified, polynucleotides encoding the antibody, such as heavy, light chains or both (or single chains in the case of a single chain antibody) or portions thereof such as those encoding the variable region, may be cloned and isolated from antibody-producing cells using means that are well known in the art. For example, the antigen combining site of the monoclonal antibody can be cloned by PCR and single-chain antibodies produced as phage-displayed recombinant antibodies or soluble antibodies in  E. coli  (see, e.g., Antibody Engineering Protocols, 1995, Humana Press, Sudhir Paul editor.) 
     Accordingly, in a further aspect, the invention provides such nucleic acids encoding the heavy chain, the light chain, a variable region, a framework region or a CDR of an antibody of the invention. In some embodiments, the nucleic acids are operably linked to expression control sequences. The invention, thus, also provides vectors and expression control sequences useful for the recombinant expression of an antibody or antigen-binding portion thereof of the invention. Those of skill in the art will be able to choose vectors and expression systems that are suitable for the host cell in which the antibody or antigen-binding portion is to be expressed. 
     Monoclonal antibodies of the invention may be produced recombinantly by expressing the encoding nucleic acids in a suitable host cell under suitable conditions. Accordingly, the invention further provides host cells comprising the nucleic acids and vectors described above. 
     Monoclonal Fab fragments may also be produced in  Escherichia coli  by recombinant techniques known to those skilled in the art. See, e.g., W. Huse,  Science  246: 1275-81 (1989); Mullinax et al.,  Proc. Nat&#39;l Acad. Sci.  87: 8095 (1990). 
     If monoclonal antibodies of a single isotype are desired for a particular application, particular isotypes can be prepared directly, by selecting from the initial fusion, or prepared secondarily, from a parental hybridoma secreting a monoclonal antibody of different isotype by using the sib selection technique to isolate class-switch variants (Steplewski, et al.,  Proc. Nat&#39;l. Acad. Sci.,  82: 8653 (1985); Spira et al.,  J. Immunol. Methods,  74: 307 (1984)). Alternatively, the isotype of a monoclonal antibody with desirable properties can be changed using antibody engineering techniques that are well-known in the art. 
     Phosphorylation site-specific antibodies of the invention, whether polyclonal or monoclonal, may be screened for epitope and phospho-specificity according to standard techniques. See, e.g., Czernik et al.,  Methods in Enzymology,  201: 264-283 (1991). For example, the antibodies may be screened against the phosphorylated and/or unphosphosphorylated peptide library by ELISA to ensure specificity for both the desired antigen (i.e. that epitope including a phosphorylation site of the invention and for reactivity only with the phosphorylated (or unphosphorylated) form of the antigen. Peptide competition assays may be carried out to confirm lack of reactivity with other phospho-epitopes on the parent protein. The antibodies may also be tested by Western blotting against cell preparations containing the parent signaling protein, e.g., cell lines over-expressing the parent protein, to confirm reactivity with the desired phosphorylated epitope/target. 
     Specificity against the desired phosphorylated epitope may also be examined by constructing mutants lacking phosphorylatable residues at positions outside the desired epitope that are known to be phosphorylated, or by mutating the desired phospho-epitope and confirming lack of reactivity. Phosphorylation site-specific antibodies of the invention may exhibit some limited cross-reactivity to related epitopes in non-target proteins. This is not unexpected as most antibodies exhibit some degree of cross-reactivity, and anti-peptide antibodies will often cross-react with epitopes having high homology to the immunizing peptide. See, e.g., Czernik, supra. Cross-reactivity with non-target proteins is readily characterized by Western blotting alongside markers of known molecular weight. Amino acid sequences of cross-reacting proteins may be examined to identify phosphorylation sites with flanking sequences that are highly homologous to that of a phosphorylation site of the invention. 
     In certain cases, polyclonal antisera may exhibit some undesirable general cross-reactivity to phosphoserine or threonine itself, which may be removed by further purification of antisera, e.g., over a phosphotyramine column. Antibodies of the invention specifically bind their target protein (i.e. a protein listed in Column A of Table 1) only when phosphorylated (or only when not phosphorylated, as the case may be) at the site disclosed in corresponding Columns D/E, and do not (substantially) bind to the other form (as compared to the form for which the antibody is specific). 
     Antibodies may be further characterized via immunohistochemical (IHC) staining using normal and diseased tissues to examine phosphorylation and activation state and level of a phosphorylation site in diseased tissue. IHC may be carried out according to well-known techniques. See, e.g., Antibodies: A Laboratory Manual, Chapter 10, Harlow &amp; Lane Eds., Cold Spring Harbor Laboratory (1988). Briefly, paraffin-embedded tissue (e.g., tumor tissue) is prepared for immunohistochemical staining by deparaffinizing tissue sections with xylene followed by ethanol; hydrating in water then PBS; unmasking antigen by heating slide in sodium citrate buffer; incubating sections in hydrogen peroxide; blocking in blocking solution; incubating slide in primary antibody and secondary antibody; and finally detecting using ABC avidin/biotin method according to manufacturer&#39;s instructions. 
     Antibodies may be further characterized by flow cytometry carried out according to standard methods. See Chow et al.,  Cytometry  ( Communications in Clinical Cytometry ) 46: 72-78 (2001). Briefly and by way of example, the following protocol for cytometric analysis may be employed: samples may be centrifuged on Ficoll gradients to remove lysed erythrocytes and cell debris. Adhering cells may be scrapped off plates and washed with PBS. Cells may then be fixed with 2% paraformaldehyde for 10 minutes at 37° C. followed by permeabilization in 90% methanol for 30 minutes on ice. Cells may then be stained with the primary phosphorylation site-specific antibody of the invention (which detects a parent signaling protein enumerated in Table 1), washed and labeled with a fluorescent-labeled secondary antibody. Additional fluorochrome-conjugated marker antibodies (e.g., CD45, CD34) may also be added at this time to aid in the subsequent identification of specific hematopoietic cell types. The cells would then be analyzed on a flow cytometer (e.g. a Beckman Coulter FC500) according to the specific protocols of the instrument used. 
     Antibodies of the invention may also be advantageously conjugated to fluorescent dyes (e.g. Alexa488, PE) for use in multi-parametric analyses along with other signal transduction (phospho-CrkL, phospho-Erk 1/2) and/or cell marker (CD34) antibodies. 
     Phosphorylation site-specific antibodies of the invention may specifically bind to a signaling protein or polypeptide listed in Table 1 only when phosphorylated at the specified serine or threonine residue, but are not limited only to binding to the listed signaling proteins of human species, per se. The invention includes antibodies that also bind conserved and highly homologous or identical phosphorylation sites in respective signaling proteins from other species (e.g., mouse, rat, monkey, yeast), in addition to binding the phosphorylation site of the human homologue. The term “homologous” refers to two or more sequences or subsequences that have at least about 85%, at least 90%, at least 95%, or higher nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using sequence comparison method (e.g., BLAST) and/or by visual inspection. Highly homologous or identical sites conserved in other species can readily be identified by standard sequence comparisons (such as BLAST). 
     Methods for making bispecific antibodies are within the purview of those skilled in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. In certain embodiments, the fusion is with an immunoglobulin heavy-chain constant domain, including at least part of the hinge, CH2, and CH3 regions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of illustrative currently known methods for generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986); WO 96/27011; Brennan et al., Science 229:81 (1985); Shalaby et al., J. Exp. Med. 175:217-225 (1992); Kostelny et al., J. Immunol. 148(5):1547-1553 (1992); Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993); Gruber et al., J. Immunol. 152:5368 (1994); and Tutt et al., J. Immunol. 147:60 (1991). Bispecific antibodies also include cross-linked or heteroconjugate antibodies. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques. 
     Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol., 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins may be linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers may be reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. A strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. See Gruber et al., J. Immunol., 152:5368 (1994). Alternatively, the antibodies can be “linear antibodies” as described in Zapata et al. Protein Eng. 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V H -C H 1-V H -C H 1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific. 
     To produce the chimeric antibodies, the portions derived from two different species (e.g., human constant region and murine variable or binding region) can be joined together chemically by conventional techniques or can be prepared as single contiguous proteins using genetic engineering techniques. The DNA molecules encoding the proteins of both the light chain and heavy chain portions of the chimeric antibody can be expressed as contiguous proteins. The method of making chimeric antibodies is disclosed in U.S. Pat. No. 5,677,427; U.S. Pat. No. 6,120,767; and U.S. Pat. No. 6,329,508, each of which is incorporated by reference in its entirety. 
     Fully human antibodies may be produced by a variety of techniques. One example is trioma methodology. The basic approach and an exemplary cell fusion partner, SPAZ-4, for use in this approach have been described by Oestberg et al., Hybridoma 2:361-367 (1983); Oestberg, U.S. Pat. No. 4,634,664; and Engleman et al., U.S. Pat. No. 4,634,666 (each of which is incorporated by reference in its entirety). 
     Human antibodies can also be produced from non-human transgenic animals having transgenes encoding at least a segment of the human immunoglobulin locus. The production and properties of animals having these properties are described in detail by, see, e.g., Lonberg et al., WO93/12227; U.S. Pat. No. 5,545,806; and Kucherlapati, et al., WO91/10741; U.S. Pat. No. 6,150,584, which are herein incorporated by reference in their entirety. 
     Various recombinant antibody library technologies may also be utilized to produce fully human antibodies. For example, one approach is to screen a DNA library from human B cells according to the general protocol outlined by Huse et al., Science 246:1275-1281 (1989). The protocol described by Huse is rendered more efficient in combination with phage-display technology. See, e.g., Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047; U.S. Pat. No. 5,969,108, (each of which is incorporated by reference in its entirety). 
     Eukaryotic ribosome can also be used as means to display a library of antibodies and isolate the binding human antibodies by screening against the target antigen, as described in Coia G, et al., J. Immunol. Methods 1: 254 (1-2):191-7 (2001); Hanes J. et al., Nat. Biotechnol. 18(12):1287-92 (2000); Proc. Natl. Acad. Sci. U.S.A. 95(24):14130-5 (1998); Proc. Natl. Acad. Sci. U.S.A. 94(10):4937-42 (1997), each which is incorporated by reference in its entirety. 
     The yeast system is also suitable for screening mammalian cell-surface or secreted proteins, such as antibodies. Antibody libraries may be displayed on the surface of yeast cells for the purpose of obtaining the human antibodies against a target antigen. This approach is described by Yeung, et al., Biotechnol. Prog. 18(2):212-20 (2002); Boeder, E. T., et al., Nat. Biotechnol. 15(6):553-7 (1997), each of which is herein incorporated by reference in its entirety. Alternatively, human antibody libraries may be expressed intracellularly and screened via the yeast two-hybrid system (WO0200729A2, which is incorporated by reference in its entirety). 
     Recombinant DNA techniques can be used to produce the recombinant phosphorylation site-specific antibodies described herein, as well as the chimeric or humanized phosphorylation site-specific antibodies, or any other genetically-altered antibodies and the fragments or conjugate thereof in any expression systems including both prokaryotic and eukaryotic expression systems, such as bacteria, yeast, insect cells, plant cells, mammalian cells (for example, NS0 cells). 
     Once produced, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present application can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, Scopes, R., Protein Purification (Springer-Verlag, N.Y., 1982)). Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent staining, and the like. (See, generally, Immunological Methods, Vols. I and II (Lefkovits and Pernis, eds., Academic Press, NY, 1979 and 1981). 
     6. Therapeutic Uses 
     In a further aspect, the invention provides methods and compositions for therapeutic uses of the peptides or proteins comprising a phosphorylation site of the invention, and phosphorylation site-specific antibodies of the invention. 
     In one embodiment, the invention provides for a method of treating or preventing carcinoma in a subject, wherein the carcinoma is associated with the phosphorylation state of a novel phosphorylation site in Table 1, whether phosphorylated or dephosphorylated, comprising: administering to a subject in need thereof a therapeutically effective amount of a peptide comprising a novel phosphorylation site (Table 1) and/or an antibody or antigen-binding fragment thereof that specifically bind a novel phosphorylation site of the invention (Table 1). The antibodies maybe full-length antibodies, genetically engineered antibodies, antibody fragments, and antibody conjugates of the invention. 
     The term “subject” refers to a vertebrate, such as for example, a mammal, or a human. Although present application are primarily concerned with the treatment of human subjects, the disclosed methods may also be used for the treatment of other mammalian subjects such as dogs and cats for veterinary purposes. 
     In one aspect, the disclosure provides a method of treating carcinoma in which a peptide or an antibody that reduces at least one biological activity of a targeted signaling protein is administered to a subject. For example, the peptide or the antibody administered may disrupt or modulate the interaction of the target signaling protein with its ligand. Alternatively, the peptide or the antibody may interfere with, thereby reducing, the down-stream signal transduction of the parent signaling protein. An antibody that specifically binds the novel serine or threonine phosphorylation site only when the serine or threonine is phosphorylated, and that does not substantially bind to the same sequence when the serine or threonine is not phosphorylated, thereby prevents downstream signal transduction triggered by a phospho-serine and/or threonine. Alternatively, an antibody that specifically binds the unphosphorylated target phosphorylation site reduces the phosphorylation at that site and thus reduces activation of the protein mediated by phosphorylation of that site. Similarly, an unphosphorylated peptide may compete with an endogenous phosphorylation site for the same target (e.g., kinases), thereby preventing or reducing the phosphorylation of the endogenous target protein. Alternatively, a peptide comprising a phosphorylated novel serine or threonine site of the invention but lacking the ability to trigger signal transduction may competitively inhibit interaction of the endogenous protein with the same down-stream ligand(s). 
     The antibodies of the invention may also be used to target cancer cells for effector-mediated cell death. The antibody disclosed herein may be administered as a fusion molecule that includes a phosphorylation site-targeting portion joined to a cytotoxic moiety to directly kill cancer cells. Alternatively, the antibody may directly kill the cancer cells through complement-mediated or antibody-dependent cellular cytotoxicity. 
     Accordingly in one embodiment, the antibodies of the present disclosure may be used to deliver a variety of cytotoxic compounds. Any cytotoxic compound can be fused to the present antibodies. The fusion can be achieved chemically or genetically (e.g., via expression as a single, fused molecule). The cytotoxic compound can be a biological, such as a polypeptide, or a small molecule. As those skilled in the art will appreciate, for small molecules, chemical fusion is used, while for biological compounds, either chemical or genetic fusion can be used. 
     Non-limiting examples of cytotoxic compounds include therapeutic drugs, radiotherapeutic agents, ribosome-inactivating proteins (RIPs), chemotherapeutic agents, toxic peptides, toxic proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as short-range radiation emitters, including, for example, short-range, high-energy α-emitters. Enzymatically active toxins and fragments thereof, including ribosome-inactivating proteins, are exemplified by saporin, luffin, momordins, ricin, trichosanthin, gelonin, abrin, etc. Procedures for preparing enzymatically active polypeptides of the immunotoxins are described in WO84/03508 and WO85/03508, which are hereby incorporated by reference. Certain cytotoxic moieties are derived from adriamycin, chlorambucil, daunomycin, methotrexate, neocarzinostatin, and platinum, for example. 
     Exemplary chemotherapeutic agents that may be attached to an antibody or antigen-binding fragment thereof include taxol, doxorubicin, verapamil, podophyllotoxin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, transplatinum, 5-fluorouracil, vincristin, vinblastin, or methotrexate. 
     Procedures for conjugating the antibodies with the cytotoxic agents have been previously described and are within the purview of one skilled in the art. 
     Alternatively, the antibody can be coupled to high energy radiation emitters, for example, a radioisotope, such as  131 I, a γ-emitter, which, when localized at the tumor site, results in a killing of several cell diameters. See, e.g., S. E. Order, “Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy”, Monoclonal Antibodies for Cancer Detection and Therapy, Baldwin et al. (eds.), pp. 303-316 (Academic Press 1985), which is hereby incorporated by reference. Other suitable radioisotopes include α-emitters, such as  212 Bi,  213 Bi, and  211 At, and β-emitters, such as  186 Re and  90 Y. 
     Because many of the signaling proteins in which novel serine or threonine phosphorylation sites of the invention occur also are expressed in normal cells and tissues, it may also be advantageous to administer a phosphorylation site-specific antibody with a constant region modified to reduce or eliminate ADCC or CDC to limit damage to normal cells. For example, effector function of an antibodies may be reduced or eliminated by utilizing an IgG1 constant domain instead of an IgG2/4 fusion domain. Other ways of eliminating effector function can be envisioned such as, e.g., mutation of the sites known to interact with FcR or insertion of a peptide in the hinge region, thereby eliminating critical sites required for FcR interaction. Variant antibodies with reduced or no effector function also include variants as described previously herein. 
     The peptides and antibodies of the invention may be used in combination with other therapies or with other agents. Other agents include but are not limited to polypeptides, small molecules, chemicals, metals, organometallic compounds, inorganic compounds, nucleic acid molecules, oligonucleotides, aptamers, spiegelmers, antisense nucleic acids, locked nucleic acid (LNA) inhibitors, peptide nucleic acid (PNA) inhibitors, immunomodulatory agents, antigen-binding fragments, prodrugs, and peptidomimetic compounds. In certain embodiments, the antibodies and peptides of the invention may be used in combination with cancer therapies known to one of skill in the art. 
     In certain aspects, the present disclosure relates to combination treatments comprising a phosphorylation site-specific antibody described herein and immunomodulatory compounds, vaccines or chemotherapy. Illustrative examples of suitable immunomodulatory agents that may be used in such combination therapies include agents that block negative regulation of T cells or antigen presenting cells (e.g., anti-CTLA4 antibodies, anti-PD-L1 antibodies, anti-PDL-2 antibodies, anti-PD-1 antibodies and the like) or agents that enhance positive co-stimulation of T cells (e.g., anti-CD40 antibodies or anti 4-1BB antibodies) or agents that increase NK cell number or T-cell activity (e.g., inhibitors such as IMiDs, thalidomide, or thalidomide analogs). Furthermore, immunomodulatory therapy could include cancer vaccines such as dendritic cells loaded with tumor cells, proteins, peptides, RNA, or DNA derived from such cells, patient derived heat-shock proteins (hsp&#39;s) or general adjuvants stimulating the immune system at various levels such as CpG, Luivac®, Biostim®, Ribomunyl®, Imudon®, Bronchovaxom® or any other compound or other adjuvant activating receptors of the innate immune system (e.g., toll like receptor agonist, anti-CTLA-4 antibodies, etc.). Also, immunomodulatory therapy could include treatment with cytokines such as IL-2, GM-CSF and IFN-gamma. 
     Furthermore, combination of antibody therapy with chemotherapeutics could be particularly useful to reduce overall tumor burden, to limit angiogenesis, to enhance tumor accessibility, to enhance susceptibility to ADCC, to result in increased immune function by providing more tumor antigen, or to increase the expression of the T cell attractant LIGHT. 
     Pharmaceutical compounds that may be used for combinatory anti-tumor therapy include, merely to illustrate: aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine. 
     These chemotherapeutic anti-tumor compounds may be categorized by their mechanism of action into groups, including, for example, the following classes of agents: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate inhibitors and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristine, vinblastine, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, mechlorethamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide, triethylenethiophosphoramide and etoposide (VP16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); immunomodulatory agents (thalidomide and analogs thereof such as lenalidomide (Revlimid, CC-5013) and CC-4047 (Actimid)), cyclophosphamide; anti-angiogenic compounds (TNP-470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prenisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers and caspase activators; and chromatin disruptors. 
     In certain embodiments, pharmaceutical compounds that may be used for combinatory anti-angiogenesis therapy include: (1) inhibitors of release of “angiogenic molecules,” such as bFGF (basic fibroblast growth factor); (2) neutralizers of angiogenic molecules, such as anti-βbFGF antibodies; and (3) inhibitors of endothelial cell response to angiogenic stimuli, including collagenase inhibitor, basement membrane turnover inhibitors, angiostatic steroids, fungal-derived angiogenesis inhibitors, platelet factor 4, thrombospondin, arthritis drugs such as D-penicillamine and gold thiomalate, vitamin D 3  analogs, alpha-interferon, and the like. For additional proposed inhibitors of angiogenesis, see Blood et al., Biochim. Biophys. Acta, 1032:89-118 (1990), Moses et al., Science, 248:1408-1410 (1990), Ingber et al., Lab. Invest., 59:44-51 (1988), and U.S. Pat. Nos. 5,092,885, 5,112,946, 5,192,744, 5,202,352, and 6,573,256. In addition, there are a wide variety of compounds that can be used to inhibit angiogenesis, for example, peptides or agents that block the VEGF-mediated angiogenesis pathway, endostatin protein or derivatives, lysine binding fragments of angiostatin, melanin or melanin-promoting compounds, plasminogen fragments (e.g., Kringles 1-3 of plasminogen), troponin subunits, inhibitors of vitronectin α v β 3 , peptides derived from Saposin B, antibiotics or analogs (e.g., tetracycline or neomycin), dienogest-containing compositions, compounds comprising a MetAP-2 inhibitory core coupled to a peptide, the compound EM-138, chalcone and its analogs, and naaladase inhibitors. See, for example, U.S. Pat. Nos. 6,395,718, 6,462,075, 6,465,431, 6,475,784, 6,482,802, 6,482,810, 6,500,431, 6,500,924, 6,518,298, 6,521,439, 6,525,019, 6,538,103, 6,544,758, 6,544,947, 6,548,477, 6,559,126, and 6,569,845. 
     7. Diagnostic Uses 
     In a further aspect, the invention provides methods for detecting and quantitating phosphoyrlation at a novel serine or threonine phosphorylation site of the invention. For example, peptides, including AQUA peptides of the invention, and antibodies of the invention are useful in diagnostic and prognostic evaluation of carcinomas, wherein the carcinoma is associated with the phosphorylation state of a novel phosphorylation site in Table 1, whether phosphorylated or dephosphorylated. 
     Methods of diagnosis can be performed in vitro using a biological sample (e.g., blood sample, lymph node biopsy or tissue) from a subject, or in vivo. The phosphorylation state or level at the serine or threonine residue identified in the corresponding row in Column D of Table 1 may be assessed. A change in the phosphorylation state or level at the phosphorylation site, as compared to a control, indicates that the subject is suffering from, or susceptible to, carcinoma. 
     In one embodiment, the phosphorylation state or level at a novel phosphorylation site is determined by an AQUA peptide comprising the phosphorylation site. The AQUA peptide may be phosphorylated or unphosphorylated at the specified serine or threonine position. 
     In another embodiment, the phosphorylation state or level at a phosphorylation site is determined by an antibody or antigen-binding fragment thereof, wherein the antibody specifically binds the phosphorylation site. The antibody may be one that only binds to the phosphorylation site when the serine or threonine residue is phosphorylated, but does not bind to the same sequence when the serine or threonine is not phosphorylated; or vice versa. 
     In particular embodiments, the antibodies of the present application are attached to labeling moieties, such as a detectable marker. One or more detectable labels can be attached to the antibodies. Exemplary labeling moieties include radiopaque dyes, radiocontrast agents, fluorescent molecules, spin-labeled molecules, enzymes, or other labeling moieties of diagnostic value, particularly in radiologic or magnetic resonance imaging techniques. 
     A radiolabeled antibody in accordance with this disclosure can be used for in vitro diagnostic tests. The specific activity of an antibody, binding portion thereof, probe, or ligand, depends upon the half-life, the isotopic purity of the radioactive label, and how the label is incorporated into the biological agent. In immunoassay tests, the higher the specific activity, in general, the better the sensitivity. Radioisotopes useful as labels, e.g., for use in diagnostics, include iodine ( 131 I or  125 I), indium ( 111 In), technetium ( 99 Tc), phosphorus ( 32 P), carbon ( 14 C), and tritium ( 3 H), or one of the therapeutic isotopes listed above. 
     Fluorophore and chromophore labeled biological agents can be prepared from standard moieties known in the art. Since antibodies and other proteins absorb light having wavelengths up to about 310 nm, the fluorescent moieties may be selected to have substantial absorption at wavelengths above 310 nm, such as for example, above 400 nm. A variety of suitable fluorescers and chromophores are described by Stryer, Science, 162:526 (1968) and Brand et al., Annual Review of Biochemistry, 41:843-868 (1972), which are hereby incorporated by reference. The antibodies can be labeled with fluorescent chromophore groups by conventional procedures such as those disclosed in U.S. Pat. Nos. 3,940,475, 4,289,747, and 4,376,110, which are hereby incorporated by reference. 
     The control may be parallel samples providing a basis for comparison, for example, biological samples drawn from a healthy subject, or biological samples drawn from healthy tissues of the same subject. Alternatively, the control may be a pre-determined reference or threshold amount. If the subject is being treated with a therapeutic agent, and the progress of the treatment is monitored by detecting the serine or threonine phosphorylation state level at a phosphorylation site of the invention, a control may be derived from biological samples drawn from the subject prior to, or during the course of the treatment. 
     In certain embodiments, antibody conjugates for diagnostic use in the present application are intended for use in vitro, where the antibody is linked to a secondary binding ligand or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase and glucose oxidase. In certain embodiments, secondary binding ligands are biotin and avidin or streptavidin compounds. 
     Antibodies of the invention may also be optimized for use in a flow cytometry (FC) assay to determine the activation/phosphorylation status of a target signaling protein in subjects before, during, and after treatment with a therapeutic agent targeted at inhibiting serine or threonine phosphorylation at the phosphorylation site disclosed herein. For example, bone marrow cells or peripheral blood cells from patients may be analyzed by flow cytometry for target signaling protein phosphorylation, as well as for markers identifying various hematopoietic cell types. In this manner, activation status of the malignant cells may be specifically characterized. Flow cytometry may be carried out according to standard methods. See, e.g., Chow et al.,  Cytometry  ( Communications in Clinical Cytometry ) 46: 72-78 (2001). 
     Alternatively, antibodies of the invention may be used in immunohistochemical (IHC) staining to detect differences in signal transduction or protein activity using normal and diseased tissues. IHC may be carried out according to well-known techniques. See, e.g., Antibodies: A Laboratory Manual, supra. 
     Peptides and antibodies of the invention may be also be optimized for use in other clinically-suitable applications, for example bead-based multiplex-type assays, such as IGEN, Luminex™ and/or Bioplex™ assay formats, or otherwise optimized for antibody arrays formats, such as reversed-phase array applications (see, e.g. Paweletz et al.,  Oncogene  20(16): 1981-89 (2001)). Accordingly, in another embodiment, the invention provides a method for the multiplex detection of the phosphorylation state or level at two or more phosphorylation sites of the invention (Table 1) in a biological sample, the method comprising utilizing two or more antibodies or AQUA peptides of the invention. In one preferred embodiment, two to five antibodies or AQUA peptides of the invention are used. In another preferred embodiment, six to ten antibodies or AQUA peptides of the invention are used, while in another preferred embodiment eleven to twenty antibodies or AQUA peptides of the invention are used. 
     In certain embodiments the diagnostic methods of the application may be used in combination with other cancer diagnostic tests. 
     The biological sample analyzed may be any sample that is suspected of having abnormal serine or threonine phosphorylation at a novel phosphorylation site of the invention, such as a homogenized neoplastic tissue sample. 
     8. Screening Assays 
     In another aspect, the invention provides a method for identifying an agent that modulates serine or threonine phosphorylation at a novel phosphorylation site of the invention, comprising: a) contacting a candidate agent with a peptide or protein comprising a novel phosphorylation site of the invention; and b) determining the phosphorylation state or level at the novel phosphorylation site. A change in the phosphorylation level of the specified serine or threonine in the presence of the test agent, as compared to a control, indicates that the candidate agent potentially modulates serine or threonine phosphorylation at a novel phosphorylation site of the invention. 
     In one embodiment, the phosphorylation state or level at a novel phosphorylation site is determined by an AQUA peptide comprising the phosphorylation site. The AQUA peptide may be phosphorylated or unphosphorylated at the specified serine or threonine position. 
     In another embodiment, the phosphorylation state or level at a phosphorylation site is determined by an antibody or antigen-binding fragment thereof, wherein the antibody specifically binds the phosphorylation site. The antibody may be one that only binds to the phosphorylation site when the serine or threonine residue is phosphorylated, but does not bind to the same sequence when the serine or threonine is not phosphorylated; or vice versa. 
     In particular embodiments, the antibodies of the present application are attached to labeling moieties, such as a detectable marker. 
     The control may be parallel samples providing a basis for comparison, for example, the phosphorylation level of the target protein or peptide in absence of the testing agent. Alternatively, the control may be a pre-determined reference or threshold amount. 
     9. Immunoassays 
     In another aspect, the present application concerns immunoassays for binding, purifying, quantifying and otherwise generally detecting the phosphorylation state or level at a novel phosphorylation site of the invention. 
     Assays may be homogeneous assays or heterogeneous assays. In a homogeneous assay the immunological reaction usually involves a phosphorylation site-specific antibody of the invention, a labeled analyte, and the sample of interest. The signal arising from the label is modified, directly or indirectly, upon the binding of the antibody to the labeled analyte. Both the immunological reaction and detection of the extent thereof are carried out in a homogeneous solution. Immunochemical labels that may be used include free radicals, radioisotopes, fluorescent dyes, enzymes, bacteriophages, coenzymes, and so forth. 
     In a heterogeneous assay approach, the reagents are usually the specimen, a phosphorylation site-specific antibody of the invention, and suitable means for producing a detectable signal. Similar specimens as described above may be used. The antibody is generally immobilized on a support, such as a bead, plate or slide, and contacted with the specimen suspected of containing the antigen in a liquid phase. The support is then separated from the liquid phase and either the support phase or the liquid phase is examined for a detectable signal using means for producing such signal. The signal is related to the presence of the analyte in the specimen. Means for producing a detectable signal include the use of radioactive labels, fluorescent labels, enzyme labels, and so forth. 
     Phosphorylation site-specific antibodies disclosed herein may be conjugated to a solid support suitable for a diagnostic assay (e.g., beads, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques, such as precipitation. 
     In certain embodiments, immunoassays are the various types of enzyme linked immunoadsorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and Western blotting, dot and slot blotting, FACS analyses, and the like may also be used. The steps of various useful immunoassays have been described in the scientific literature, such as, e.g., Nakamura et al., in Enzyme Immunoassays: Heterogeneous and Homogeneous Systems, Chapter 27 (1987), incorporated herein by reference. 
     In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are based upon the detection of radioactive, fluorescent, biological or enzymatic tags. Of course, one may find additional advantages through the use of a secondary binding ligand such as a second antibody or a biotin/avidin ligand binding arrangement, as is known in the art. 
     The antibody used in the detection may itself be conjugated to a detectable label, wherein one would then simply detect this label. The amount of the primary immune complexes in the composition would, thereby, be determined. 
     Alternatively, the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody. In these cases, the second binding ligand may be linked to a detectable label. The second binding ligand is itself often an antibody, which may thus be termed a “secondary” antibody. The primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under conditions effective and for a period of time sufficient to allow the formation of secondary immune complexes. The secondary immune complexes are washed extensively to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complex is detected. 
     An enzyme linked immunoadsorbent assay (ELISA) is a type of binding assay. In one type of ELISA, phosphorylation site-specific antibodies disclosed herein are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a suspected neoplastic tissue sample is added to the wells. After binding and washing to remove non-specifically bound immune complexes, the bound target signaling protein may be detected. 
     In another type of ELISA, the neoplastic tissue samples are immobilized onto the well surface and then contacted with the phosphorylation site-specific antibodies disclosed herein. After binding and washing to remove non-specifically bound immune complexes, the bound phosphorylation site-specific antibodies are detected. 
     Irrespective of the format used, ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. 
     The radioimmunoassay (RIA) is an analytical technique which depends on the competition (affinity) of an antigen for antigen-binding sites on antibody molecules. Standard curves are constructed from data gathered from a series of samples each containing the same known concentration of labeled antigen, and various, but known, concentrations of unlabeled antigen. Antigens are labeled with a radioactive isotope tracer. The mixture is incubated in contact with an antibody. Then the free antigen is separated from the antibody and the antigen bound thereto. Then, by use of a suitable detector, such as a gamma or beta radiation detector, the percent of either the bound or free labeled antigen or both is determined. This procedure is repeated for a number of samples containing various known concentrations of unlabeled antigens and the results are plotted as a standard graph. The percent of bound tracer antigens is plotted as a function of the antigen concentration. Typically, as the total antigen concentration increases the relative amount of the tracer antigen bound to the antibody decreases. After the standard graph is prepared, it is thereafter used to determine the concentration of antigen in samples undergoing analysis. 
     In an analysis, the sample in which the concentration of antigen is to be determined is mixed with a known amount of tracer antigen. Tracer antigen is the same antigen known to be in the sample but which has been labeled with a suitable radioactive isotope. The sample with tracer is then incubated in contact with the antibody. Then it can be counted in a suitable detector which counts the free antigen remaining in the sample. The antigen bound to the antibody or immunoadsorbent may also be similarly counted. Then, from the standard curve, the concentration of antigen in the original sample is determined. 
     10. Pharmaceutical Formulations and Methods of Administration 
     Methods of administration of therapeutic agents, particularly peptide and antibody therapeutics, are well-known to those of skill in the art. 
     Peptides of the invention can be administered in the same manner as conventional peptide type pharmaceuticals. Preferably, peptides are administered parenterally, for example, intravenously, intramuscularly, intraperitoneally, or subcutaneously. When administered orally, peptides may be proteolytically hydrolyzed. Therefore, oral application may not be usually effective. However, peptides can be administered orally as a formulation wherein peptides are not easily hydrolyzed in a digestive tract, such as liposome-microcapsules. Peptides may be also administered in suppositories, sublingual tablets, or intranasal spray. 
     If administered parenterally, a preferred pharmaceutical composition is an aqueous solution that, in addition to a peptide of the invention as an active ingredient, may contain for example, buffers such as phosphate, acetate, etc., osmotic pressure-adjusting agents such as sodium chloride, sucrose, and sorbitol, etc., antioxidative or antioxygenic agents, such as ascorbic acid or tocopherol and preservatives, such as antibiotics. The parenterally administered composition also may be a solution readily usable or in a lyophilized form which is dissolved in sterile water before administration. 
     The pharmaceutical formulations, dosage forms, and uses described below generally apply to antibody-based therapeutic agents, but are also useful and can be modified, where necessary, for making and using therapeutic agents of the disclosure that are not antibodies. 
     To achieve the desired therapeutic effect, the phosphorylation site-specific antibodies or antigen-binding fragments thereof can be administered in a variety of unit dosage forms. The dose will vary according to the particular antibody. For example, different antibodies may have different masses and/or affinities, and thus require different dosage levels. Antibodies prepared as Fab or other fragments will also require differing dosages than the equivalent intact immunoglobulins, as they are of considerably smaller mass than intact immunoglobulins, and thus require lower dosages to reach the same molar levels in the patient&#39;s blood. The dose will also vary depending on the manner of administration, the particular symptoms of the patient being treated, the overall health, condition, size, and age of the patient, and the judgment of the prescribing physician. Dosage levels of the antibodies for human subjects are generally between about 1 mg per kg and about 100 mg per kg per patient per treatment, such as for example, between about 5 mg per kg and about 50 mg per kg per patient per treatment. In terms of plasma concentrations, the antibody concentrations may be in the range from about 25 μg/mL to about 500 μg/mL. However, greater amounts may be required for extreme cases and smaller amounts may be sufficient for milder cases. 
     Administration of an antibody will generally be performed by a parenteral route, typically via injection such as intra-articular or intravascular injection (e.g., intravenous infusion) or intramuscular injection. Other routes of administration, e.g., oral (p.o.), may be used if desired and practicable for the particular antibody to be administered. An antibody can also be administered in a variety of unit dosage forms and their dosages will also vary with the size, potency, and in vivo half-life of the particular antibody being administered. Doses of a phosphorylation site-specific antibody will also vary depending on the manner of administration, the particular symptoms of the patient being treated, the overall health, condition, size, and age of the patient, and the judgment of the prescribing physician. 
     The frequency of administration may also be adjusted according to various parameters. These include the clinical response, the plasma half-life of the antibody, and the levels of the antibody in a body fluid, such as, blood, plasma, serum, or synovial fluid. To guide adjustment of the frequency of administration, levels of the antibody in the body fluid may be monitored during the course of treatment. 
     Formulations particularly useful for antibody-based therapeutic agents are also described in U.S. Patent App. Publication Nos. 20030202972, 20040091490 and 20050158316. In certain embodiments, the liquid formulations of the application are substantially free of surfactant and/or inorganic salts. In another specific embodiment, the liquid formulations have a pH ranging from about 5.0 to about 7.0. In yet another specific embodiment, the liquid formulations comprise histidine at a concentration ranging from about 1 mM to about 100 mM. In still another specific embodiment, the liquid formulations comprise histidine at a concentration ranging from 1 mM to 100 mM. It is also contemplated that the liquid formulations may further comprise one or more excipients such as a saccharide, an amino acid (e.g., arginine, lysine, and methionine) and a polyol. Additional descriptions and methods of preparing and analyzing liquid formulations can be found, for example, in PCT publications WO 03/106644, WO 04/066957, and WO 04/091658. 
     Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the pharmaceutical compositions of the application. 
     In certain embodiments, formulations of the subject antibodies are pyrogen-free formulations which are substantially free of endotoxins and/or related pyrogenic substances. Endotoxins include toxins that are confined inside microorganisms and are released when the microorganisms are broken down or die. Pyrogenic substances also include fever-inducing, thermostable substances (glycoproteins) from the outer membrane of bacteria and other microorganisms. Both of these substances can cause fever, hypotension and shock if administered to humans. Due to the potential harmful effects, it is advantageous to remove even low amounts of endotoxins from intravenously administered pharmaceutical drug solutions. The Food &amp; Drug Administration (“FDA”) has set an upper limit of 5 endotoxin units (EU) per dose per kilogram body weight in a single one hour period for intravenous drug applications (The United States Pharmacopeial Convention, Pharmacopeial Forum 26 (1):223 (2000)). When therapeutic proteins are administered in amounts of several hundred or thousand milligrams per kilogram body weight, as can be the case with monoclonal antibodies, it is advantageous to remove even trace amounts of endotoxin. 
     The amount of the formulation which will be therapeutically effective can be determined by standard clinical techniques. In addition, in vitro assays may optionally be used to help identify optimal dosage ranges. The precise dose to be used in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient&#39;s circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. The dosage of the compositions to be administered can be determined by the skilled artisan without undue experimentation in conjunction with standard dose-response studies. Relevant circumstances to be considered in making those determinations include the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, and the severity of the patient&#39;s symptoms. For example, the actual patient body weight may be used to calculate the dose of the formulations in milliliters (mL) to be administered. There may be no downward adjustment to “ideal” weight. In such a situation, an appropriate dose may be calculated by the following formula: 
       Dose (mL)=[patient weight (kg)×dose level (mg/kg)/drug concentration (mg/mL)]
 
     For the purpose of treatment of disease, the appropriate dosage of the compounds (for example, antibodies) will depend on the severity and course of disease, the patient&#39;s clinical history and response, the toxicity of the antibodies, and the discretion of the attending physician. The initial candidate dosage may be administered to a patient. The proper dosage and treatment regimen can be established by monitoring the progress of therapy using conventional techniques known to those of skill in the art. 
     The formulations of the application can be distributed as articles of manufacture comprising packaging material and a pharmaceutical agent which comprises, e.g., the antibody and a pharmaceutically acceptable carrier as appropriate to the mode of administration. The packaging material will include a label which indicates that the formulation is for use in the treatment of prostate cancer. 
     11. Kits 
     Antibodies and peptides (including AQUA peptides) of the invention may also be used within a kit for detecting the phosphorylation state or level at a novel phosphorylation site of the invention, comprising at least one of the following: an AQUA peptide comprising the phosphorylation site, or an antibody or an antigen-binding fragment thereof that binds to an amino acid sequence comprising the phosphorylation site. Such a kit may further comprise a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay. Where the antibody is labeled with an enzyme, the kit will include substrates and co-factors required by the enzyme. In addition, other additives may be included such as stabilizers, buffers and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay. Particularly, the reagents may be provided as dry powders, usually lyophilized, including excipients that, on dissolution, will provide a reagent solution having the appropriate concentration. 
     The following Examples are provided only to further illustrate the invention, and are not intended to limit its scope, except as provided in the claims appended hereto. The invention encompasses modifications and variations of the methods taught herein which would be obvious to one of ordinary skill in the art. 
     Example 1 
     Isolation of Phospho-tyrosine, Phospho-serine and Phospho-threonine Containing Peptides from Extracts of Carcinoma and Leukemia Cell Lines and Tissues and Identification of Novel Phosphorylation Sites 
     In order to discover novel serine or threonine phosphorylation sites in carcinoma, IAP isolation techniques were used to identify phosphoserine and/or threonine-containing peptides in cell extracts from human carcinoma cell lines and patient cell lines identified in Column G of Table 1 including Jurkat, Adult mouse brain, Embryo mouse brain, H128, H1703, H3255, H446, H524, H838, HEL, HT29, HeLa, K562, Kyse140, M059J, M059K, MKN-45, mouse brain, mouse heart, mouse liver, MV4-11, N06CS91, SCLC T3, SEM, XY2(0607)-140. Tryptic phosphoserine and/or threonine-containing peptides were purified and analyzed from extracts of each of the cell lines mentioned above, as follows. Cells were cultured in DMEM medium or RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. 
     Suspension cells were harvested by low speed centrifugation. After complete aspiration of medium, cells were resuspended in 1 mL lysis buffer per 1.25×10 8  cells (20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium vanadate, supplemented or not with 2.5 mM sodium pyro-phosphate, 1 mM B-glycerol-phosphate) and sonicated. 
     Adherent cells at about 80% confluency were starved in medium without serum overnight and stimulated, with ligand depending on the cell type or not stimulated. After complete aspiration of medium from the plates, cells were scraped off the plate in 10 ml lysis buffer per 2×10 8  cells (20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium vanadate, supplemented with 2.5 mM sodium pyrophosphate, 1 mM B-glycerol-phosphate) and sonicated. 
     Frozen tissue samples were cut to small pieces, homogenize in lysis buffer (20 mM HEPES pH 8.0, 9 M Urea, 1 mN sodium vanadate, supplemented with 2.5 mM sodium pyrophosphate, 1 mM b-glycerol-phosphate, 1 ml lysis buffer for 100 mg of frozen tissue) using a polytron for 2 times of 20 sec. each time. Homogenate is then briefly sonicated. 
     Sonicated cell lysates were cleared by centrifugation at 20,000×g, and proteins were reduced with DTT at a final concentration of 4.1 mM and alkylated with iodoacetamide at 8.3 mM. For digestion with trypsin, protein extracts were diluted in 20 mM HEPES pH 8.0 to a final concentration of 2 M urea and soluble TLCK-trypsin (Worthington) was added at 10-20 μg/mL. Digestion was performed for 1-2 days at room temperature. 
     Trifluoroacetic acid (TFA) was added to protein digests to a final concentration of 1%, precipitate was removed by centrifugation, and digests were loaded onto Sep-Pak C 18  columns (Waters) equilibrated with 0.1% TFA. A column volume of 0.7-1.0 ml was used per 2×10 8  cells. Columns were washed with 15 volumes of 0.1% TFA, followed by 4 volumes of 5% acetonitrile (MeCN) in 0.1% TFA. Peptide fraction I was obtained by eluting columns with 2 volumes each of 8, 12, and 15% MeCN in 0.1% TFA and combining the eluates. Fractions II and III were a combination of eluates after eluting columns with 18, 22, 25% MeCN in 0.1% TFA and with 30, 35, 40% MeCN in 0.1% TFA, respectively. All peptide fractions were lyophilized. 
     Peptides from each fraction corresponding to 2×10 8  cells were dissolved in 1 ml of IAP buffer (20 mM Tris/HCl or 50 mM MOPS pH 7.2, 10 mM sodium phosphate, 50 mM NaCl) and insoluble matter (mainly in peptide fractions III) was removed by centrifugation. IAP was performed on each peptide fraction separately. The phosphoserine or threonine monoclonal antibody P-Tyr-100 (Cell Signaling Technology, Inc., catalog number 9411) was coupled at 4 mg/ml beads to protein G (Roche), respectively. Immobilized antibody (15 μL, 60 μg) was added as 1:1 slurry in IAP buffer to 1 ml of each peptide fraction, and the mixture was incubated overnight at 4° C. with gentle rotation. The immobilized antibody beads were washed three times with 1 ml IAP buffer and twice with 1 ml water, all at 4° C. Peptides were eluted from beads by incubation with 75 μl of 0.1% TFA at room temperature for 10 minutes. 
     Alternatively, one single peptide fraction was obtained from Sep-Pak C18 columns by elution with 2 volumes each of 10%, 15%, 20%, 25%, 30%, 35% and 40% acetonitirile in 0.1% TFA and combination of all eluates. IAP on this peptide fraction was performed as follows: Afterlyophilization, peptide was dissolved in 1.4 ml IAP buffer (MOPS pH 7.2, 10 mM sodium phosphate, 50 mM NaCl) and insoluble matter was removed by centrifugation. Immobilized antibody (40 μl, 160 μg) was added as 1:1 slurry in IAP buffer, and the mixture was incubated overnight at 4° C. with gentle shaking The immobilized antibody beads were washed three times with 1 ml IAP buffer and twice with 1 ml water, all at 4° C. Peptides were eluted from beads by incubation with 55 μl of 0.15% TFA at room temperature for 10 min (eluate 1), followed by a wash of the beads (eluate 2) with 45 μl of 0.15% TFA. Both eluates were combined. 
     Analysis by LC-MS/MS Mass Spectrometry. 
     40 μl or more of IAP eluate were purified by 0.2 μl StageTips or ZipTips. Peptides were eluted from the microcolumns with 1 μl of 40% MeCN, 0.1% TFA (fractions I and II) or 1 μl of 60% MeCN, 0.1% TFA (fraction III) into 7.6-9.0 μl of 0.4% acetic acid/0.005% heptafluorobutyric acid. For single fraction analysis, 1 μl of 60% MeCN, 0.1% TFA, was used for elution from the microcolumns. This sample was loaded onto a 10 cm×75 μm PicoFrit capillary column (New Objective) packed with Magic C18 AQ reversed-phase resin (Michrom Bioresources) using a Famos autosampler with an inert sample injection valve (Dionex). The column was then developed with a 45-min linear gradient of acetonitrile delivered at 200 nl/min (Ultimate, Dionex), and tandem mass spectra were collected in a data-dependent manner with an LTQ ion trap mass spectrometer essentially as described by Gygi et al., supra. 
     Database Analysis &amp; Assignments. 
     MS/MS spectra were evaluated using TurboSequest in the Sequest Browser package (v. 27, rev. 12) supplied as part of BioWorks 3.0 (ThermoFinnigan). Individual MS/MS spectra were extracted from the raw data file using the Sequest Browser program CreateDta, with the following settings: bottom MW, 700; top MW, 4,500; minimum number of ions, 20 (40 for LTQ); minimum TIC, 4×10 5  (2×10 3  for LTQ); and precursor charge state, unspecified. Spectra were extracted from the beginning of the raw data file before sample injection to the end of the eluting gradient. The IonQuest and VuDta programs were not used to further select MS/MS spectra for Sequest analysis. MS/MS spectra were evaluated with the following TurboSequest parameters: peptide mass tolerance, 2.5; fragment ion tolerance, 0.0 (1.0 for LTQ); maximum number of differential amino acids per modification, 4; mass type parent, average; mass type fragment, average; maximum number of internal cleavage sites, 10; neutral losses of water and ammonia from b and y ions were considered in the correlation analysis. Proteolytic enzyme was specified except for spectra collected from elastase digests. 
     Searches were performed against the NCBI human protein database (NCBI RefSeq protein release #11; 8 May 2005; 1,826,611 proteins, including 47,859 human proteins. Peptides that did not match RefSeq were compared to NCBI GenPept release #148; 15 Jun. 2005 release date; 2,479,172 proteins, including 196,054 human proteins.). Cysteine carboxamidomethylation was specified as a static modification, and phosphorylation was allowed as a variable modification on serine or threonine residues. It was determined that restricting phosphorylation to serine or threonine residues had little effect on the number of phosphorylation sites assigned. 
     In proteomics research, it is desirable to validate protein identifications based solely on the observation of a single peptide in one experimental result, in order to indicate that the protein is, in fact, present in a sample. This has led to the development of statistical methods for validating peptide assignments, which are not yet universally accepted, and guidelines for the publication of protein and peptide identification results (see Carr et al.,  Mol. Cell. Proteomics  3: 531-533 (2004)), which were followed in this Example. However, because the immunoaffinity strategy separates phosphorylated peptides from unphosphorylated peptides, observing just one phosphopeptide from a protein is a common result, since many phosphorylated proteins have only one serine and/or threonine-phosphorylated site. For this reason, it is appropriate to use additional criteria to validate phosphopeptide assignments. Assignments are likely to be correct if any of these additional criteria are met: (i) the same phosphopeptide sequence is assigned to co-eluting ions with different charge states, since the MS/MS spectrum changes markedly with charge state; (ii) the phosphorylation site is found in more than one peptide sequence context due to sequence overlaps from incomplete proteolysis or use of proteases other than trypsin; (iii) the phosphorylation site is found in more than one peptide sequence context due to homologous but not identical protein isoforms; (iv) the phosphorylation site is found in more than one peptide sequence context due to homologous but not identical proteins among species; and (v) phosphorylation sites validated by MS/MS analysis of synthetic phosphopeptides corresponding to assigned sequences, since the ion trap mass spectrometer produces highly reproducible MS/MS spectra. The last criterion is routinely used to confirm novel site assignments of particular interest. 
     All spectra and all sequence assignments made by Sequest were imported into a relational database. The following Sequest scoring thresholds were used to select phosphopeptide assignments that are likely to be correct: RSp&lt;6, XCorr≧2.2, and DeltaCN&gt;0.099. Further, the sequence assignments could be accepted or rejected with respect to accuracy by using the following conservative, two-step process. 
     In the first step, a subset of high-scoring sequence assignments should be selected by filtering for XCorr values of at least 1.5 for a charge state of +1, 2.2 for +2, and 3.3 for +3, allowing a maximum RSp value of 10. Assignments in this subset should be rejected if any of the following criteria are satisfied: (i) the spectrum contains at least one major peak (at least 10% as intense as the most intense ion in the spectrum) that can not be mapped to the assigned sequence as an a, b, or y ion, as an ion arising from neutral-loss of water or ammonia from a b or y ion, or as a multiply protonated ion; (ii) the spectrum does not contain a series of b or y ions equivalent to at least six uninterrupted residues; or (iii) the sequence is not observed at least five times in all the studies conducted (except for overlapping sequences due to incomplete proteolysis or use of proteases other than trypsin). 
     In the second step, assignments with below-threshold scores should be accepted if the low-scoring spectrum shows a high degree of similarity to a high-scoring spectrum collected in another study, which simulates a true reference library-searching strategy. 
     Example 2 
     Production of Phosphorylation site-Specific Polyclonal Antibodies 
     Polyclonal antibodies that specifically bind a novel phosphorylation site of the invention (Table 1) only when the serine or threonine residue is phosphorylated (and does not bind to the same sequence when the serine or threonine is not phosphorylated), and vice versa, are produced according to standard methods by first constructing a synthetic peptide antigen comprising the phosphorylation site and then immunizing an animal to raise antibodies against the antigen, as further described below. Production of exemplary polyclonal antibodies is provided below. 
     A. AP-4 (Threonine 37). 
     An 24 amino acid phospho-peptide antigen, EVIGGLCSLANIPLt*PETQRDQER (where t*=phosphothreonine) that corresponds to the sequence encompassing the threonine 37 phosphorylation site in human AP-4 protein (see Row 44 of Table 1; SEQ ID NO: 43), plus cysteine on the C-terminal for coupling, is constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer. See A NTIBODIES : A L ABORATORY  M ANUAL , supra.; Merrifield, supra. This peptide is then coupled to KLH and used to immunize animals to produce (and subsequently screen) phospho-specific FOXO3A (ser 294) polyclonal antibodies as described in Immunization/Screening below. 
     B. AHCP (Threonine 195). 
     A 17 amino acid phospho-peptide antigen, TAAGISt*PAPVAGLGPR (where t*=phosphothreonine) that corresponds to the sequence encompassing the threonine 195 phosphorylation site in human AHCP transcriptional regulator protein (see Row 15 of Table 1 (SEQ ID NO: 16)), plus cysteine on the C-terminal for coupling, is constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer. See A NTIBODIES : A L ABORATORY  M ANUAL , supra; Merrifield, supra. This peptide is then coupled to KLH and used to immunize animals to produce (and subsequently screen) phospho-specific AHCP (Thr 195) polyclonal antibodies as described in Immunization/Screening below. 
     Immunization/Screening. 
     A synthetic phospho-peptide antigen as described in A-C above is coupled to KLH, and rabbits are injected intradermally (ID) on the back with antigen in complete Freunds adjuvant (500 μg antigen per rabbit). The rabbits are boosted with same antigen in incomplete Freund adjuvant (250 μg antigen per rabbit) every three weeks. After the fifth boost, bleeds are collected. The sera are purified by Protein A-affinity chromatography by standard methods (see A NTIBODIES : A L ABORATORY  M ANUAL , Cold Spring Harbor, supra.). The eluted immunoglobulins are further loaded onto an unphosphorylated synthetic peptide antigen-resin Knotes column to pull out antibodies that bind the unphosphorylated form of the phosphorylation sites. The flow through fraction is collected and applied onto a phospho-synthetic peptide antigen-resin column to isolate antibodies that bind the phosphorylated form of the phosphorylation sites. After washing the column extensively, the bound antibodies (i.e. antibodies that bind the phosphorylated peptides described in A-C above, but do not bind the unphosphorylated form of the peptides) are eluted and kept in antibody storage buffer. 
     The isolated antibody is then tested for phospho-specificity using Western blot assay using an appropriate cell line that expresses (or overexpresses) target phospho-protein (i.e. phosphorylated AP-4 or AHCP), found in for example, Jurkat cells. Cells are cultured in DMEM or RPMI supplemented with 10% FCS. Cell are collected, washed with PBS and directly lysed in cell lysis buffer. The protein concentration of cell lysates is then measured. The loading buffer is added into cell lysate and the mixture is boiled at 100° C. for 5 minutes. 20 μl (10 μg protein) of sample is then added onto 7.5% SDS-PAGE gel. 
     A standard Western blot may be performed according to the Immunoblotting Protocol set out in the C ELL  S IGNALING  T ECHNOLOGY , I NC.  2003-04 Catalogue, p. 390. The isolated phosphorylation site-specific antibody is used at dilution 1:1000. Phospho-specificity of the antibody will be shown by binding of only the phosphorylated form of the target amino acid sequence. Isolated phosphorylation site-specific polyclonal antibody does not (substantially) recognize the same target sequence when not phosphorylated at the specified serine or threonine position (e.g., the antibody does not bind to AHCP in the non-stimulated cells, when threonine 195 is not phosphorylated). 
     In order to confirm the specificity of the isolated antibody, different cell lysates containing various phosphorylated signaling proteins other than the target protein are prepared. The Western blot assay is performed again using these cell lysates. The phosphorylation site-specific polyclonal antibody isolated as described above is used (1:1000 dilution) to test reactivity with the different phosphorylated non-target proteins. The phosphorylation site-specific antibody does not significantly cross-react with other phosphorylated signaling proteins that do not have the described phosphorylation site, although occasionally slight binding to a highly homologous sequence on another protein may be observed. In such case the antibody may be further purified using affinity chromatography, or the specific immunoreactivity cloned by rabbit hybridoma technology. 
     Example 3 
     Production of Phosphorylation Site-Specific Monoclonal Antibodies 
     Monoclonal antibodies that specifically bind a novel phosphorylation site of the invention (Table 1) only when the serine or threonine residue is phosphorylated (and does not bind to the same sequence when the serine or threonine is not phosphorylated) are produced according to standard methods by first constructing a synthetic peptide antigen comprising the phosphorylation site and then immunizing an animal to raise antibodies against the antigen, and harvesting spleen cells from such animals to produce fusion hybridomas, as further described below. Production of exemplary monoclonal antibodies is provided below. 
     A. ADD2 (Threonine 711) 
     An 8 amino acid phospho-peptide antigen, FRt*PSFLK (where t*=phosphothreonine) that corresponds to the sequence encompassing the threonine 711 phosphorylation site in human ADD2 protein (see Row 9 of Table 1 (SEQ ID NO: 8)), plus cysteine on the C-terminal for coupling, is constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer. See A NTIBODIES : A L ABORATORY  M ANUAL , supra.; Merrifield, supra. This peptide is then coupled to KLH and used to immunize animals and harvest spleen cells for generation (and subsequent screening) of phospho-specific monoclonal ADD2 (thr 711) antibodies as described in Immunization/Fusion/Screening below. 
     B. AHNAK (serine 637) 
     A 10 amino acid phospho-peptide antigen, MPTFs*TPGAK (where s*=phosphoserine) that corresponds to the sequence encompassing the serine 637 phosphorylation site in human AHNAK protein (see Row 16 of Table 1 (SEQ ID NO: 15)), plus cysteine on the C-terminal for coupling, is constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer. See A NTIBODIES : A L ABORATORY  M ANUAL , supra.; Merrifield, supra. This peptide is then coupled to KLH and used to immunize animals and harvest spleen cells for generation (and subsequent screening) of phospho-specific monoclonal AHNAK (ser 637) antibodies as described in Immunization/Fusion/Screening below. 
     Immunization/Fusion/Screening. 
     A synthetic phospho-peptide antigen as described in A-C above is coupled to KLH, and BALB/C mice are injected intradermally (ID) on the back with antigen in complete Freunds adjuvant (e.g., 50 μg antigen per mouse). The mice are boosted with same antigen in incomplete Freund adjuvant (e.g. 25 μg antigen per mouse) every three weeks. After the fifth boost, the animals are sacrificed and spleens are harvested. 
     Harvested spleen cells are fused to SP2/0 mouse myeloma fusion partner cells according to the standard protocol of Kohler and Milstein (1975). Colonies originating from the fusion are screened by ELISA for reactivity to the phospho-peptide and non-phospho-peptide forms of the antigen and by Western blot analysis (as described in Example 1 above). Colonies found to be positive by ELISA to the phospho-peptide while negative to the non-phospho-peptide are further characterized by Western blot analysis. Colonies found to be positive by Western blot analysis are subcloned by limited dilution. Mouse ascites are produced from a single clone obtained from subcloning, and tested for phospho-specificity (against the PSD-95, Rictor or B-CK) phospho-peptide antigen, as the case may be) on ELISA. Clones identified as positive on Western blot analysis using cell culture supernatant as having phospho-specificity, as indicated by a strong band in the induced lane and a weak band in the uninduced lane of the blot, are isolated and subcloned as clones producing monoclonal antibodies with the desired specificity. 
     Ascites fluid from isolated clones may be further tested by Western blot analysis. The ascites fluid should produce similar results on Western blot analysis as observed previously with the cell culture supernatant, indicating phospho-specificity against the phosphorylated target. 
     Example 4 
     Production and Use of AQUA Peptides for Detecting and Quantitating Phosphorylation at a Novel Phosphorylation Site 
     Heavy-isotope labeled peptides (AQUA peptides (internal standards)) for the detecting and quantitating a novel phosphorylation site of the invention (Table 1) only when the serine or threonine residue is phosphorylated are produced according to the standard AQUA methodology (see Gygi et al., Gerber et al., supra.) methods by first constructing a synthetic peptide standard corresponding to the phosphorylation site sequence and incorporating a heavy-isotope label. Subsequently, the MS n  and LC-SRM signature of the peptide standard is validated, and the AQUA peptide is used to quantify native peptide in a biological sample, such as a digested cell extract. Production and use of exemplary AQUA peptides is provided below. 
     A. ARID1A (Serine 1604). 
     An AQUA peptide comprising the sequence, TSPSKs*PFLHSGMK (s*=phosphoserine; sequence incorporating  14 C/ 15 N-labeled proline (indicated by bold P), which corresponds to the serine 1604 phosphorylation site in human ARID1A (see Row 53 in Table 1 (SEQ ID NO: 52)), is constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer (see Merrifield, supra.) as further described below in Synthesis &amp; MS/MS Signature. The ARID1A (ser 1604) AQUA peptide is then spiked into a biological sample to quantify the amount of phosphorylated ARID1A (ser 1604) in the sample, as further described below in Analysis &amp; Quantification. 
     B. BAT8 (Threonine 44). 
     An AQUA peptide comprising the sequence VHGSLGDt*PR (t*=phosphothreonine; sequence incorporating  14 C/ 15 N-labeled valine (indicated by bold V), which corresponds to the threonine 44 phosphorylation site in human BAT8 (see Row 66 in Table 1 (SEQ ID NO: 65)), is constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer (see Merrifield, supra.) as further described below in Synthesis &amp; MS/MS Signature. The BAT8 (thr 44) AQUA peptide is then spiked into a biological sample to quantify the amount of phosphorylated BAT8 (thr 44) in the sample, as further described below in Analysis &amp; Quantification. 
     Synthesis &amp; MS/MS Spectra. 
     Fluorenylmethoxycarbonyl (Fmoc)-derivatized amino acid monomers may be obtained from AnaSpec (San Jose, Calif.). Fmoc-derivatized stable-isotope monomers containing one  15 N and five to nine  13 C atoms may be obtained from Cambridge Isotope Laboratories (Andover, Mass.). Preloaded Wang resins may be obtained from Applied Biosystems. Synthesis scales may vary from 5 to 25 μmol. Amino acids are activated in situ with 1-H-benzotriazolium, 1-bis(dimethylamino) methylene]-hexafluorophosphate (1-),3-oxide:1-hydroxybenzotriazole hydrate and coupled at a 5-fold molar excess over peptide. Each coupling cycle is followed by capping with acetic anhydride to avoid accumulation of one-residue deletion peptide by-products. After synthesis peptide-resins are treated with a standard scavenger-containing trifluoroacetic acid (TFA)-water cleavage solution, and the peptides are precipitated by addition to cold ether. Peptides (i.e. a desired AQUA peptide described in A-D above) are purified by reversed-phase C18 HPLC using standard TFA/acetonitrile gradients and characterized by matrix-assisted laser desorption ionization-time of flight (Biflex III, Bruker Daltonics, Billerica, Mass.) and ion-trap (ThermoFinnigan, LCQ DecaXP or LTQ) MS. 
     MS/MS spectra for each AQUA peptide should exhibit a strong y-type ion peak as the most intense fragment ion that is suitable for use in an SRM monitoring/analysis. Reverse-phase microcapillary columns (0.1 Å˜150-220 mm) are prepared according to standard methods. An Agilent 1100 liquid chromatograph may be used to develop and deliver a solvent gradient [0.4% acetic acid/0.005% heptafluorobutyric acid (HFBA)/7% methanol and 0.4% acetic acid/0.005% HFBA/65% methanol/35% acetonitrile] to the microcapillary column by means of a flow splitter. Samples are then directly loaded onto the microcapillary column by using a FAMOS inert capillary autosampler (LC Packings, San Francisco) after the flow split. Peptides are reconstituted in 6% acetic acid/0.01% TFA before injection. 
     Analysis &amp; Quantification. 
     Target protein (e.g. a phosphorylated proteins of A-D above) in a biological sample is quantified using a validated AQUA peptide (as described above). The IAP method is then applied to the complex mixture of peptides derived from proteolytic cleavage of crude cell extracts to which the AQUA peptides have been spiked in. 
     LC-SRM of the entire sample is then carried out. MS/MS may be performed by using a ThermoFinnigan (San Jose, Calif.) mass spectrometer (LCQ DecaXP ion trap or TSQ Quantum triple quadrupole or LTQ). On the DecaXP, parent ions are isolated at 1.6 m/z width, the ion injection time being limited to 150 ms per microscan, with two microscans per peptide averaged, and with an AGC setting of 1×10 8 ; on the Quantum, Q1 is kept at 0.4 and Q3 at 0.8 m/z with a scan time of 200 ms per peptide. On both instruments, analyte and internal standard are analyzed in alternation within a previously known reverse-phase retention window; well-resolved pairs of internal standard and analyte are analyzed in separate retention segments to improve duty cycle. Data are processed by integrating the appropriate peaks in an extracted ion chromatogram (60.15 m/z from the fragment monitored) for the native and internal standard, followed by calculation of the ratio of peak areas multiplied by the absolute amount of internal standard (e.g., 500 fmol). 
     Example 5 
     Development of the Phospho-4ET (Ser258) Polyclonal Antibody 
     A 13 amino acid phospho-peptide antigen, RRTAsVKEGIVEC (where s=phosphoserine), corresponding to residues 255-267 of human 4ET encompassing the serine 259 of SEQ ID NO: 726 (cysteine was already present on the N-terminus and thus did not need to be added for coupling), was constructed according to standard synthesis techniques using, e.g., a Rainin/Protein Technologies, Inc., Symphony peptide synthesizer. See A NTIBODIES : A L ABORATORY  M ANUAL , supra.; Merrifield, supra. Note that although this antibody recognizes phoshorylated serine 259 in context of the peptide set forth above as SEQ ID NO: 726, because of the alternate numbering of the amino acids in the full length protein, this antibody is referred to as being p-4ET (Se258)-specific (and not phospho-4ET (Ser259)-specific). 
     The peptide was then coupled to KLH, and rabbits were then injected intradermally (ID) on the back with antigen in complete Freunds adjuvant (500 μg antigen per rabbit). The rabbits were boosted with the same antigen in incomplete Freund adjuvant (250 μg antigen per rabbit) every three weeks. After the fifth boost, the bleeds were collected. The sera were purified by Protein A-affinity chromatography as previously described (see A NTIBODIES : A L ABORATORY  M ANUAL , Cold Spring Harbor, supra.). The eluted immunoglobulins are then loaded onto a resin -RRTAsVKEGIVEC Knotes column. After washing the column extensively, the phospho-4ET (Ser258) antibodies were eluted and kept in antibody storage buffer. 
     The antibody was further tested for phospho-specificity by Western blot analysis. Cells were washed with PBS and directly lysed in cell lysis buffer. NIH/3T3 cells were cultured in DMEM supplemented with 10% CS. MKN45 cells were grown in RPMI 1640 medium with 10% FBS, 1× Pen/Strep. The cells were starved overnight, either treated with DMSO or 1 uM of Su11274. 
     4ET is a putative Akt substrate. MKN45 is a gastric cancer cell lines that has amplified c-Met driving the cancer cell growth. MKN45 has constitutively active c-Met which phosphorylates Akt. Su11274 is a c-Met kinase inhibitor. Upon treatment with Su11274, c-Met and Akt phosphorylation decreases in MKN45 cells, and therefore, we also saw 4ET phosphorylation decrease. Insulin activates Akt through PI3K. With Insulin treatment, Akt phosphorylation increases, which phosphorylates 4ET. When NIH/3T3 cells were serum-starved overnight, and untreated or treated by insulin (150 nM, 15 minutes). Mkn45 cells were serum-starved overnight, and untreated or treated by Su11274 (1 microM, 3 hours). 
     As shown in  FIG. 2 , a standard Western blot was performed according to the Immunoblotting Protocol set out in the Cell Signaling Technology 2009-10 Catalogue and Technical Reference, p. 57. The phospho-4ET (Ser258) polyclonal antibody was used at dilution 1:100. The results of the Western blot—see FIG.  2 —show that the antibody recognizes a ˜140 kDa phospho-protein (phospho-4ET Ser258), which is the predicted size of phospho-4ET protein. 
     Example 6 
     Production of a Phospho-4ET (Ser258) Phosphospecific Monoclonal Antibody 
     A phospho-4ET (Ser258) (i.e., a phospho 4ET (Ser259), depending on numbering of the amino acids in the full length protein) phosphospecific rabbit monoclonal antibody, may be produced from spleen cells of the immunized rabbit described in Example 5, above. Harvested spleen cells are fused to a myeloma fusion partner cells according to the standard protocol of Kohler and Milstein (1975). Colonies originating from the fusion are screened by ELISA for reactivity to the phospho-peptide and non-phospho-peptide forms of the antigen and by Western blot analysis (as described in Example 1 above). Colonies found to be positive by ELISA to the phospho-peptide while negative to the non-phospho-peptide are further characterized by Western blot analysis. Colonies found to be positive by Western blot analysis are subcloned by limited dilution. Mouse ascites are produced from a single clone obtained from subcloning, and tested for phospho-specificity (against the PSD-95, Rictor or B-CK) phospho-peptide antigen, as the case may be) on ELISA. Clones identified as positive on Western blot analysis using cell culture supernatant as having phospho-specificity, as indicated by a strong band in the induced lane and a weak band in the uninduced lane of the blot, are isolated and subcloned as clones producing monoclonal antibodies with the desired specificity. 
     Ascites fluid from isolated clones may be further tested by Western blot analysis. The ascites fluid should produce similar results on Western blot analysis as observed previously with the cell culture supernatant, indicating phospho-specificity against the phosphorylated target. 
     Example 7 
     Detection of 4ET Phosphorylation In Cytometric Assay 
     The 4ETphosphospecific antibodies described in Examples 5 or 6 may be used in flow cytometry to detect phospho-4ET in a biological sample. A sample of cells may be taken to be analyzed by Western blot analysis. The remaining cells are fixed with 1% paraformaldehyde for 10 minutes at 37° C., followed by cell permeabilization 90% with methanol for 30 minutes on ice. The fixed cells are then stained with the phospho-4ET primary antibody for 60 minutes at room temperature. The cells are then washed and stained with an Alexa 488-labeled secondary antibody for 30 minutes at room temperature. The cells may then be analyzed on a Beckman Coulter EPICS-XL flow cytometer. 
     The cytometric results are expected to match the Western results described above, further demonstrating the specificity of the 4ET antibody for the activated/phosphorylated 4ET protein. 
     Example 8 
     Detection of Constitutively Active 4ET in Cells using Flow Cytometry 
     4ET phosphospecific antibody described in Examples 5 or 6 above may also be used in flow cytometry to detect phospho-4ET in a biological sample. Serum-starved cells may be incubated with or without a 4ET inhibitor SF1126 for 4 hours at 37° C. The cells are then fixed with 2% paraformaldehyde for 10 minutes at 37° C. followed by cell permeabilization 90% with methanol for 30 minutes on ice. The fixed cells are stained with the Alexa 488-conjugated 4ET primary antibody for 1 hour at room temperature. The cells may then be analyzed on a Beckman Coulter EPICS-XL flow cytometer. 
     The cytometric results are again expected to demonstrate the specificity of the 4ET antibody for the activated 4ET protein and the assay&#39;s ability to detect the activity and efficacy of a 4ET inhibitor. In the presence of the drug, a population of the cells will show less staining with the antibody, indicating that the drug is active against 4ET. 
     EQUIVALENTS 
     Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.